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Abstract
Understanding how structural modifications affect the biological activity of
small molecules is one of the central themes in medicinal chemistry. By no means
is structure-activity relationship (SAR) analysis a priori dependent on compu-
tational methods. However, as molecular data sets grow in size, we quickly
approach our limits to access and compare structures and associated biological
properties so that computational data processing and analysis often become
essential.
Here, different types of approaches of varying computational complexity for
the analysis of SAR information are presented, which can be applied in the con-
text of screening and chemical optimization projects. The first part of this thesis
is dedicated to machine-learning strategies that aim at de novo ligand prediction
and the preferential detection of potent hits in virtual screening. High empha-
sis is put on benchmarking of different strategies and a thorough evaluation of
their utility in practical applications. However, an often claimed disadvantage
of these prediction methods is their black box character because they do not
necessarily reveal which structural features are associated with biological ac-
tivity. Therefore, these methods are complemented by more descriptive SAR
analysis approaches showing a higher degree of interpretability. Concepts from
information theory are adapted to identify activity-relevant structure-derived
descriptors. Furthermore, compound data mining methods exploring prespeci-
fied properties of available bioactive compounds on a large scale are designed
to systematically relate molecular transformations to activity changes. Finally,
these approaches are complemented by graphical methods that primarily help to
access and visualize SAR data in congeneric series of compounds and allow the
formulation of intuitive SAR rules applicable to the design of new compounds.
The compendium of SAR analysis tools introduced in this thesis investigates
SARs from different perspectives.
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Chapter 1
Introduction
Chemoinformatics encompasses the development and application of computa-
tional methods to solve chemical problems. Although the term chemoinformat-
ics was only introduced about a decade ago, it refers to a research field with
a long tradition because individual areas of chemoinformatics, such as chemi-
cal structure representation and searching, molecular modeling, and computer-
assisted structure elucidation, have their origins back in the 1960s [1]. Since
then, the interest in computational methods in chemistry has continuously
grown. The rising popularity is largely ascribed to increasing amounts of data
that are produced and cannot be dealt with without computational means [2].
In particular, the introduction of combinatorial chemistry and high-throughput
screening (HTS) has triggered the need for computational data management
and analysis which is facilitated by continuing advances in computational power.
These technological innovations have also paved the way for the establishment
of chemoinformatics methods in the pharmaceutical industry.
Pharmaceutically-oriented chemoinformatics focuses on small molecules
and their interactions with targets, i.e., their biological activity. A prime ob-
jective of chemoinformatics methods is the identification of compounds with
desired biological activities that might ultimately become drug candidates. To
these ends, it is of central importance to analyze and understand the rela-
tionship between chemical structure and biological activity of small molecules.
Currently available approaches to structure-activity relationship (SAR) analysis
are multifaceted and of rather different methodological complexity. A general
distinction can be made between methodologies that primarily help to access
and visualize SAR data obtained from HTS or chemical optimization campaigns
and those that ultimately predict biological activities. In this thesis, both kinds
of methodologies are employed for the analysis and exploitation of SARs.
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Prediction Methods in SAR Analysis
Virtual screening (VS) techniques process large databases of compounds in sil-
ico and are often considered as a cost-efficient complement to HTS [3]. Ligand-
based VS (LBVS) utilizes information from known bioactive molecules to iden-
tify novel structures exhibiting the desired bioactivity. From a conceptual point
of view, LBVS is based on the similarity-property principle (SPP) [4] that was
articulated by Johnson and Maggiora in 1990 and states that overall structurally
similar molecules should have similar biological properties. This `holistic' view of
molecular similarity [5] provides the basis for similarity searching [6]. Following
this approach, one or multiple known bioactive molecules are used as reference
compounds for comparison with database compounds of unknown bioactivity.
The degree of `whole molecule'-similarity between a database compound and
the reference set is quantitatively assessed through the representation of en-
tire compounds by sets of structure-derived descriptors and the application of
a mathematical function that measures the similarity between descriptor sets.
Database compounds are then ranked in order of decreasing similarity to the
reference set. According to the SPP, top-ranked molecules are most likely to
exhibit the desired bioactivity and constitute prime candidates for biological
testing. In compound classification approaches, test molecules are usually com-
pared to active and inactive reference compounds and assigned to the class to
which they are more similar.
A more refined view of molecular similarity is used in the analysis of phar-
macophores [7] or quantitative structure-activity relationships (QSARs) [8].
These methods focus on `local' similarities [5] in the study of biological activity
determinants. Pharmacophore analysis aims at generating a hypothesis about
the spatial arrangement of groups of functionalities in a molecule that render it
active by forming interactions with a biological target of interest. These feature
arrangements determine the pharmacophore model that is subsequently used
in database screening to prioritize molecules with similar geometric features.
QSAR correlates biological activities of congeneric compounds with selected
structural features and/or properties represented as numerical chemical descrip-
tors. For a set of reference molecules, a numerical relationship between potency
and selected descriptors is established to deduce a regression model that takes
descriptor values of any compound as input and returns its predicted activity
value. It follows that the selection of activity-relevant descriptors is highly crit-
ical for the prediction quality of QSAR models. Furthermore, QSAR models
are usually built from series of structurally closely related compounds. There-
fore, test compounds of a different chemotype than the reference molecules fall
outside of the applicability domain of most QSAR models and their activity
cannot be reliably predicted [9].
3Limitations of Prediction Methods
Over the past few years, the integration of machine-learning and artificial intel-
ligence concepts has led to increasingly sophisticated QSAR and LBVS methods
with improved prediction accuracies [10,11]. Nevertheless, in many cases, these
methods still fail to produce reliable predictions for test compounds, even in the
presence of highly similar reference compounds [12]. These observations can be
explained by the limited validity of the concept underlying these approaches:
although the SPP is intuitive and a central paradigm in medicinal chemistry,
it is frequently observed that small modifications of chemical structure can
significantly alter compound activity [13]. This finding can be rationalized by
the specificity of molecular recognition processes that require a high degree of
complementarity between interacting surfaces. For example, the precise fit of a
molecule into a binding site and the formation of key interactions with a target
can easily be hindered by a small structural modification that changes molecular
shape or charge distribution. The term activity cliff refers to compound pairs
showing high structural similarity but large differences in activity [14]. Activity
cliffs are exploited by medicinal chemists in hit-to-lead and lead optimization
projects where small structural modifications are systematically applied to an
initial hit compound in order to achieve improved compound potency [13]. On
the other hand, activity cliffs strongly complicate molecular similarity analysis
and represent challenges for QSAR and LBVS applications, often making them
a hopeless endeavor [12]. In light of the limited applicability of quantitative
prediction and compound classification methods and their strong dependency
on the nature of the SARs present in the activity class under study (vide in-
fra), it is attractive to extend the spectrum of available SAR analysis methods
with descriptive approaches that aim at the extraction of interpretable SAR
information from compound data sets. These methods are primarily designed
to guide compound design in hit-to-lead and lead optimization campaigns but
do not generalize extracted patterns to new data in an automated manner.
Furthermore, these approaches circumvent the black box character of many
prediction methods that do not enable the user to trace back prediction re-
sults to molecular structure and do not reveal which structural features are
ultimately activity-relevant.
Data Mining and Visualization Techniques in
SAR Analysis
Various computational data mining and visualization methods have been devel-
oped to systematically identify interesting SAR features in activity-annotated
compound data sets and present them in an interpretable way [15]. Scopes of
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these methodologies are highly variable, ranging from the mere structuring of
SAR data to the automated extraction of actual SAR information [16]. For ex-
ample, standard clustering which is often applied in the analysis of large screen-
ing data sets makes use of whole-molecule similarity to group structurally simi-
lar compounds together. Often, single clusters contain congeneric series of com-
pounds that show only small structural variations. In these cases, a subsequent
visual inspection of clustered structures may lead to the recognition of SAR pat-
terns, but the retrieval of interpretable SAR information is left to the medicinal
chemist [15,16]. More informative are substructure-centric approaches that pro-
vide direct access to bioactivity values associated with structural fragments. A
data structure called scaffold tree [17] systematically generates molecular build-
ing blocks from sets of bioactive compounds by first pruning all side chains and
then iteratively removing rings from molecular structures. The organization of
the generated substructures in a hierarchy and their annotation with bioactiv-
ity values of the compounds from which they were extracted [18] enables the
identification of activity-prevalent molecular frameworks (also termed scaffolds)
which can subsequently be exploited to design novel active compounds [19].
Such data mining approaches are not limited to the study of compounds sharing
the same bioactivity. For example, the systematic comparison of substructures
across different targets and target families allows to distinguish fragments that
exclusively occur in ligands sharing a specific bioactivity [20,21] from molecular
entities that promiscuously bind to many different targets [22, 23] and pose a
high risk of adverse drug reactions [24]. For later stages of medicinal chemistry
efforts that focus on the optimization of series of structurally similar com-
pounds, understanding potency effects of chemical substitutions is of central
importance. For this purpose, computational approaches have been designed
that either highlight interesting activity patterns for a particular chemotype
under study [25] or systematically investigate effects of common chemical sub-
stituents on ligand potency across different activity classes [26, 27].
Conceptually different from the above mentioned methodologies are so-
called SAR profiling methods that integrate the analyses of the structural simi-
larity of and potency differences between bioactive compounds and characterize
the nature of the SARs underlying a compound set [16]. In principle, three dif-
ferent SAR categories are distinguished [28]. Continuous SARs are found in sets
of compounds where gradual structural changes result in only small to moderate
changes in compound potency, and increasingly diverse structures fall within
the same potency range. In compound sets showing a discontinuous SAR type,
small changes in compound structure lead to large-magnitude changes in po-
tency. Activity cliffs represent the extreme form of SAR discontinuity. However,
continuous and discontinuous SARs are not mutually exclusive and often co-
occur in different subsets of a compound class. The SAR in these data sets is
therefore termed heterogeneous. Knowledge about the SAR type inherent to a
5class of compounds is of paramount importance and of high practical utility.
Whereas discontinous SARs are considered as an indicator for the evolvability
of compound sets and can be used for the prioritization of hits for further opti-
mization, continuous SARs are a prerequisite for the successful applicability of
QSAR and LBVS methods (vide supra). Numerical functions have been devised
to quantitatively describe the nature of SARs [29, 30] and have only recently
been complemented by a number of graphical visualization methods that pro-
vide an intuitive access to global and local SARs underlying compound data
sets and reveal the presence of interpretable SAR rules [31].
Research Topics
In this thesis, various aspects of SAR analysis are investigated and compu-
tational methodologies that aid in the elucidation and exploitation of SAR
information in different ways are presented. These approaches can be grouped
thematically into the four areas of machine-learning, information theory, data
mining, and visualization techniques. In the following, a brief overview of all
research projects presented in this dissertation is given. A classification of the
projects according to key methodological aspects is provided in Table 1.0-1.
Support Vector Machines in Orphan and Potency-
Directed Screening
The term support vector machine (SVM) [32] refers to a machine-learning tech-
nique that has gained wide popularity in LBVS because of its ability to build
complex but robust prediction models. Though originally introduced for classi-
fication, SVMs have been adapted to generate rankings of test databases and
sort compounds by decreasing likelihood of being active [33]. We were interested
in the specific tailoring of SVM strategies to two particularly challenging tasks
in LBVS: orphan and potency-directed screening.
Orphan screening [11] aims at the identification of ligands for targets for
which no known ligands are available. LBVS is usually not applicable in the
absence of known active molecules. However, recent studies have introduced
LBVS approaches that employ ligand information from similar targets to predict
ligands for orphan targets [3437]. Here, the key question is how to best define
target similarity and weight the influence of ligands from different targets in
the prediction model. To address this question, we employed different strategies
to integrate a variety of target similarity functions and/or differently composed
ligand reference sets into SVM learning and systematically compared them in
simulated virtual screening trials on two different target protein systems.
Potency-directed screening approaches the question as to how compound
potency information can be integrated into LBVS as an additional search pa-
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rameter. In contrast to QSAR modeling, LBVS typically does not take com-
pound potency into consideration, although the ability to direct search calcu-
lations towards the recognition of potent hits would certainly be attractive for
practical applications. Therefore, we designed SVM-based strategies that do
not only learn to separate active from inactive molecules but also distinguish
between highly, intermediately, or weakly active compounds by incorporating
categorized potency labels of reference molecules into model training. To assess
their ability to enrich database selection sets with potent hits, the strategies
were benchmarked on four HTS data sets.
Selection of Compound Class-Specific Descriptors
Descriptors that capture compound class-specific and biological activity-relevant
information are of high interest for the exploration of structure-activity relation-
ships and a major determinant for the success of LBVS and QSAR applications.
The identification of compound class-specific information generally requires the
comparison of descriptor value ranges and information content in a set of com-
pounds having a desired property and data sets where all or at least the majority
of compounds lack this property. This is in principle possible through adapta-
tions of the Shannon entropy concept [38] from information theory. However,
previous adaptations of this concept for descriptor profiling are insufficient to
select discriminatory descriptors for data sets that dramatically differ in size.
To circumvent these difficulties, we transformed a previously introduced infor-
mation entropic strategy into mutual information analysis, a related concept,
and investigated its utility to identify discriminatory descriptors on more than
160 activity classes.
Systematic Profiling of Activity Cliffs
Activity cliffs are considered to contain high SAR information content and have
important implications for drug discovery efforts from more than one point
of view (vide supra). Although activity cliffs have been intensely studied in
individual compound sets, an open question is how they are globally distributed
across available bioactive compounds and protein targets. Furthermore, the
frequency of multi-target cliffs, i.e., pairs of similar compounds showing large
potency differences for multiple targets, is currently unknown. Therefore, we
designed and carried out a large-scale data mining study that systematically
searched for single- and multi-target activity cliffs in public domain compounds
with reported activity against human targets.
7Potency Effects of Molecular Transformations
In medicinal chemistry, potency effects of structural modifications are often
studied on a case-by-case basis for series of structurally related compounds.
However, it would also be interesting to know whether certain structural mod-
ifications have a higher propensity to retain or considerably change compound
potency than others, irrespective of the chemotype or specific bioactivity of
the compound they are applied to. To investigate this question, we used the
framework of matched molecular pairs (MMPs) [39] to systematically extract
molecular transformations from publicly available compound data annotated
with activity values against human targets. An MMP is defined as a pair of
two structurally related compounds that differ only at a single localized site
and are hence distinguished by a defined substructure. Hence, a characteris-
tic of an MMP is that the compounds forming the pair are related to each
other by a well-defined transformation. Identified molecular transformations
were then associated with potency changes and defined criteria were applied to
identify chemical substitutions that frequently introduce activity cliffs or con-
sistently produce only small to moderate changes across different compound
classes and biological targets. Furthermore, potency-retaining structural modi-
fications, herein referred to as bioisosteric replacements, were also investigated
at the level of individual target families.
SAR Analysis of Analogous Compound Series
In compound optimization during later stages of medicinal chemistry efforts,
SAR exploration primarily aims at the analysis and design of analogs of ac-
tive compounds with further improved properties. A central issue in lead op-
timization is the improvement of compound potency. SARs for analog series
are traditionally studied using R-group tables that contain the core structure
common to a series of analogs and rows displaying the substituents of indi-
vidual compounds. Although user-friendly extensions of R-group tables have
been developed, SAR features resulting from combinations of R-groups at mul-
tiple substitution sites cannot be analyzed in a straightforward and consistent
manner. For this reason, we aimed to develop a visualization method that is
specifically tailored towards a systematic exploration and intuitive interpreta-
tion of SAR features involving different R-groups and their combinations. To
assess the potential of our newly designed data structure to uncover SAR rules,
we inspected multiple data sets for the occurrence of predefined information-rich
SAR patterns.
Another important theme in lead optimization is the study of molecular
specifity of active compounds. Although many currently marketed drugs are
known to interact with multiple targets [40], cross-reactivity can also lead to
severe side effects and might be a major reason for the failure of many drugs in
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Table 1.0-1: Research projects
methodology projects key aspects
machine-learning 1. orphan screening LBVS, SVM, benchmarking
2. potency-directed screening
information theory 1. selection of compound
class-specific descriptors
information entropic functions for
molecular descriptor profiling
data mining 1. activity cliff profiling large-scale analyses of public
domain compound data2. potency effects of molecular
transformations
3. SAR transfer
visualization SAR analysis in analog series: graphical methods, intuitive
access to information-rich SAR
patterns, derivation of SAR
rules
1. substituent potency effects
2. multi-target SAR
3. SAR transfer
clinical trials [41]. Therefore, rendering compounds with multi-target activity
target-selective is a major goal of chemical optimization efforts and requires the
systematic comparison of SARs for multiple target. However, the computational
study of multi-target SARs (mtSARs) is still in its infancy. To these ends, we
developed a methodological framework for the study of mtSARs that comprises
a uniform R-group decomposition of analogs, their comparison on the basis of
pharmacophore feature edit distances, and their organization in a previously
reported hierachical structure [42] that reflects SAR discontinuity at substitu-
tion sites and their combinations. We then tested the approach for its ability
to identify substitution sites that are selectivity determinants and to determine
preference orders for chemical modifications to improve target selectivity.
In light of the objective of comprehensively improving compound proper-
ties in lead optimization before moving a drug candidate to later stages of drug
discovery, it frequently happens that a compound series displaying an otherwise
promising SAR fails to reach further development, perhaps due to inescapable
metabolic or toxicological issues. In such situations, one would ideally like to
build upon prior knowledge, utilize available SAR information, and evaluate
the possibility of an SAR transfer, i.e., the exploration of an alternative com-
pound series that displays similar SAR characteristics and potency progression
but lacks the liabilities associated with the original chemotype. SAR transfer
is also interesting from the point of view that combining the SAR analyses of
two chemically differently explored series with transferable SAR might reveal
more information than their separate examination. However, a comprehensive
literature search did not reveal computational methods available to aid in the
identification of such parallel series. This motivated us to design a data min-
ing approach that enables the identification of alternative analog series with
9different core structures, corresponding substitution patterns, and compara-
ble potency progression. We applied the methodology to search for alternative
chemotypes for selected analog series and to systematically assess SAR transfer
potential in a public compound repository.
Thesis Outline
This thesis is structured as follows. Chapter 2 introduces fundamental concepts
of molecular representations in chemoinformatics including the linear notation
of molecular graphs, numerical chemical descriptors, and fingerprints. Further-
more, a standard similarity measure for the comparison of small molecule fin-
gerprint representations is briefly described. The second part of the chapter
discusses the increasing availability of public domain bioactivity data and gives
a short overview about major compound databases that are of paramount im-
portance for computer-aided drug discovery and chemoinformatics.
Chapter 3 reports ligand prediction for orphan targets using support vector
machines. First, different approaches to orphan screening are summarized and
an introduction into SVM theory is given. Then our study investigating the role
of target information in finding ligands for orphan targets is reported in detail
and implications of the results for practical applications are discussed.
Chapter 4 describes the adaptation of SVM strategies from orphan screen-
ing to potency-oriented LBVS. The design and results of our benchmark study
on four HTS data sets are presented and the practical utility of potency-directed
SVM strategies for early-stage drug discovery is discussed in light of our find-
ings.
Chapter 5 addresses the selection of descriptors capturing compound class-
specific information. Concepts from information theory are presented and their
potential to identify discriminatory descriptors is compared on a large array of
activity classes. Furthermore, representative examples are chosen to illustrate
benefits and shortcomings of individual methods in detail.
Chapter 6 investigates the occurrence of activity cliffs in public domain
compound data. Special emphasis is put on activity cliff distributions in differ-
ent target families and a frequency analysis of multi-target activity cliffs.
Chapter 7 introduces the concept of matched molecular pairs and highlights
its utility as a consistent reference framework for the identification of molec-
ular transformations. A public domain compound repository is systematically
searched for molecular transformations that are related to resulting potency
changes. Sets of chemical replacements with a high potential to introduce ac-
tivity cliffs or produce compounds with similar potency levels are identified.
Chapter 8 reports a newly designed graph structure representing entire
series of analogs in a consistent manner. Graph components are designed to
represent well-defined SAR patterns and provide immediate access to activity-
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relevant substitution sites and R-group combinations. Exemplary analyses of
different analog series illustrate how SAR determinants are identified on the
basis of interactive graphical analysis and how such insights can be utilized to
design new analogs.
Chapter 9 discusses the adaptation of a previously introduced hierarchical
tree-like graph structure for a parallel SAR analysis of multiple targets. Two
exemplary applications are reported that illustrate the ability of the approach
to derive simple rules for the design of substitutions that are likely to yield
target-selective compounds.
Chapter 10 presents a novel computational approach to study the transfer
of SAR information from one chemical series to another. The new methodology
can be applied to search for alternative analog series if one series is known
or, alternatively, to systematically assess SAR transfer potential in compound
databases. For both settings, exemplary applications are reported. Possibilities
to further rationalize the process of SAR transfer are outlined.
Chapter 11 summarizes major findings and general conclusions of the work
presented in this dissertation.
Chapter 2
Molecular Representations and
Compound Databases
This chapter discusses basic concepts of molecular representations and similar-
ity analysis, which are recurrent themes throughout this thesis, and reports on
public domain repositories of compound structures and activity data as indis-
pensable tools for pharmaceutical research in academic environments.
The analysis of structure-activity relationships requires defined represen-
tations of compounds that can be related to their biological activity. Further-
more, in many instances, the extraction of SAR information from compound
data sets frequently relies on pairwise structural comparisons of small molecules
and, hence, on the application of similarity measures that assess the degree of
structural relatedness between compounds. In this chapter, frequently employed
representations for small molecules are introduced in section 2.1, with a focus
on fingerprint representations and their similarity assessment. Because publicly
available bioactivity data provides essential resources for structure-activity data
mining and the evaluation of chemoinformatics and drug design methods, sec-
tion 2.2 is dedicated to the description of different categories of freely accessible
compound databases.
2.1 Molecular Representations
Probably the most well-known description of compounds is the molecular graph
representation. In a chemical graph, the atoms composing a molecule are rep-
resented as nodes and bonded atoms are connected by edges indicating the
type of bond, e.g., a single, double, or aromatic bond. A graph does not rep-
resent three-dimensional structure information but the topology of a molecule.
The graph can also be annotated with stereochemical information, which de-
fines the relative spatial arrangements of selected atoms. To process and store
molecular graphs on a computer, they are often encoded as connection tables
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that are composed of an atom list and a bond list. In the atom list, the atoms of
the molecules are provided in a sequential order, whereas the bond list specifies
connections between pairs of atoms.
2.1.1 Linear Notation
A more compact and readable description of molecular graphs are linear nota-
tions, such as the popular Simplified Molecular Input Line System (SMILES)
[43], which capture the structure of a molecule in form of an unambiguous
text string using alphanumeric characters. They allow the efficient storage and
fast processing of large numbers of molecules. The SMILES language uses the
following basic rules for encoding molecules [43]:
1. Atoms are represented by their atomic symbols. Hydrogen atoms saturating
free valences are not explicitly denoted.
2. Neighboring atoms stand next to each other and bonds are characterized as
being single (-), double (=), triple (#), or aromatic (:). Single and aromatic
bonds are usually omitted.
3. Enclosures in parentheses specify branches in the molecular structure.
4. For the linear representation of cyclic structures, a bond is broken in each
ring and the connecting ring atoms are followed by the same digit in the
textual representation.
5. Atoms in aromatic rings are indicated by lower case letters.
Figure 2.1-1 uses intuitive examples to illustrate the general concepts of the
SMILES language. Although SMILES strings are unambiguous in the descrip-
tion of chemical structures, they are not unique because multiple valid SMILES
representations exist for the same molecular graph, as also illustrated in Figure
2.1-1. To facilitate the comparison of molecular structures by SMILES rep-
resentations and enable a fast check for molecular identity, algorithms have
been introduced that ensure that the same SMILES string, also termed canon-
ical SMILES, is always calculated for a given molecular graph [44]. Canonical
SMILES strings are often used to ensure uniqueness of molecules in a database.
2.1.2 Molecular Descriptors
The majority of chemoinformatics methods rely on the representation of molec-
ular structure and properties by numerical descriptors. Such descriptors are
suitable as input for statistical and data mining methods. Accordingly, prop-
erty descriptors are frequently employed in diversity analysis, representative
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N C CCC=C N#CC CC(F)CC CC(C)CC(=O)OC
Atoms Bonds Branches
Rings Aromaticity
Clc1cc(Cl)ccc1
c1c(Cl)cccc1Cl
OC1CCCCC1
C1CCCCC1O
c1ccc2ccoc2c1
o1c2c(cccc2)cc1
C1=CCC2CCCCC2C1
C12C(CCCC1)CC=CC2
Figure 2.1-1: SMILES concepts Examples for the illustration of basic SMILES syntax
rules are provided. Each molecular structure is annotated with one or multiple valid SMILES
strings.
compound subset selection, combinatorial library design, and QSAR investiga-
tions.
Literally thousands of different molecular descriptors of greatly varying
mathematical complexity are available [45]. Molecular descriptors are often
classified as one-, two-, or three-dimensional (1D, 2D, or 3D), depending on
the molecular representation from which they are calculated [3]. 1D descriptors
are derived from the chemical formula. Examples include bulk properties, such
as molecular weight, or simple atom counts. 2D descriptors are typically derived
from a molecular graph representation and comprise, for example, topological
descriptors or computational approximations to experimental measurements,
such as solubilities or dipole moments. 3D descriptors are based on molecular
conformations and often account for molecular surfaces, volumes, or surface-
derived properties.
Typically, combinations of many descriptors are calculated for molecular
data sets that then constitute chemical reference spaces where each descriptor
adds a dimension to the space. In this reference space, the position of a molecule
is determined by its descriptor values that serve as coordinates and similarity
between molecules is defined by their spatial proximity that can be calculated
by various measures [6]. Many descriptor spaces that are utilized in chemoin-
formatics are high-dimensional. However, for applications such as compound
classification or QSAR, the dimensionality of chemical reference spaces is often
reduced in order to focus on features that are most descriptive  and predic-
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keyed fingerprint pharmacophore fingerprint
circular fingerprint
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donor
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cationic
anionic
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Figure 2.1-2: Fingerprints (a) In a keyed structural fingerprint, each bit accounts for
the presence of a defined structural fragment. Here, bit positions encoding an aromatic ring,
a carbonyl group, a heteroatom-containing ring, and a nitrogen attached to three carbon
atoms are highlighted. (b) In a pharmacophore fingerprint, each bit accounts for the spatial
arrangement of a defined atomic feature combination. Here, bits that account for defined
geometric arrangements of the combinations donor - acceptor - anionic and donor - acceptor
- cationic are highlighted. (c) In circular fingerprints, local atom environments are mapped
to individual bit positions. Around a selected atom, three circular layers up to a diameter
of four bonds are drawn, and the extracted substructural fragments are shown on the right.
Attachment points constituting non-hydrogen atoms are marked by an asterisk.
tive  for a given data set and to provide a basis for chemical interpretation of
the results.
2.1.3 Fingerprints
Fingerprints are a special form of a complex descriptor capturing feature dis-
tributions as bit string representations [46]. Apart from a general classifica-
tion into 2D and 3D fingerprints in analogy to the categorization for molecu-
lar descriptors, four broad classes of fingerprints are distinguished: keyed and
path-based fingerprints, pharmacophore-based fingerprints, binary circular fin-
gerprints, and circular fingerprints considering counts [47].
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Keyed fingerprints consist of a fixed number of bits where each bit accounts
for the presence (i.e., the bit is set to one) or absence (the bit is set to zero)
of a predefined structural fragment, as shown in Figure 2.1-2a. A popular ex-
ample is the publicly available set of 166 MDL structural keys, also known as
MACCS keys.1 Path-based fingerprints extract all unique linear fragments up
to a prespecified atom number from a molecular graph that are then projected
into a fixed-sized bit vector. Despite their conceptual differences, keyed and
path-based fingerprints were found to produce similar compound rankings in
similarity searching [47].
Figure 2.1-2b illustrates the design principle of a pharmacophore fingerprint
where each bit monitors the presence of a predefined geometrical arrangement
of atomic features. To encode a molecule in this bit string format, each atom is
assigned to one of multiple predefined pharmacophore features (e.g., hydrogen
(H-)bond acceptor or donor) and then all possible combinations of (usually two
to four) pharmacophore features and their (binned) pairwise atom distances are
recorded. In 2D pharmacophore fingerprint design, atom distances are usually
calculated as graph distances (i.e., the number of bonds in the shortest path
between two atoms) whereas 3D pharmacophore fingerprints calculate atom dis-
tances using 3D atomic coordinates. For all spatial feature arrangements present
in a molecule, the relevant bits are set to one. The typed graph distance (TGD)
fingerprint implemented in the chemical computing software Molecular Oper-
ating Environment (MOE) represents a two-point pharmacophore-type finger-
print that is calculated from the 2D molecular graph. It is composed of 420
bits accounting for 15 binned distances between atom pairs in a molecule, with
each atom assigned to one of seven possible features (anion, cation, donor,
acceptor, hydrophobe, polar, none of the aforementioned).
Circular fingerprints are designed to capture local atom environments.
Around each atom in a molecule, circular atom environments up to a speci-
fied bond distance range are calculated, and each resulting structural fragment
is assigned to a fixed position in the fingerprint. Whereas binary circular fin-
gerprints encode only the presence or absence of specific atom environments,
circular fingerprints using counts also consider the frequencies of occurrence
of these environments. Extended-connectivity fingerprints (ECFPs) [48] imple-
mented in the scientific software Pipeline Pilot are currently the most popular
binary circular fingerprints. ECFP4 captures three different substructures with
bond diameters zero, two, and four around each atom of a molecule, as schemat-
ically depicted in Figure 2.1-2c.
Fingerprint comparisons between two compounds are often used to quantify
their molecular similarity. A variety of different similarity coefficients has been
1Symyx Software, San Ramon, CA, USA; URL: http://www.symyx.com/
Software (e.g., for the calculation of fingerprints) and databases used in this work are sum-
marized in Appendix A.
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introduced for this purpose, with the Tanimoto coefficient (Tc) being the most
frequently employed similarity measure for binary fingerprints [46]. For two
molecules A and B, the Tc calculates fingerprint overlap by
Tc(A,B) =
c
a+ b− c (2.1)
where a corresponds to the number of bits set on in the fingerprint representa-
tion of molecule A, b is the number of bits set on in the fingerprint representation
of B, and c reports the number of bits set on in both fingerprints. It follows
that the Tc yields values in the range from zero (minimal similarity) to one
(maximal similarity). The Tc is frequently employed in similarity searching to
assess similarities between reference and test (database) compounds.
2.2 Public Domain Compound Databases
Different from genome sequencing projects that are often carried out by large
publicly funded consortia, most drug discovery-relevant compound data has
been generated in proprietary pharmaceutical environments (although the
amount of data originating from academic settings is currently on the rise).
Consequently, such data have only been sparsely distributed in the public do-
main. Only recently, a few pharmaceutical companies have begun to release
rather significant amounts of small molecule activity data [49]. However, lim-
ited compound data availability has been, and continues to be, a problematic
issue for computer-aided drug discovery and chemoinformatics [50]. Only over
the past few years have public domain data repositories evolved to the extent
that compound data mining is beginning to yield discovery-relevant insights.
One can roughly distinguish between five categories of public domain com-
pound repositories. For each category, prototypic databases are discussed.
1. First, there are collections of largely non-annotated drug-like molecules.
The ZINC database [51] contains millions of compounds offered by chemical
vendors and provides modeled 3D conformations of these molecules.
2. Other databases collect biological screening data. As a consequence of the
Molecular Libraries Initiative of the US National Institutes of Health [52],
the repository PubChem BioAssay [53] has become the major source of
compound screening data.
3. In addition, there are databases compiling drug and clinical trials data in-
cluding, first and foremost, the online resources of the US Federal Drug
Administration2 and also databases such as DrugBank [54].
2http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
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4. A variety of relatively small specialized databases have also been intro-
duced that contain compound information for specific protein families in-
cluding, for example, ligands of G protein-coupled receptors (GPCRs) [55]
or peptide-like and other small molecule inhibitors of proteases [56].
5. Finally, with BindingDB [57, 58] and ChEMBL [59], two large databases
have been introduced that contain activity measurements and target an-
notations for compounds from different stages of medicinal chemistry pro-
grams. In general, the information contained in current ligand-target data-
bases is extracted from the medicinal chemistry literature and patent re-
sources. BindingDB and ChEMBL contain different types of affinity data
(i.e., inhibitor dissociation constants (Ki), half maximal inhibitory concen-
trations (IC50), half maximal effective concentrations (EC50), etc.) for a
broad spectrum of target classes, with inhibitory/antagonistic potency data
for kinases, proteases, and GPCRs being most abundant in both databases.
Importantly, these databases are not only a source of drug discovery-relevant
information, but also research tools for method development in computa-
tional medicinal chemistry and chemoinformatics. The scientific activities
of many academic research groups critically depend on the public avail-
ability of such data and, as detailed later, compound data sets extracted
from BindingDB and ChEMBL have been abundantly used throughout this
thesis.
An important caveat that should be considered when using data from public
compound databases is that molecular representations for compounds from dif-
ferent sources are most likely not consistent. Therefore, all compound data sets
used in projects of this dissertation must be standardized using tools provided
in MOE or Pipeline Pilot. The standardization process includes, for example,
the removal of salts and the protonation of strong bases and deprotonation of
strong acids. Although such modifications might potentially alter activity de-
terminants in molecules, this process is indispensable to ensure uniformness of
molecular representations.
Source Information
Sections of the text in this chapter have been taken from [6062].

Chapter 3
Ligand Prediction for Orphan
Targets
Traditionally, drug discovery research has a strong single-target focus and lead
optimization efforts predominantly aim at the design of target-selective small
molecules for therapeutic intervention [63]. However, evidence is accumulating
that many pharmaceutically relevant compounds do not, as originally thought,
engage in specific single-target interactions but act on multiple targets to elicit
their biological effects [64, 65]. The beneficial effect of multi-target inhibition
can be explained by the finding that single-point modifications of biological
systems are often compensated by other mechanisms [66], which might make
single-target drugs less effective than one might anticipate based on their high
potency values measured in vitro. In light of these observations, the analysis of
compound activity against biological networks becomes increasingly important
and is reflected by the emerging trend in drug discovery to depart from the
single-target focus and test compounds against multiple targets. This approach
is related to chemogenomics [67] that is commonly understood as the systematic
exploration of interactions between all therapeutic protein targets and possible
small molecule drugs.
As alternatives to brute-force compound screening, computational methods
have increasingly been investigated to aid in this process. For example, target
fishing aims at the identification of all likely targets for a small molecule and
involves profiling of compounds against arrays of target-directed computational
models such as Bayesian classifiers [68]. Other studies have employed a more
integrated view on ligand-target interactions. For example, Schuffenhauer et al.
have introduced homology-based similarity searching that investigates how
similarity searching can be utilized to identify ligands interacting with the same
target and also ligands binding to homologous targets [34]. Such studies take
into account that homologous proteins usually have similar binding sites and
therefore also structurally related ligands. This concept is particularly attractive
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for the identification of ligands for orphan targets, i.e., targets for which no
ligand information is available, which was traditionally beyond the scope of
LBVS methods. Furthermore, homology-based similarity searching has recently
been complemented by the adaptation of machine-learning methods to orphan
screening.
In particular, multi-task learning using support vector machines (SVMs)
has produced promising results in simulated orphan screening trials [35,36,69]
and yielded better search performance than homology-based similarity search-
ing in exhaustive benchmark calculations [35]. SVMs were originally developed
for binary object classification. In a typical chemoinformatics SVM applica-
tion, training compounds belonging to two different classes (e.g., active and
inactive) are projected into chemical feature space and the SVM subsequently
derives a hyperplane in this space to separate the two classes. Test compounds
are classified based on which side of the hyperplane they fall. Alternatively, if
the aim is a ranking of the test database, compounds are sorted by their signed
distance to the hyperplane [33, 70]. Furthermore, the use of kernel functions
in SVM learning enables the classifier to derive a more complex (non-linear)
decision boundary and generalize to cases in which the two classes are not lin-
early separable. Kernel functions can also be thought of as similarity functions
that determine how training and test objects are compared in SVM learning
and classification. Multi-task learning tries to improve the generalization per-
formance of a classifier by learning multiple related tasks simultaneously while
using a shared representation of the tasks. Multi-task learning is especially ben-
eficial in comparison to independent training strategies if high commonalities
exist among the learning tasks and training examples for individual tasks are
rare. In the context of chemogenomics and orphan screening, the integration of
multiple related tasks corresponds to the parallel learning of ligand characteris-
tics for multiple targets with the similarity of targets defining the relatedness of
the tasks. Learning in combined target-ligand space can be elegantly achieved
by using `true' and `false' target-ligand pairs as training examples (instead of
active and inactive compounds for a single target) and is facilitated through
the design of target-ligand kernel functions that account for pairwise similarities
of target-ligand combinations. A target-ligand kernel is frequently calculated as
the product of separate kernel functions for pairs of proteins and pairs of ligands.
State-of-the art protein kernels used in ligand prediction include, for example,
a sequence homology-based classification kernel [35]. Furthermore, among var-
ious ligand descriptors that can be used, 2D fingerprints have been found to
be efficient small molecule representations for SVMs [70]. Fingerprint similarity
can be captured, for example, by calculating the scalar product of bit vectors.
However, many other types of kernel functions combining biological target and
chemical ligand information can be envisioned, and one might expect that the
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biological information content captured by the design of such kernel functions
plays a major role for SVM-based ligand prediction.
To investigate the role of kernel functions for the prediction of ligands for
orphan targets, we implemented a variety of target-ligand kernels with a par-
ticular focus on target kernels capturing different types of target information
including sequence, secondary structure, tertiary structure, biophysical prop-
erties, ontologies, or structural taxonomy. Using two different SVM strategies
that learn from multiple targets, these kernels were tested in ligand predictions
for simulated orphan targets in two target protein systems characterized by
the presence of different inter-target relationships [71]. For comparison, we also
implemented a standard SVM trained on compounds active or inactive against
the protein that is most closely related to the orphan target. The methodolog-
ical background, design and results of our study are reported in this chapter.
Section 3.1 gives an introduction to SVM theory. In section 3.2, specific SVM
adaptations to learning from multiple targets are discussed and the three dif-
ferent SVM strategies that we used for orphan screening are presented. Section
3.3 reports the design of different kernel functions that are the focus of in-
vestigation. Section 3.4 presents the study design including the assembly of
appropriate test systems and search calculations that were carried out for test-
ing the various kernel functions in combination with our three different SVM
strategies. Results of our study are reported in section 3.5 and conclusions and
general implications of the results for practical orphan screening are discussed
in section 3.6.
3.1 Support Vector Machine Theory
The term support vector machine refers to a supervised machine learning
technique [32, 72]. A computational model is built based on a training set
to associate class labels of objects with feature vectors. SVM learning for
the purpose of virtual compound screening makes use of training examples
{xi, yi} (i = 1, . . . , n) with xi ∈ Rd being the feature vector (fingerprint rep-
resentation) and yi ∈ {−1,+1} the class label (positive or negative; active or
inactive) of training compound i. An SVM derives the normal vector w (with
Euclidean norm ||w||) and the scalar b (called bias) to define a hyperplane H
that best separates positive from negative training examples:
H : 〈w,x〉+ b = 0 (3.1)
where 〈·, ·〉 defines a scalar product.
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Figure 3.1-1: Maximum margin hyperplane Two classes are separated by the max-
imum margin hyperplane H that is defined by its normal vector w and its distance to the
origin (|b| / ||w||). Support vectors are highlighted in red and located on hyperplanes H1 and
H2 parallel to the decision hyperplane H.
3.1.1 Classification in Original Feature Spaces
For linearly separable training data, an infinite number of hyperplanes exist to
correctly classify the data. As shown in Figure 3.1-1, the hyperplane selected
by the SVM is the one that maximizes the distance (called margin) from the
nearest training data points, thereby minimizing the so-termed structural risk
of overfitting the training data and enhancing the generalization performance
of the classifier. Without loss of generality, the following inequality constraints
to be met by the training data for correct classification can be formulated:
yi (〈w,x〉+ b) ≥ +1 ∀i (3.2)
The molecules for which equality holds in equation 3.2 are nearest to the hyper-
plane H and are termed support vectors. The distance from H to the support
vectors from the positive and the negative training class is 1/ ||w||, meaning that
maximizing 1/ ||w|| or minimizing ||w||, given the conditions in equation 3.2,
yields the maximum margin hyperplane. If a perfect linear separation of train-
ing examples is impossible, no solution for the optimization problem is found.
To overcome this problem, violations of the strict constraints specified in equa-
tion 3.2 are permitted by the introduction of slack variables ξi, which allows
training examples to be located within or on the incorrect side of the margin.
The value of the slack variable ξi correlates with the degree of misclassification
of the incorrectly positioned training compound i, as illustrated in Figure 3.1-2.
A cost factor C is introduced for penalizing training errors and is adjustable to
find a compromise between an optimal fit for the training data and the size of
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the margin. The newly introduced parameters ξi and C lead to the following
reformulation of the minimization problem:
minimize: V (w, ξ) = ||w||2 + C
∑
i
ξi (3.3)
subject to: yi (〈xi,w〉+ b) ≥ 1− ξi with ξi ≥ 0 ∀i (3.4)
Optimization problems under constraints can be solved by the introduction of
Lagrange multipliers [72], which yields a convex quadratic programming prob-
lem amenable to standard methods:
maximize: LD =
∑
i
αi − 1
2
∑
i,j
αiαjyiyj 〈xi,xj〉 (3.5)
subject to:
∑
i
αiyi = 0 with 0 ≤ αi ≤ C ∀i (3.6)
Solving the Lagrangian optimization problem results in the normal vector
w =
∑
i αiyixi with αi being non-negative Lagrange multipliers. Since only
support vectors (i.e., those vectors falling on the edge, within, or on the incor-
rect side of the margin) are assigned factors αi greater than zero, the position of
the hyperplane is exclusively determined by these critical vectors, which facil-
itates computations in high-dimensional feature spaces. Once the optimization
problem formulated in equations 3.5 and 3.6 has been solved and w and b have
been deduced, a test molecule x is classified on the basis of the decision function
f(x) = sgn
( n∑
i=1
αiyi 〈xi,x〉+ b
)
(3.7)
This means that compounds with f(x) = +1 are assigned to the positive class
and those with f(x) = −1 to the negative class. Geometrically, the sign indi-
cates on which side of the hyperplane a test molecule falls.
3.1.2 Classification in Transformed Feature Spaces
In many cases, a planar surface might not be capable of separating the data cor-
rectly. To solve this problem, the data can be projected into a high-dimensional
space H, which might make a linear separation of the training data possible. If
one assumes that the projection is accomplished using a mapping Φ : Rd → H,
then the optimization problem specified in equation 3.5 requires the calcu-
lation of scalar products in H, which is expressed by 〈Φ(xi),Φ(xj)〉. How-
ever, the replacement of scalar products in H by suitable kernel functions, i.e.,
K(xi,xj) =
〈
Φ(xi),Φ(xj)
〉
, removes the need for an explicit formulation of the
high-dimensional feature space H, which is referred to as the kernel-trick [73]
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Figure 3.1-2: Hyperplane for imperfect separation Slack variables (ξi) permit
the misclassification of some training compounds and correlate with their distance to the
margin, as indicated by dashed lines in red.
and illustrated in Figure 3.1-3. The embedding function Φ(x) does not have to
be known because the scalar product in the decision function f(x) can also be
replaced by the kernel function:
f(x) = sgn
( n∑
i=1
αiyiK (xi,x) + b
)
(3.8)
Frequently used kernels for the comparison of fingerprint representations,
also termed ligand kernels Kligand(·, ·) in the following, are the linear kernel (i.e.,
the standard scalar product), the Tanimoto kernel [74] encoding the Tanimoto
coefficient as a kernel function, and the Gaussian or radial basis function kernel
[75].
Klinear(xi,xj) = 〈xi,xj〉 (3.9)
KTanimoto(xi,xj) =
〈xi,xj〉
〈xi,xi〉+ 〈xj,xj〉 − 〈xi,xj〉 (3.10)
KGaussian(xi,xj) = exp
(−γ|xi − xj|2) (3.11)
The Gaussian kernel depends on the parameter γ (also called width) that im-
plicitly regulates the number of support vectors defining the maximum margin
hyperplane. The number of support vectors increases with an increasing value
of γ and raises the risk of overfitting the training data. On the other hand,
selecting a too small value for γ results in a very smooth decision boundary
that does not classify the training data with sufficient accuracy [33]. Hence,
similarly to the cost factor C, the choice of an appropriate parameter value is
critical to SVM classification performance.
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Figure 3.1-3: Kernel trick Data points are projected into a higher-dimensional space
by using the reported embedding function Φ(x). The transformation makes the two classes
linearly separable. For the determination of the decision boundary, scalar products must be
calculated in the transformed feature space. However, the explicit transformation of data
points and subsequent calculation of scalar products in the higher-dimensional space can be
avoided because
〈
Φ(x),Φ(z)
〉
corresponds to and can be replaced by the polynomial kernel
K(x, z) = 〈x, z〉2.
3.1.3 From Classification to Ranking
To adapt SVM to virtual compound screening, the transformation of the clas-
sification into a ranking function is highly desirable. This can be achieved in
a straightforward manner by defining the rank of a test molecule x according
to the distance from its projection Φ(x) to the separating hyperplane deter-
mined in H. Thus, test molecules are ranked from the most distant compound
on the positive half-space to the most distant compound on the negative half-
space. This ranking methodology corresponds to removing the signum function
in equation 3.8 and sorting molecules in decreasing order of
g(x) =
n∑
i=1
αiyiK (xi,x) (3.12)
As a constant term, the bias b can be removed from the ranking function.
3.2 Chemogenomics-Oriented SVM Strategies
In the following, two different SVM strategies that learn from multiple targets
and have previously been applied to orphan screening are briefly explained:
SVM using target-ligand kernel (SVM TLK) and SVM linear combination
(SVM LC). The two strategies are conceptually different since SVM TLK is
a prime example for multi-task learning (vide supra), whereas SVM LC does
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target space ligand space
Kneedle(ti,tj) = 0.26
SSGADYPDELQCLDAPVLSQAKC
NVGKGQPSVLQVVNLPIVERPVC
Kcombined((ti,xi),(tj,xj)) = 0.26 1
target-ligand space
Klinear(xi,xj) = 1
Figure 3.2-1: Target-ligand kernel The comparison of two target-ligand pairs via a
target-ligand kernel function is divided into two independent tasks. In this case, the similarity
of protein targets is quantified by sequence comparison, while ligand similarity is assessed
through comparison of fingerprint representations. The product of the two similarity scores
is taken to recombine target and ligand information. The figure is adapted from [71].
not learn from multiple training sets simultaneously but builds separate classi-
fication models that are subsequently integrated into a single ranking function.
Both methods were found to produce similar results in virtual screening trials
that aimed at enriching small database selection sets with ligands for simulated
orphan targets [35]. Furthermore, a much simpler approach to orphan screening
using a standard binary SVM is introduced.
3.2.1 SVM with Target-Ligand Kernel
In recent chemogenomics-oriented studies [3537], not only compounds but also
true and false protein-compound pairs were used to train SVMs in order to en-
able learning and classification for multiple targets in parallel. For doing so,
scalar products between target-ligand pairs occurring in the objective func-
tion of the SVM optimization problem (equation 3.5) and the decision function
(equation 3.7) are replaced by suitable kernel functions accounting for the sim-
ilarity of protein-small molecule pairs in combined target-ligand space. Anal-
ogously to the mapping of molecules into high-dimensional descriptor spaces,
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a target-ligand pair (ti,xi) is projected into a high-dimensional target-ligand
space using an implicit embedding function Φ(ti,xi) given by the kernel function
Ktarget-ligand
(
(ti,xi), (tj,xj)
)
=
〈
Φ(ti,xi),Φ(tj,xj)
〉
(3.13)
To capture interactions between features of a molecule (represented by feature
vector Φligand(xi) in high-dimensional ligand space) and features of its protein
target (represented by Φtarget(ti) in high-dimensional target space), it was sug-
gested to represent the target-ligand pair by the set of all possible products of
features of the target and the ligand, which corresponds to the tensor product
of their feature vectors [36]:
Φ(ti,xi) = Φtarget(ti)⊗ Φligand(xi) (3.14)
Inserting this definition for Φ(t,x) into equation 3.13 yields
Ktarget-ligand
(
(ti,xi), (tj,xj)
)
=〈
Φtarget(ti)⊗ Φligand(xi),Φtarget(tj)⊗ Φligand(xj)
〉
(3.15)
The application of linear algebra leads to the following factorization of the scalar
product between two tensor product vectors:〈
Φtarget(ti)⊗ Φligand(xi),Φtarget(tj)⊗ Φligand(xj)
〉
=〈
Φtarget(ti),Φtarget(tj)
〉× 〈Φligand(xi),Φligand(xj)〉 (3.16)
Equation 3.16 shows that the comparison of two target-ligand pairs can be re-
duced to the separate assessment of target and ligand similarities in target and
ligand space, respectively, which also avoids the computationally prohibitive cal-
culation of tensor product vectors. The use of kernels functions further reduces
the complexity of the problem and leads to equation 3.17, generally defining
the target-ligand kernel as the product of two separate kernels for the target
pair and the ligand pair:
Ktarget-ligand
(
(ti,xi), (tj,xj)
)
= Ktarget(ti, tj)×Kligand(xi,xj) (3.17)
The design principle of target-ligand kernels is illustrated in Figure 3.2-1. Inde-
pendent kernels for protein and ligand representations are used to account for
pairwise target and ligand similarities and combined to calculate the similarity
of the protein-molecule pairs in target-ligand space.
For orphan screening, a model is built using true and false target-ligand
pairs. The false target-ligand pairs are usually derived by combining the same
targets that are found in the known target-ligand pairs with randomly selected
compounds from the screening database, assuming that most database com-
pounds are inactive. All test compounds are then combined with the orphan
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Figure 3.2-2: Orphan screening with SVM TLK Targets in the reference set
are paired with their known ligands and presumably inactive compounds taken from the
screening database to build positive and negative training examples, respectively, for SVM
learning. A decision boundary is derived in combined target-ligand space. Test compounds
are subsequently paired with the orphan target, projected into target-ligand space, and sorted
by their signed distance to the hyperplane.
target and classified by the derived decision function. Analogously to the trans-
formation applied to conventional small molecule classifiers, a ranking of ligands
for an orphan target can be obtained by sorting the orphan target-ligand pairs
according to their signed distance from the maximum margin hyperplane (see
equation 3.12). Orphan screening using SVM TLK is illustrated in Figure 3.2-2.
3.2.2 SVM Linear Combination
SVM LC was introduced to learn a model for a particular target tj, which
sets it apart from the SVM TLK approach that learns to generally classify
target-ligand pairs as true or false. Nevertheless, SVM LC is distinct from con-
ventional small molecule classifiers in that it makes use of ligand sets with
different bioactivities for learning. For each target ti in the training set, an
individual normal vector wi is calculated by learning a binary SVM classifica-
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learned hyperplane
for target t1
learned hyperplane
for target t2
assumed hyperplane
for orphan target t3
K(t1,t3) = 1
K(t2,t3) = 3
w
1 w2 w3 = 1×w1+ 3×w2
Figure 3.2-3: Orphan screening with SVM LC For each target in the reference set,
an individual SVM model is built. The normal vectors of the decision hyperplanes are then
linearly combined to yield a final SVM model for sorting the test database and prioritizing
molecules for the orphan target. The linear factors for the individual normal vectors are
determined by the similarity of the corresponding reference target to the orphan target, as
measured by a target kernel function. The figure is adapted from [76].
tion function for its ligand set Li (that is used as positive class and combined
with a set of randomly selected database molecules as negative class). The vec-
tor wi corresponds to the normal vector of the maximum margin hyperplane
Hi =
{
x|〈wi,Φligand(x)〉 + b = 0}. For the target of interest tj, a final normal
vector wfinalj is built by linearly combining the individual wi:
wfinalj =
∑
i
s(ti, tj)wi (3.18)
where a similarity function s(ti, tj) is used to determine linear factors for indi-
vidual normal vectors. Hence, the higher the similarity between targets ti and
tj, the more contributes the normal vector wi to the final vector wfinalj . If lig-
ands for tj are available, wj usually contributes most to the model. If tj is an
orphan target, then wfinalj does not contain the term wj, as exemplarily shown
in Figure 3.2-3 for an orphan target t3 and two reference targets t1 and t2. The
similarity function s(ti, tj) can also be thought of as a target kernel function so
that
wj =
∑
i
Ktarget(ti, tj)wi (3.19)
To obtain a compound ranking and prioritize molecules as potential lig-
ands for target tj, test molecules are sorted in descending order of g(x) =〈
wfinalj ,Φligand(x)
〉
.
3.2.3 Homology-Based SVM
A much less complex search strategy for orphan screening is homology-based
SVM, which, as revealed by its name, incorporates design principles of homology-
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based similarity searching. Among all available targets in the training set, the
nearest neighbor, i.e., the target that is most closely related to the orphan
target, is determined. Then the ligand set of the nearest neighbor is used as
positive training class and an arbitrarily chosen subset of the screening data-
base as negative class for deriving a standard SVM ranking function, as given
by equation 3.12.
3.3 Target and Ligand Kernels
We aimed at a systematic investigation of different kernel functions in the three
presented SVM strategies for orphan screening, with a particular focus on target
kernel functions used by SVM TLK and SVM LC. Using fingerprints as small
molecule representations, we considered the linear (equation 3.9) and Gaussian
(equation 3.11) kernel as ligand kernels for our study since they had shown
good search performance for fingerprints in previous virtual screening trials
[33,70,77]. The ligand kernels were complemented by 11 different target kernels.
(a) Uniform kernel between two targets (ti, tj):
Kuniform(ti, tj) = 1 (3.20)
In this case, differences between targets are not considered. For the TLK search
strategy, using Kuniform corresponds to pooling training molecules for all pro-
teins and deriving a standard SVM model on the pooled compounds.
(b) Needle kernel is the percentage sequence identity SI for a protein pair (ti, tj)
computed using the Needleman-Wunsch algorithm for pairwise global sequence
alignment implemented in EMBOSS [78].
Kneedle(ti, tj) = SI(ti, tj) (3.21)
(c) Water kernel. Each protein pair (ti, tj) is also subjected to pairwise lo-
cal sequence alignment using the Smith-Waterman algorithm implemented in
EMBOSS and the alignment scores SSW(ti, tj) are expressed in logarithmic form:
Kwater(ti, tj) = lnSSW(ti, tj) (3.22)
(d) PROFEAT kernel. The PROFEAT server [79] computes 1 447 protein de-
scriptors from protein sequence including descriptors developed by Dubchak et
al. [80] that account for the composition, transition, and distribution of struc-
tural and physicochemical properties, such as hydrophobicity, polarity, charge,
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and solvent accessibility. Each descriptor is separately normalized to the value
range [0,1] and each target ti is represented by a vector ΦP (ti) of 1 447 normal-
ized descriptor values. The PROFEAT kernel is then defined as
KPROFEAT(ti, tj) =
〈
ΦP (ti),ΦP (tj)
〉
(3.23)
(e) Spectrum kernel is a string kernel introduced by Leslie et al. [81]. It compares
sequence strings representing k -mers. Here conventional 3-mers were computed
for target sequences. Each protein ti is represented by a 203 dimensional vector
ΦS(ti) (for 20 amino acids) where each dimension corresponds to a possible
string of three amino acids and reports the count of the number of occurrences
of this fragment in the sequence of ti. To account for different lengths of protein
sequences, the kernel is normalized as follows:
Kspectrum(ti, tj) =
〈ΦS(ti),ΦS(tj)〉√〈ΦS(ti),ΦS(ti)〉 〈ΦS(tj),ΦS(tj)〉 (3.24)
(f) SSEA kernel. For each target, the secondary structure is predicted by
PSIPRED [82] resulting in a string of residues each represented by one of three
letters for the states helix, strand, or coil. Strings for a target pair (ti, tj) are
then globally aligned using the dynamic programming algorithm implemented
in the SSEA web server [83], which yields a score SSSEA(ti, tj) in the range
[0,100]. This score is directly used as target kernel:
KSSEA(ti, tj) = SSSEA(ti, tj) (3.25)
(g) GO kernel. Gene Ontology (GO) [84] terms of the Molecular Function
category are extracted for all protein targets from the UniProt Knowledgebase
[85]. The GO kernel for a target pair (ti, tj) counts the number of identical GO
terms in the GO term sets of ti and tj [86].
(h) Cleavage kernel. Peptidases act on specific substrates and their catalytic
activity is often restricted to specific sequence recognition sites. For all targets,
available cleavage sites of their substrates are extracted from the MEROPS [56]
and CutDB [87] databases that collect cleavage sites in natural and synthetic
substrates. Cleavage site patterns are reduced to two residues on either side
of the scissile bond and for each target ti, a position-specific frequency matrix
is generated. The columns of the matrix are then concatenated to form a 4 ×
20 dimensional feature vector ΦC(ti) and the cleavage kernel is calculated as
follows:
Kcleavage(ti, tj) =
〈ΦC(ti),ΦC(tj)〉√〈ΦC(ti),ΦC(ti)〉 〈ΦC(tj),ΦC(tj)〉 (3.26)
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(i) SCOP kernel. The SCOP database [88] is hierarchically structured into
protein folds, superfamilies, families, and domains and can be represented as a
directed acyclic graph (DAG). For a target ti, ΦSc(ti) contains as many features
as there are nodes in the graph and each feature is set to one if the corresponding
node is part of ti's SCOP hierarchy and zero otherwise. The SCOP kernel is
then defined as follows
KSCOP(ti, tj) = 2
〈ΦSc(ti),ΦSc(tj)〉 (3.27)
(j)Topmatch kernel. All protein targets are represented by a 3D substructure
comprising all amino acids within an 8 Å radius of the target's catalytic residues.
Residues falling within this radius are computed with MOE and then subjected
to structure comparison using TopMatch-web [89]. For a target pair (ti, tj),
TopMatch-web computes a relative similarity score ST within the range [0,100]
that is directly used as the target kernel:
KTopmatch(ti, tj) = ST (ti, tj) (3.28)
(k)MEROPS kernel. The MEROPS database [56] is hierarchically structured
into catalytic types, so-called protein clans, families, and subfamilies and can
also be visualized as a DAG. Hence, ΦM(ti) can be defined analogously to ΦSc(ti)
and the MEROPS kernel is given by
KMEROPS(ti, tj) = 2
〈ΦM (ti),ΦM (tj)〉 (3.29)
A note on the general validity of the kernel functions is found in Appendix B.
3.4 Data and Calculations
We applied the three different SVM strategies using the described kernel func-
tions to search for inhibitors of individual proteases in two different target sets
that were regarded as orphan targets and hence not included during SVM learn-
ing.
3.4.1 Target and Ligand Systems
Two sets of reference targets were assembled that represented different degrees
of inter-target relationships. The first target set included 12 proteases belonging
to nine different families (Table 3.4-1) and showing four different catalytic mech-
anisms: cathepsin D and renin are aspartate proteases; thrombin and trypsin are
serine proteases; cathepsin L, calpain 2, and caspase 3 are cysteine proteases;
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and matrix metalloproteases 2 and 8, methionyl aminopeptidase 2, glutamate
carboxypeptidase 2, and angiotensin-converting enzyme 2 are metalloproteases.
Proteases possessing the same catalytic machinery can either be closely or dis-
tantly related in sequence, as illustrated in Figure 3.4-1, which organizes targets
into clans, families, and subfamilies following the classification scheme of the
MEROPS peptidase database. Based on the MEROPS hierarchy, the nearest
neighbor target for each protease in our test set was determined. If several
nearest neighbor candidates were suggested for a given target based on the
MEROPS hierarchy, the protease with highest sequence identity to the target
was chosen. For all 12 targets, ligand sets were assembled from the MDL Drug
Data Report (MDDR), a commercial database storing structural and activity
data for biologically relevant compounds, BindingDB, and original literature
sources. In total, 1 359 different protease inhibitors were collected. As reported
in Table 3.4-1, each ligand set contained between 14 and 281 compounds having
a potency of at least 1 µM (Ki or IC50) against the target. Ligand sets were
mutually exclusive in their composition, i.e., a compound reported to inhibit
multiple protease targets was only assigned to the target it was most potent
against.
The second target set included 11 proteases and was taken from [35]. These
targets included the cysteine proteases calpain 1 and 2, caspase 1 and 3, and
Table 3.4-1: Target and ligand data set 1
target abbr. MEROPS ID PDB
entry
#ligands NN tar-
get
angiotensin-converting enzyme 2 ace2 M02.006 1r42 28 mmp2
calpain 2 cal2 C02.002 1kfu 49 catL
caspase 3 cas3 C14.003 1cp3 264 catL
cathepsin D catD A01.009 1lyb 70 ren
cathepsin L catL C01.032 1mhw 78 cal2
glutamate carboxypeptidase 2 mgcp M28.010 2oot 14 mmp8
methionyl aminopeptidase 2 metap2 M24.002 1b6a 254 mgcp
matrix metalloprotease 2 mmp2 M10.003 1qib 83 mmp8
matrix metalloprotease 8 mmp8 M10.002 1bzs 16 mmp2
renin ren A01.007 2ren 164 catD
thrombin thr S01.217 1ppb 281 try
trypsin try S01.127 1trn 58 thr
For each target protein, a target name abbreviation (abbr.), its MEROPS identifier (ID), a
corresponding Protein Data Bank (PDB) [90] entry, the number of ligands (#ligands), and
the nearest neighbor (NN) target are reported. The MEROPS identifier is composed of a
family-based component (e.g., thrombin and trypsin both belong to the family S01) and an
individual target-based component. The PDB entry refers to the 3D protein structure used
in calculating the Topmatch kernel and is cross-linked to the SCOP entry used in calculating
the SCOP kernel.
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Figure 3.4-1: Target
relationships The
relationships between the
proteases in the target
sets 1 (top) and 2 (bot-
tom) are illustrated. The
MEROPS classification
scheme (i.e., type, clan,
family, and subfamily)
is applied. From the
subfamily to the type
level, target similarity is
fading away. The figure
is adapted from [71].
cathepsin B, L, K, and S, and the serine proteases factor Xa, thrombin, and
trypsin, as summarized in Table 3.4-2. Relationships between these targets are
also illustrated in Figure 3.4-1. Ligand sets for these targets were assembled as
described above. For proteases shared among both test systems (i.e., calpain 2,
caspase 3, cathepsin L, thrombin, and trypsin), the same ligand sets were used.
As reported in Figure 3.4-1, the inter-target and nearest neighbor relationships
differed between target sets 1 and 2. Whereas each target in set 2 had a nearest
neighbor that belonged to the same subfamily, several targets in set 1 had
nearest neighbors sharing the same catalytic mechanism, but lacking further
evidence of evolutionary relationships. The different inter-target relationships
found in data sets 1 and 2 were explored in SVM modeling and ligand-target
prediction.
3.4.2 Search Calculations
The performance of alternative kernel functions and SVM ranking strategies
was evaluated in systematic search calculations on the two protease systems.
All proteases of a system were in turn regarded as orphan targets and hence not
included during SVM learning. The model was built on the remaining targets
and their ligand sets in the system. As a background database for SVM analysis,
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Table 3.4-2: Target and ligand data set 2
target abbr. MEROPS ID PDB entry #ligands NN target
calpain 1 cal1 C02.001 1tlo 46 cal2
calpain 2 cal2 C02.002 1kfu 49 cal1
caspase 1 cas1 C14.001 1ice 21 cas3
caspase 3 cas3 C14.003 1gfw 264 cas1
cathepsin B catB C01.060 1gmy 17 catS
cathepsin K catK C01.036 1yk7 223 catS
cathepsin L catL C01.032 1mhw 78 catK
cathepsin S catS C01.034 1ms6 221 catK
factor Xa faXa S01.216 1mq5 783 thr
thrombin thr S01.217 1ppb 281 faXa
trypsin try S01.127 1trn 58 faXa
For each target protein, a target name abbreviation (abbr.), its MEROPS identifier (ID), a
corresponding Protein Data Bank (PDB) entry, the number of ligands (#ligands), and the
nearest neighbor (NN) target are reported.
100 000 compounds were randomly chosen from the ZINC database. MACCS
structural keys and the TGD fingerprint were used as ligand descriptors.
For each reported combination of kernel function(s) and SVM strategy, ten
different randomly selected training and test sets were studied for each simu-
lated orphan target and the search results were averaged. As negative training
examples, 1 000 database compounds were randomly selected in each case. For
SVM TLK, the 1 000 compounds were combined with each reference target to
build false target-ligand pairs, and for SVM LC, they served as negative training
class for each individual model. For simple SVM calculations on each target,
five inhibitors of the nearest neighbor target were used as positive training
molecules, while for SVM TLK and LC five for each of the remaining targets in
the protease set were used. The inhibitor set of the orphanized target was not
used during SVM learning but added to the background database as potential
database hits during testing. As a measure of performance, recovery rates (num-
ber of correctly identified orphan target inhibitors divided by their total number
in the test database) were calculated for database selection sets of increasing
size and averaged over the ten independent trials per target. All calculations
were carried out using SVMlight, a freely available SVM implementation [91].
With exception of the parameter γ in the Gaussian kernel that was set to 0.01
after preliminary test calculations, all calculation parameters were SVMlight de-
fault settings to ensure reproducibility of the calculations. Perl scripts were
applied to calculate SVM linear combinations and analyze the results.
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Table 3.5-1: Search results for ligand prediction using homology-based
SVM (set 1)
MACCS TGD
lineara Gaussiana lineara Gaussiana
100b 1000b 100b 1000b 100b 1000b 100b 1000b
ace2 0.0 0.9 0.0 0.9 0.9 14.8 0.4 17.4
cal2 19.1 60.2 22.1 63.4 4.8 30.7 5.0 30.2
cas3 2.6 9.5 2.4 10.0 0.6 8.5 0.2 5.4
catD 15.4 51.5 16.0 54.5 40.5 72.2 38.6 77.1
catL 10.4 34.7 10.0 35.1 8.0 23.6 6.2 25.2
mgcp 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
metap2 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0
mmp2 49.6 77.1 54.7 78.7 75.6 94.0 77.6 95.3
mmp8 49.1 59.1 50.9 59.1 57.3 67.3 57.3 68.2
ren 30.3 57.9 32.0 58.2 44.3 59.1 41.3 59.9
thr 27.7 70.3 28.0 71.3 28.9 80.5 29.7 81.1
try 36.9 61.4 38.5 61.2 46.9 74.4 46.2 78.7
average 20.1 40.3 21.2 41.0 25.6 43.8 25.2 44.9
a Kernel. b Set size. Recovery rates (in %) are reported for all targets in data set 1 averaged
over ten independent trials per target. Target abbreviations are used according to Table 3.4-1.
The results reported for the Gaussian kernel were obtained with the parameter γ set to 0.01.
3.5 Results
The results of systematic search calculations are described in the following.
First, global kernel performance was assessed. Then target- and set-specific
differences in prediction rates for alternative target-ligand kernels and the de-
pendence of successful ligand prediction on the nearest neighbor reference target
of a simulated orphan target were investigated.
3.5.1 Global Kernel Performance
We first investigated the relative performance of ligand kernels in homology-
based SVM calculations searching for active compounds of orphan targets. Table
3.5-1 reports compound recovery rates for activity classes of target set 1, the
MACCS and TGD fingerprints, and database selection sets of 100 and 1 000
compounds. In these calculations, both ligand kernels produced comparable
recovery rates. In some instances, the search calculations failed for any kernel
and in others, high recovery rates were consistently observed. Because there
was no apparent preference for a ligand kernel in our test calculations, we
selected the linear kernel that has lower computational complexity for further
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Figure 3.5-1: Global kernel performance (set 1) For the MACCS and TGD fin-
gerprints, recovery rates for SVM TLK and LC strategies are shown for 11 alternative target
kernels and selection sets of 100 database compounds. Recovery rates are averaged over all
12 targets and ten independent search trials per target. The figure is adapted from [71].
calculations and combined this kernel with the 11 different target kernels for
SVM TLK and LC ligand prediction calculations.
For the 11 different target-ligand kernel combinations, average results for
target set 1 and selection sets of 100 database compounds are shown in Figure
3.5-1 and Appendix Tables B-1 and B-2 report recovery rates on a per target
basis. The SVM TLK and LC search strategies were found to produce similar
compound recovery rates of approximately 8% to 28% for both fingerprints and
all target kernels for a database selection set size of 100 compounds. By and
large, there was relatively little variation in kernel performance, much less so
than anticipated given the significant differences in target kernel complexity
and encoded protein information. The PROFEAT kernel, which is based on
biophysical descriptors calculated from protein sequence, did not produce higher
recovery rates than the uniform kernel that does not take protein similarity
into account and hence served as a reference for target kernels. Differences in
kernel performance were rather subtle but the overall highest recovery rates
were achieved with the MEROPS kernel that encodes a hierarchical protein
organization scheme.
Equivalent observations were made for target set 2. Figure 3.5-2 reports
average results of the search calculations on set 2 and Appendix Tables B-3
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Figure 3.5-2: Global kernel performance (set 2) Search results for target set 2
are shown corresponding to Figure 3.5-1. The figure is adapted from [71].
and B-4 report recovery rates on a per target basis. In this case, the recovery
rates were generally higher than for set 1, ranging from approximately 18%
to 33%, but differences between SVM search strategies and alternative kernels
were even smaller than those observed for target set 1. The uniform kernel
produced average recovery rates of close to 20% and several kernels taking
protein similarity at different levels into account performed only slightly better.
Here, the hierarchical SCOP and MEROPS kernels and the Topmatch kernel
that is based on active site structural similarity performed equally well, but only
slightly better than the sequence similarity-based needle kernel. Thus, taken
together, the results of systematic SVM calculations on our two target sets
revealed surprisingly little differences in search performance for target kernels
of different design.
3.5.2 Target-Dependent Kernel Performance
As described in section 3.3, the overall best-performing MEROPS kernel dif-
fers from other target kernels in that it assigns high weights to closely related
targets, due to its exponential formalism (see equation 3.29). In order to ex-
plore the contributions of the most closely related targets to ligand recovery, we
analyzed the search performance for all individual set 1 targets in SVM TLK
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Figure 3.5-3: Target-dependent kernel performance (set 1) For all targets
of set 1, recovery rates are shown for homology-based SVM ranking and for the SVM TLK
search strategy in combination with the MEROPS target kernel. Recovery rates are compared
for selection sets of 100 compounds averaged over ten independent trials per target. Target
abbreviations are used according to Table 3.4-1. The figure is adapted from [71].
calculations using the MEROPS kernel and, in addition, homology-based SVM
calculations. In the latter case, the SVM was trained on the ligands of the target
most closely related to the orphanized target. The results of these SVM TLK
and homology-based SVM calculations are shown in Figure 3.5-3. Significant
differences in target-dependent search performance were observed. The search
performance was found to be highly dependent on the degree of relatedness
between the orphan target and its nearest neighbor. For those targets having
a closely related nearest neighbor at the subfamily level (i.e., cathepsin D and
renin, matrix metalloproteases 2 and 8, thrombin and trypsin; see Figure 3.4-1),
highest recovery rates were observed. For these targets, simple SVM calcula-
tions using the ligands of the nearest neighbor as positive training examples
matched the performance of SVM TLK calculations using the MEROPS ker-
nel. By contrast, homology-based SVM calculations produced only low recovery
rates, or failed, for targets that had no closely related neighbor (i.e., all cysteine
proteases in set 1, methionyl aminopeptidase 2, glutamate carboxypeptidase 2,
and angiotensin-converting enzyme 2; see Figure 3.4-1). The cumulative recall
curves shown in Figure 3.5-4a and 3.5-4b illustrate the close correspondence be-
tween homology-based SVM and SVM TLK calculations when a closely related
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Figure 3.5-4: Cumulative
recall curves Representative re-
call curves for homology-based
SVM and SVM TLK in combi-
nation with the MEROPS kernel
are shown for three targets, (a)
cathepsin D, (b) matrix metallo-
protease 2, and (c) calpain 2, us-
ing TGD as the ligand descriptor.
Recovery rates are averaged over
ten independent trials per target.
Target abbreviations are used ac-
cording to Table 3.4-1. The figure
is adapted from [71].
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nearest neighbor target was available. However, Figure 3.5-4c shows that taking
additional target and ligand information into account when no closely related
neighbor was available further improved the search performance, a trend that
was especially observed for larger database selection sets.
Different from target set 1, each target in set 2 had a nearest neighbor at
the subfamily level (Figure 3.4-1). Accordingly, one would expect better target-
dependent search performance for targets in set 2 than in set 1. The SVM TLK
search calculations with the MEROPS target kernel shown in Figure 3.5-5 con-
firm this expectation. The majority of targets in set 2 produced recovery rates
of at least 20% (with the MACCS fingerprint as ligand representation). In this
case, SVM control calculations were also carried out after pooling the ligands
of all members of the orphan target's subfamily for training. As illustrated in
Figure 3.5-5, the recovery rates observed in these SVM control calculations were
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Figure 3.5-5: Target-dependent kernel performance (set 2) For all targets
of set 2, recovery rates are shown for simple SVM ranking and for the SVM TLK search
strategy in combination with the MEROPS target kernel. For simple SVM ranking, ligands
of all members of the orphanized target's subfamily were pooled and used as the positive
training class. Recovery rates are shown for a selection set of 100 compounds averaged over
ten independent trials per target. Target abbreviations are used according to Table 3.4-2.
The figure is adapted from [71].
almost indistinguishable from those of SVM TLK calculations. Furthermore, in
Appendix Table B-5, recovery rates for standard SVM calculations on set 2
targets are reported for selection sets of 100 compounds when either only lig-
ands of the nearest neighbor target were used for training (i.e., homology-based
SVM) or, alternatively, ligands of all subfamily members were pooled. The re-
sults demonstrate that recovery rates for targets having several closely related
subfamily members further improved when ligands from all related targets were
taken into account compared to ligands of only the most closely related target.
3.5.3 Nearest Neighbor Effects
The findings discussed above reflect a strong influence of ligand information of
nearest neighbor targets on ligand prediction for orphanized targets. In order
to evaluate the magnitude of nearest neighbor effects, SVM TLK calculations
using the MEROPS kernel were also carried out after removal of the ligands
of the nearest neighbor target from SVM learning. The search results for set 1
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Figure 3.5-6: Dependence of search performance on ligands of nearest
neighbor targets For all set 1 targets, search results are reported for the SVM TLK
search strategy in combination with the MEROPS kernel. Green bars show recovery rates
obtained by learning with ligands of all reference targets, whereas yellow bars show recovery
rates obtained when the ligands of the nearest neighbor are excluded from the training set.
Recovery rates are shown for a selection set of 100 compounds averaged over ten independent
trials per target. Target abbreviations are used according to Table 3.4-1. The figure is adapted
from [71].
targets are shown in Figure 3.5-6 and Appendix Table B-6 reports the compar-
ison of SVM TLK and LC calculations. As can be seen in Figure 3.5-6, removal
of ligands led to a sharp decline in recovery rates when a nearest neighbor tar-
get was available at the subfamily level (effects observed in SVM TLK and LC
calculations were similar). By contrast, removal of ligands for targets where no
closely related neighbor was available had only little influence on the search
performance. Thus, these findings further corroborated the crucial role of near-
est neighbor ligand information for orphan target ligand prediction using SVM
techniques.
3.6 Conclusions
In this chapter, we have investigated different strategies for SVM-based ligand
prediction for simulated orphan targets with special emphasis on the evalua-
tion of alternative target kernel functions that capture protein information at
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different levels. Information about orphan targets was not included in SVM
model building. Thus, the approaches investigated here aimed at de novo lig-
and predictions. The way target information was taken into account presented a
major variable in these calculations and, accordingly, target kernels of different
complexity and information content were designed and evaluated. Surprisingly,
these alternative kernel functions influenced the calculations much less than
one might anticipate. Rather, nearest neighbor effects were found to be the
major determinant of ligand prediction performance. In particular, when lig-
and information from one or more closely related targets was available, simple
SVM calculations utilizing this information met the search performance of SVM
TLK and LC calculations. For SVM-based ligand prediction on orphan targets,
these findings have significant implications. Rather than focusing on informa-
tion provided by reference systems capturing protein hierarchies, searching for
targets with known ligands that are closely related to orphan targets (e.g., at
the subfamily level) should be a primary objective. For this purpose, simple de-
tection of sequence similarity might often be sufficient. In the presence of strong
nearest neighbor relationships, SVM-based strategies for ligand prediction can
be simplified. In these cases, simple SVM calculations using nearest neighbor
ligands for learning are expected to produce promising results. By contrast, if
no closely related targets can be identified, SVM learning using target kernels
capturing protein hierarchy information is likely to be a preferred approach.
Thus, SVM strategies for ligand prediction can be adjusted based on an initial
exploration of target relationships.
Source Information
Sections of the text in this chapter have been taken from [71,77].

Chapter 4
Preferential Detection of Potent
Hits in Ligand-Based Virtual
Screening
Many ligand similarity-based methods exist that are utilized to mine databases
for novel active compounds. However, with the exception of QSAR models,
these approaches typically do not consider compound potency as search in-
formation [5]. Thus far, it has only rarely been attempted to incorporate po-
tency information into LBVS search algorithms [92], although search strategies
tailored to the preferential detection of potent hits would certainly be highly
attractive for practical applications.
Potency information has recently been integrated into an SVM-based
approach to the prediction of selectivity toward human adenosine receptors
(hARs) [93]. Here, a multi-label approach (termed ct-SVM) was used to con-
struct a single model integrating binary classifiers for four different hAR sub-
types. Furthermore, three models based on increasingly strict criteria for thresh-
old activity (i.e., Ki threshold values of 500, 250, and 100 nM) were applied
sequentially to quantify the biological affinity of test compounds. This analysis
demonstrated that SVM-based classification provides an interesting alternative
to traditional regression-based QSAR modeling. This study aimed at the an-
notation of test compounds with predefined potency ranges and represents a
non-QSAR SVM-based classification of different biological activity levels.
Considering the learning from multiple classes with different affinity ranges
as a typical multi-task problem, we decided to adapt the different SVM strate-
gies presented in Chapter 3 to potency-directed virtual screening. For this pur-
pose, we developed a new structure-activity kernel function and constructed a
potency-oriented SVM linear combination that were tested on different public
domain screening data sets and compared to conventional SVM ranking [76], as
reported in this chapter. Section 4.1 describes the composition of the test data
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sets, the applied SVM strategies, and search calculations. In section 4.2, the
performance of the three SVM search strategies in the benchmark calculations
is reported and conclusions of the study are discussed in section 4.3.
4.1 Data, Search Strategies, and Calculations
To provide a practically relevant search scenario, four different HTS sets were
selected as test data sets for the evaluation of our two potency-directed SVM
search strategies. Furthermore, a standard binary SVM was included as control
in the search calculations to set a baseline performance expectation.
4.1.1 High-Throughput Screening Data Sets
The four HTS data sets were extracted from PubChem BioAssay and in-
cluded inhibition assays for enzyme targets hydroxyacyl-coenzyme A dehydro-
genase type II (assay identifier (AID) 886), 15-human lipoxygenase (AID 887),
15-hydroxyprostaglandin dehydrogenase (AID 894), and aldehyde dehydroge-
nase 1 (AID 1030). All assays were designated as confirmatory assays, indicating
that compounds had been tested at different concentrations to generate dose-
response curves. Compound potencies were reported as half-maximal inhibitory
concentrations (IC50 values). Compounds with incomplete or ambiguous activ-
ity annotations were removed from these data sets. Then, a 2D unique version
of each compound set was generated, i.e., stereoconfigurations of molecules were
ignored and of compounds sharing the same 2D graph only the one with highest
potency was retained. The composition of the so-prepared compound data sets
is summarized in Table 4.1-1. It should be emphasized that active compounds
in all four data sets covered wide potency ranges of more than three orders of
magnitude. Furthermore, in each data set, there were many more weakly than
highly potent compounds and, in addition, many more inactive than active com-
pounds. Thus, for potency-directed LBVS, these data sets provided challenging
test cases. For each data set, potency intervals were defined to divide active
compounds into four potency categories, termed C1C4, with potency values
decreasing from C1 to C4. For each category, the negative decadic logarithm of
the potency value of its lower potency threshold was calculated and used as its
annotation, pAct, as also reported in Table 4.1-1.
4.1.2 Support Vector Machine Search Strategies
We investigated standard SVM calculations as well as two potency-directed
SVM techniques including a structure-activity kernel taking reference com-
pound potency differences directly into account and, in addition, a linear com-
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Table 4.1-1: Data sets
AID target #act #inact range pAct cat #mol #ref
886
hydroxyacyl-
coenzyme A
dehydrogenase type II
2 409 68 845
10100 nM 7 C1 20 5
100 nM1 µM 6 C2 128 32
110 µM 5 C3 803 200
10100 µM 4 C4 1 458 364
887
15-human
lipoxygenase
998 70 822
2200 nM 6.7 C1 16 5
200 nM2 µM 5.7 C2 93 29
220 µM 4.7 C3 711 222
20200 µM 3.7 C4 178 55
894
15-hydroxy-
prostaglandin
dehydrogenase
6 318 139 805
1100 nM 7 C1 12 5
100 nM1 µM 6 C2 115 47
110 µM 5 C3 1 452 605
10100 µM 4 C4 4 739 1 974
1030
aldehyde
dehydrogenase 1
15 817 197 666
10100 nM 7 C1 138 5
100 nM1 µM 6 C2 946 34
110 µM 5 C3 6 091 220
10100 µM 4 C4 8 642 313
For four confirmatory high-throughput screening data sets, the numbers of active (#act) and
inactive (#inact) compounds are reported. For each data set, the potency ranges (range) of
the four categories C1-C4 (cat) into which active compounds were divided and the potency
threshold values pAct are given. Furthermore, the numbers of molecules per potency category
(#mol) and reference compounds (#ref) taken from each category are reported.
bination of different SVM hyperplanes derived for reference compounds falling
into different potency ranges.
4.1.2.1 Standard SVM
For standard SVM calculations, compound training sets of different composi-
tion are used. First, active reference compounds from all potency categories are
pooled to provide the positive training class, and confirmed inactive molecules
are used as the negative training class, as shown in Figure 4.1-1 on the left. Then
the maximum margin hyperplane is derived and test molecules with unkown
activity status are ranked by their signed distance to the decision boundary
(equation 3.12). This SVM strategy is named SVMpooled. Furthermore, for con-
trol calculations, positive reference sets exclusively containing highly potent
compounds are also utilized, as illustrated in Figure 4.1-1 on the right. A stan-
dard SVM using positive reference sets consisting only of compounds taken
from the potency range C1 is termed SVM1Cat. Accordingly, a standard SVM
with active training compounds falling into the categories C1 and C2 is referred
to as SVM2Cat.
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actives
ranking
direction 
high low
potency
inactives
Figure 4.1-1: Standard SVM In SVMpooled (left), known active compounds from all
potency categories are pooled to form the positive training set, and confirmed inactive com-
pounds constitute the negative training class. Test compounds are ranked according to their
signed distance from the hyperplane represented by the arrow. For control calculations (right),
only reference compounds from the two highest potency categories are used as positive train-
ing examples. The figure is adapted from [76].
4.1.2.2 SVM Linear Combination
SVM LC is adapted for potency-directed SVM searching. Therefore, for each
potency category Ci, a hyperplane is constructed using known active ligands
of Ci as positive training objects and inactive reference compounds as negative
examples. To obtain one overall ranking function, the individual normal vectors
wi of all hyperplanes are then linearly combined to a single vector wcombined by
applying
wcombined =
n∑
i=1
fiwi with fi = ai − min
j=1,...,n
(aj) + 1 (4.1)
where fi denotes the linear factor, ai the pAct of potency category Ci, and n
the total number of categories. Test compounds are then ranked by g(x) =〈
Φ(x),wcombined
〉
. For this strategy termed LCsimple, fi increases linearly with
the pAct of the potency category Ci. To further increase weights on highly
active compounds, the LCsquared strategy is introduced that utilizes the square
product of the linear factors used in LCsimple as the potency category-specific
weight for the linear combination:
wcombined =
n∑
i=1
fiwi with fi =
(
ai − min
j=1,...,n
(aj) + 1
)2
(4.2)
4.1.2.3 SVM with Structure-Activity Kernel
In analogy to the target-ligand kernel discussed in Chapter 3, we designed a
structure-activity kernel (SAK). For SVM using the SAK in learning and rank-
ing (SVM SAK), we represent each compound i as a fingerprint-potency cate-
gory pair (xi, ai). Accordingly, the comparison of two compounds is divided into
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a separate assessment of their structural similarity and their activity similarity
by two different kernel functions Kstructure and Kactivity that are then combined
to build the SAK:
K
(
(xi, ai), (xk, ak)
)
= Kstructure(xi,xk)×Kactivity(ai, ak) (4.3)
The design principle of the SAK is illustrated in Figure 4.1-2. To make SVM
SAK directly comparable to SVM LC (vide infra), the activity kernel is defined
as
Kactivity(ai, ak) = max
j=1,...,n
(aj)− min
j=1,...,n
(aj) + 1− |ai − ak| (4.4)
for the approach SAKsimple or as
Kactivity(ai, ak) =
(
max
j=1,...,n
(aj)− min
j=1,...,n
(aj) + 1− |ai − ak|
)2
(4.5)
for the approach SAKsquared. As in equations 4.1 and 4.2, ai denotes the pAct
of potency category Ci and n the total number of categories.
For SVM training, positive training objects are obtained by combining the
fingerprint combination of each known active compound with its potency cat-
egory threshold value and negative training examples by combining the finger-
print representation of inactive reference compounds with all possible potency
category threshold values. Then a hyperplane is derived to separate true com-
pound fingerprint-potency pairings from false pairing (Figure 4.1-2). For the
classification of molecules with unknown activity, test compounds are assigned
the threshold value ahigh of the highest potency category, i.e., ahigh = max(aj),
and a ranking is generated by determining the signed distance from the pairs
(x, ahigh) to the hyperplane H derived in structure-activity reference space. Test
compounds are paired with ahigh because we aim at the detection of potent hits
and want to sort test compounds according to their likelihood of belonging to
the highest potency category. It should be noted that, by setting ak to ahigh, the
kernel function Kactivity(ai, ak) becomes identical to the factor fi in the linear
combination.
4.1.3 Search Calculations
The performance of the alternative SVM ranking strategies was evaluated in
search calculations on the four PubChem HTS data sets. Compounds were en-
coded as MACCS or ECFP4 bit strings. To compare fingerprint representations,
the Tanimoto kernel (see equation 3.10) was utilized. For test calculations, ref-
erence compound sets were assembled to reflect the potency distribution in
each data set. Accordingly, five compounds belonging to the highest potency
category were randomly selected in each case and reference compounds of the
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activity space structure space
Kstructure(x1,x2) = 0.4Kactivity(a1,a2) = 0.59
IC50
Kcombined((a1,x1),(a2,x2)) = 0.59   0.4
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Figure 4.1-2: SVM with structure-activity kernel The comparison of two
fingerprint-potency category pairs is divided into two independent tasks such that the struc-
tural similarity and activity similarity of two compounds are first separately determined and
then combined. A hyperplane is constructed to separate true fingerprint-potency category
pairings from false pairings. The figure is adapted from [76].
other categories were chosen such that the reference-to-test molecule ratio was
approximately the same for all potency categories, as reported in Table 4.1-1.
Positive training classes mirroring the potency distribution of a data set are
termed potency-balanced. Control calculations were carried out with reference
sets containing only highly potent compounds. These biased reference sets were
used to evaluate whether potent reference compounds would lead to the prefer-
ential detection of potent hits. For all assays and SVM strategies, 1 000 inactive
compounds were taken as negative training examples. All remaining molecules
from each data set were utilized as screening database. For each combination of
a search strategy and fingerprint, ten different trials with randomly assembled
reference and test sets were carried out. As a measure of performance, recovery
rates were calculated for database selection sets of increasing size and averaged
over the ten independent trials per target.
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All calculations were carried out using SVMlight with default settings for
calculation parameters and Perl scripts were applied to calculate SVM linear
combinations and organize the results.
4.2 Results
With our study, we aimed to investigate whether compound potency could be
incorporated as a search parameter in SVM-based virtual screening to further
refine search calculation.
4.2.1 Search Performance
We first compared our three alternative SVM strategies for potency-balanced
reference sets. The results for ECFP4 and MACCS representations are reported
in Figure 4.2-1 and Appendix Figure C-1, respectively. In these figures, com-
pound recall of all active compounds (regardless of their potency) and of the
most potent compounds (categories C1, C2) is separately monitored. Com-
pound recall was generally higher for ECFP4 than for MACCS. Overall, the
average recovery rates of all active compounds were comparable for standard
SVM (SVMpooled) and advanced SVM strategies. However, in all cases, SVM
SAK and LC calculations were found to retrieve a higher percentage of highly
potent compounds than standard SVM calculations. Although search results for
SVM SAK and LC were very similar, some underlying trends and character-
istics of the individual methods were detected. Independent of the fingerprint
representation, SVM SAK usually identified more active compounds belonging
to the highest potency category C1 than LC. Because the overall compound
recall was comparable for all advanced strategies using ECFP4 as fingerprint
representation, SVM SAK was considered as the preferred strategy for this
fingerprint. However, for the MACCS fingerprint, overall compound recall was
consistently higher for LC than for SVM SAK so that there was no clear advan-
tage of one over the other method. Furthermore, the search results for simple
and squared weights were also comparable. However, the use of simple weights
often led to slightly higher recovery rates for all active compounds, whereas
squared weights favored the recovery of highly potent molecules.
In Figure 4.2-2 and Appendix Figure C-2, average recovery rates are re-
ported for a constant selection set size of 1 000 database compounds. Depend-
ing on the HTS data set, recovery rates for all active compounds ranged from
ca. 3% to 20%. For potent (C1, C2) compounds, higher recovery rates were
observed ranging, on average, from approximately 10% to 60%. Here it should
be taken into account that many more weakly than highly potent compounds
were available in each data set. The comparison of the recall rates of alter-
native SVM strategies for selection sets of 1 000 database compounds further
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Figure 4.2-1: Cumulative recall curves for potency-balanced reference sets
For each bioassay, cumulative recall curves are shown for all active compounds and the highest
potency categories (C1 and C2) and different SVM strategies using ECFP4 as fingerprint
representation. Recall curves represent the average of ten independent trials using different
reference sets. Potency-balanced reference sets consist of compounds spanning the entire
potency range in a data set. The figure is adapted from [76].
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Figure 4.2-2: Support vector machine performance for database selection
sets of constant size Recovery rates are shown for the ECFP4 representation, potency-
balanced reference sets, and database selection sets of 1 000 compounds. The results are
averaged over 10 independent trials per data set. The figure is adapted from [76].
illustrated that SVM SAK and LC calculations consistently detected more po-
tent compounds than standard SVM calculations. Thus, potency-directed SVM
searching reached the recall performance of standard SVM classification but led
to the desired preferential detection of hits having higher potency.
4.2.2 Control Calculations
We next carried out standard SVM calculations on active reference sets ex-
clusively consisting of potent compounds. The results were then compared to
standard SVM and SAK calculations for potency-balanced reference sets. These
control calculations were carried out to reveal whether the potency of reference
compounds determined the outcome of the search calculations relative to ad-
vanced SVM strategies. The results for the ECFP4 and MACCS representations
are reported in Figure 4.2-3 and Appendix Figure C-3, respectively. It can be
seen that standard SVM using only the five most potent reference compounds
as positive training examples (strategy SVM1Cat) produced recovery rates of
potent compounds that were significantly lower compared to advanced strate-
gies, which was especially obvious for the recall of potent compounds belonging
to category C2. In most cases, even standard SVM using potency-balanced ref-
erence sets recognized more C2 compounds. Of course, the C1 reference set
was the smallest of all and hence contained the least information about active
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molecules. Accordingly, when adding reference compounds falling into potency
category C2 to the positive training class (strategy SVM2Cat), recovery rates
of potent compounds increased and were found to be overall comparable to
advanced strategies (or even slightly better in case of the MACCS fingerprint).
Thus, the exclusive use of highly potent reference compounds in standard SVM
calculations also led to the preferential detection of potent screening hits. How-
ever, there was a price to pay because, in this case, the recovery rates of all
active compounds were substantially reduced for standard SVM calculations.
Thus, overall much better recall rates of active compounds were obtained for
balanced reference sets where potency-directed SVM searching provided a clear
enrichment of potent screening hits.
4.3 Conclusions
This chapter introduced SVM-based techniques for potency-directed LBVS, for
which alternative methods are currently not available. For many similarity-
based search methods, the incorporation of potency as a search parameter is
a difficult problem. However, in the context of SVM learning, the use of ker-
nel functions and their combination provides a basis for the design and im-
plementation of a multi-parametric search approach. SVM LC learns separate
hyperplanes for training sets of different activity ranges and then combines
them by associating a potency-dependent weighting scheme. By contrast, the
SAK approach introduced herein compares compound pairs simultaneously in
activity and structure space by evaluating structural similarity on the basis of
whole-molecule fingerprint descriptors and multiplying it with an assessment
of activity similarity for pairs of ligands. Using balanced (unbiased) compound
reference sets, both advanced SVM techniques met the active compound recall
performance of conventional SVM calculations but achieved a clear enrichment
of potent hits. In addition, we demonstrated that reference sets biased towards
compounds having high potency also led to an enrichment of potent hits in
standard SVM calculations, but only at the cost of overall recall performance.
These findings have a number of implications for practical SVM database search
applications. We deliberately performed our analysis on HTS data to eliminate
the influence of molecular complexity effects [94] on the search results. In typical
screening libraries, hits with different potency usually have comparable molec-
ular weight and topological complexity because they are not (yet) chemically
optimized with respect to a specific biological activity. This avoids complica-
tions that are often associated with benchmark calculations and also practical
applications. In typical benchmark settings, highly optimized and potent com-
pounds are usually added to screening databases consisting of lower complexity
compounds, which generally yields artificially high recall rates [11] because
highly complex reference and active database compounds are relatively easy
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Figure 4.2-3: Control calculations using highly potent reference compounds
For each bioassay, recall curves are shown for all active compounds and the two highest
potency categories (C1 and C2). Compound recall is monitored for different SVM strategies
using ECFP4 averaged over 10 independent trials. The following strategies are compared:
standard SVM with reference compounds from potency category 1 (`1Cat'), 1 and 2 (`2Cat'),
and all categories (`Pooled') and SVM structure-activity kernel (SAK). SAKsimple is shown
for sets 886 and 894, SAKsquared for sets 887 and 1030. The figure is adapted from [76].
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to distinguish from screening molecules having lower complexity. However, the
situation is completely different when highly complex reference compounds are
utilized to search for hits having average screening database complexity, which
has been shown to provide the by far most difficult practical search scenario for
fingerprint-based methods [95]. These considerations would suggest to rather
focus on screening hits as reference compounds, even if many of them might
only be weakly potent. For SVM learning, we now introduce techniques that
take relative compound potency into account and are particularly well suited
for this task. Selecting a spectrum of available screening hits for learning, the
SVM SAK and LC techniques would be expected to detect many active com-
pounds and direct the search towards potent hits, if available in a screening
database. Such calculations should be particularly promising if reference com-
pounds and potential hits would originate from the same screening collection
(where many active compounds might have similar chemical properties). For
example, this would make the application of these methods attractive in the
context of sequential screening [96] where initial screening hits from a fraction
of the database are used as reference compounds for search calculations to pri-
oritize another subset of the database (with a putative enrichment of additional
hits) for the next round of experimental screening.
Source Information
Sections of the text in this chapter have been taken from [76].
Chapter 5
Selection of Compound
Class-Specific Descriptors
Numerical descriptors of chemical structure and properties play a central role in
chemoinformatics, and literally thousands of different descriptors are currently
available [45]. Descriptors that capture compound class-specific and biological
activity-relevant information are of high interest for the exploration of structure-
activity relationships. However, the identification of such descriptors is far from
being a trivial task. Thus, selection algorithms capable of finding descriptors
that contain compound class-specific information are highly desired. A generally
applicable way to identify discriminatory descriptors is to compare their data
distributions for a given compound activity class and a large database where
the vast majority of compounds do not have the desired activity. A descriptor
contains compound class-specific information if the value distributions of the
descriptor significantly differ for the two compound data sets. By contrast, if
value distributions for a descriptor are very similar for the two data sets, i.e., if
each descriptor value occurs with roughly the same frequency for the activity
class and the database, then the descriptor provides only very little set-specific
information. Albeit simple in theory, a systematic descriptor selection is com-
plicated by the fact that different descriptors usually have different units and
value ranges so that identified differences in descriptor settings cannot be eas-
ily compared. Therefore, descriptor selection approaches that make use of the
Shannon entropy (SE) concept [38] from information theory have been devel-
oped to quantify the variability of different descriptors independent of their
value ranges by representing data distributions as histograms with a defined
number of bins [97]. Furthermore, to quantitatively compare the overlap of de-
scriptor value distributions for two different data sets and rank descriptors by
their ability to distinguish between compounds of different sources, an exten-
sion of the SE approach termed Differential Shannon Entropy (DSE) [98] was
introduced. However, as pointed out in this chapter, the DSE approach is intrin-
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sically limited in its ability to select set-specific descriptors for compound data
sets of very different size. This implies that the DSE approach is not amenable
to the exploration of structure-activity relationships in a meaningful way be-
cause the identification of descriptors that capture biological activity-relevant
information typically requires the comparison of a given activity class contain-
ing only a few dozen or hundred molecules and a large database comprising
thousands or even millions of compounds. To circumvent these difficulties and
reliably assess the class-specific information content of descriptors, we trans-
formed the DSE formalism into mutual information analysis, another concept
from information theory, and evaluated our approach by descriptor ranking
and correlation analysis on 168 compound activity classes [99]. This chapter
describes the evolution from initial Shannon entropy applications to our mu-
tual information-based approach in a stepwise manner. The Shannon entropy
concept is introduced in section 5.1. Details of the DSE approach and identi-
fied shortcomings are discussed in section 5.2. The transformation of the DSE
formalism into mutual information is integral part of section 5.3. A systematic
comparison of descriptor rankings produced by DSE and our newly introduced
approach is reported in section 5.4. The chapter ends with concluding remarks
in section 5.5. All descriptors used in this chapter are available in MOE.
5.1 Shannon Entropy
Introduced in a landmark paper by Claude Shannon in 1948 and originally
developed for applications in digital communication, Shannon entropy [38] is a
concept from information theory to quantify the average information contained
in a message. In the context of molecular descriptor analysis, the message
is simply the value of a descriptor calculated for a compound and the SE is
given by the average information content of all values of this descriptor for a
compound set. The information content of a certain descriptor value depends
on the frequency with which this value occurs in a set of compounds and is
calculated as the negative base 2 logarithm of its frequency of occurrence (or
probability) pi (i.e., − log2(pi)). Hence, the information content increases with
decreasing frequency of occurrence, which is rather intuitive because a rare
descriptor value obviously conveys more information about a compound than
a frequently occurring value. SE defines the average information contained in a
descriptor D and is given by
H(D) = −
n∑
i=1
pi log2(pi) (5.1)
where n corresponds to the number of possible values the descriptor adopts. The
higher H (D) becomes, the more information is captured by the descriptor D.
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Figure 5.1-1: Descriptor histograms and corresponding SEs Two exemplary
descriptor histograms calculated from 100 000 compounds randomly taken from ZINC are
shown, and the corresponding SE values are reported. The descriptors b_1rotN and vsa_-
acid represent a high- and a low-entropy descriptor, respectively.
The Shannon entropy H (D) is maximal when all descriptor values have the
same frequency of occurrence, resulting in an SE equal to log2(n). By contrast,
H (D) is minimal and adopts a value of zero if only one descriptor value is ob-
served, i.e., if the frequency of a particular descriptor value is one. To facilitate
the quantitative comparison of the average information content of different de-
scriptors, a consistent data representation format for their value distributions is
desirable. Therefore, all descriptor distributions are represented as histograms
where the complete data range of a descriptor is divided into the same number
of equally sized data intervals. Exemplary histogram representations of value
distributions and the corresponding SE are shown in Figure 5.1-1. For 100 000
compounds randomly taken from the ZINC database, value distributions of the
descriptors b_1rotN (number of rotatable single bonds) and vsa_acid (ap-
proximation to the sum of van der Waals surface areas of acidic atoms) are
reduced to a discrete set of possible values by partitioning the range between
the minimum and maximum value into 16 evenly spaced data intervals. As
can be seen, the descriptor b_1rotN varies greatly among the database com-
pounds, whereas the values of the descriptor vsa_acid mostly fall into a single
bin. The differences between these distributions and their information content
are reflected by the calculated SE values of 2.986 for b_1rotN and 0.895 for
vsa_acid.
In addition to comparing SEs for different descriptors, the information con-
tent of a descriptor for two different compound sets A and B can also be com-
pared. For this purpose, exactly the same bin definitions (i.e., partitions) must
be used to represent the value distributions for the two data sets. Therefore,
the range of values the descriptor adopts for the union of sets A and B is deter-
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Figure 5.2-1: Discriminatory and non-discriminatory descriptors Exemplary
descriptor value distributions are shown for a class of 123 phosphodiesterase 5A inhibitors
(red) and 100 000 ZINC compounds (blue). Histograms for the (number of) rings descriptor
are distinct and cover mostly different value ranges; hence this descriptor contains class-
specific information. Histograms for the b_1rotN (number of rotatable bonds) descriptor
are shown that largely overlap. Therefore, this descriptor is unsuitable to discriminate between
the activity class and the reference database.
mined and then divided into a predefined number of equally sized bins. However,
the comparison of SEs for two compound sets only accounts for differences in
the variability of the corresponding distributions but does not provide infor-
mation about the distribution overlap. Quantifying the overlap of descriptor
value distributions for different data sets is important because descriptors with
little overlap can be utilized to distinguish between compounds from different
sources.
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5.2 Differential Shannon Entropy
In order to compare descriptor value settings for any two classes of compounds,
e.g., two different databases or active versus inactive compounds, the SE con-
cepts needs to be extended. Discriminatory and non-discriminatory descriptors
for comparison of an exemplary activity class, i.e., a set of phosphodiesterase
inhibitors taken from the ChEMBL, and the ZINC subset are shown in Fig-
ure 5.2-1. Most active compounds contain more than four rings, whereas ZINC
molecules consist mostly of one to four rings. Thus, the descriptor rings can
be utilized to discriminate between these compound classes. Of course, the dis-
crimination is not perfect because the two histograms overlap. Furthermore,
the number of rotatable single bonds is compared for the two data sets. As
illustrated in Figure 5.2-1, histograms for the descriptor b_1rotN are highly
variable for both data sets but cover a similar value range. Hence, this descrip-
tor is clearly non-discriminatory. This example emphasizes an important point,
namely that descriptors that are information-rich for single data sets are not
necessarily suitable to distinguish between different sets.
The DSE method was introduced to quantify how much information about
a given compound class is contained in the value distribution of a descriptor
when compared to another [98]. As illustrated in Figure 5.2-2, DSE calculations
for a descriptor D and two compound classes A and B involve the following
steps: First, for both sets, the descriptor value distributions are represented as
histograms using an equi-distant binning scheme. From these two histograms,
the set-specific Shannon entropies HA(D) and HB(D) are calculated. Then, a
single histogram accounting for the distribution of the entire population of com-
pounds from both sets is generated. For this combined histogram, the frequency
for a bin i is calculated according to the following equation:
fAB(i) =
n× fA(i) +m× fB(i)
n+m
(5.2)
Here, n corresponds to the number of molecules in set A and m to the number
of molecules in set B. In addition, fA(i) and fB(i) report bin frequencies for
setsA and B. Based on the combined histogram, HAB(D) is calculated. Finally,
DSE is defined as
DSE(D) = HAB(D)− HA(D) +HB(D)
2
(5.3)
In Figure 5.2-3, descriptor value distributions binned into 16 data intervals are
compared for 10 000 ZINC and 10 000 MDDR compounds and combined his-
tograms are reported. For all ZINC compounds, values for the shape descriptor
(topological index) KierA1 fall into the six lowest bins, with more than 60%
of all values accumulating in the third bin, such that the distribution becomes
rather narrow. Although this descriptor also preferably adopts low values for
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Figure 5.2-2: DSE
calculation All steps
involved in DSE cal-
culation are illustrated
for two hypothetical
classes of the same size,
classes A and B. In this
example, the value range
of descriptor D is divided
into six bins. The figure
is adapted from [62].
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4. SE calculation for combined histogram
D
HAB(D) = 2.09
5. DSE calculation
DSE(D) = 2.09 - ((2.10 + 2.05) / 2) = 0.015
MDDR compounds, descriptor values are more evenly spread and the right tail
of the MDDR distribution shows that high descriptor values are obtained for
a compound subset. Because high descriptor values are exclusively detected for
MDDR compounds, the descriptor carries at least some set-specific information.
By contrast, for the surface area descriptor SlogP_VSA5, the distributions for
ZINC and MDDR compounds are almost identical.
With its highly populated third bin and right tail, the shape of the combined
histogram for the descriptor KierA1 clearly reflects distinct characteristics of
the two underlying distributions. Since the MDDR and ZINC distributions for
the descriptor SlogP_VSA5 were highly similar, it is not surprising that the
combined histogram is also hardly distinguishable from the distributions of the
individual data sets. As reported in Figure 5.2-3, KierA1 and SlogP_VSA5
obtain DSE values of 0.157 and 0.007, respectively. Hence, in this example, DSE
successfully quantifies how much set-specific information is captured by the two
descriptors.
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Figure 5.2-3: Assessment of discriminatory power by DSE For the descriptors
KierA1 and SlogP_VSA5, individual and combined histograms for MDDR and ZINC
compounds are shown and corresponding DSE values are reported.
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Figure 5.2-4: Combined histograms for DSE and MI-DSE For the descriptor
rings and the two value distributions shown in Figure 5.2-1, the combined DSE histogram
is shown in (a) and the combined MI-DSE histogram in (b).
However, a problem arises if the two compound classes are of significantly
different size. In this case, the combined histogram is much influenced by the
larger class and its value distribution is biased, as illustrated in Figure 5.2-
4a. Although the descriptor rings shows distinct value distributions for the
exemplary activity class and the ZINC subset (see Figure 5.2-1), the combined
histogram reflects the descriptor distribution of the much larger ZINC subset.
Hence, HAB(D) is essentially equal to HB(D) and equation 5.3 can be reduced
to
DSE(D) ≈ HB(D)−HA(D)
2
(5.4)
Thus, under these conditions, the magnitude of DSE is mostly determined by
descriptors that display high variability in the large compound class but only
little variability in the activity class. Then, DSE does no longer quantitatively
account for value range dependencies, i.e., the overlap of data distributions,
although this is meant to be a key feature of the DSE approach. Therefore, in
this case, the method cannot be applied in a meaningful way.
5.3 Mutual Information-DSE
When trying to identify descriptors that contain activity class-specific infor-
mation, we are always faced with large or very large differences in compound
class size. Here, the small class is represented by an activity class and the large
class by a database where the vast majority of the compounds do not belong to
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the activity class. Therefore, we have developed a descriptor selection approach
that is independent of the size of the compound classes under consideration.
In information theory, the concept that quantifies the amount of informa-
tion about a class of objects (compounds) captured by a descriptor is known
as (average) mutual information (MI) [100]. MI exactly describes how much
information about the class is contained in the value of a descriptor. Formally,
MI is defined as the difference between the Shannon entropy of the descriptor
for two combined classes and the conditional Shannon entropy of the descriptor
given the class:
MI(D,C) = H(D)−H(D|C) (5.5)
Here, D is the descriptor and C is the class. H(D|C) quantifies the additional
information content of D for class C. For two classes A and B, H(D|C) is given
by
H(D|C) = Pr(C = A)×HA(D) + Pr(C = B)×HB(D) (5.6)
By setting the probabilities Pr(C = A) = Pr(C = B) = 0.5 (which can be seen
as an unbiased estimator for the probability that a molecule belongs to either
class), the class size dependence of MI is eliminated and the following equation
is obtained
MI(D,C) = H(D)− HA(D) +HB(D)
2
(5.7)
Because of the inequality MI(D,C) ≤ H(C) = 1 (see Appendix D for further
information), the calculated MI is normalized to the range [0,1].
We now return to the DSE formalism and the calculation of bin frequencies
for combined histograms. Instead of using equation 5.2 where compound classes
were weighted according to their size, we calculate the frequencies as follows
fAB(i) =
fA(i) + fB(i)
2
(5.8)
On the basis of these frequencies, we can generate the combined histogram
of the value distributions of our two compound classes. In the following, we
use the term normalized for a combined histogram that is calculated based on
frequencies calculated according to equation 5.8 instead of equation 5.2. The
normalized histogram for the descriptor rings is shown in Figure 5.2-4b. In
contrast to the original histogram in Figure 5.2-4a, the normalized histogram
reflects both the value distribution of the descriptor within the activity class and
the screening database. Calculating Hnorm(D) from the normalized histogram
yields a modified DSE score that exactly corresponds to equation 5.7 and is
therefore termed Mutual Information-DSE (MI-DSE):
MI-DSE(D) = Hnorm(D)− HA(D) +HB(D)
2
(5.9)
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This quantity also corresponds to the Jensen-Shannon divergence of descriptor
value distributions [101]. The MI-DSE measure has the desired property of
yielding normalized scores between zero and one, reflecting the significance of
descriptors to capture differential information content. A score of zero indicates
that the descriptor distributions for compound classes A and B are identical
and that the descriptor captures no class-specific information, whereas a score
of one indicates that the value distributions are fully disjoint and that the
descriptor can thus perfectly distinguish between A and B.
5.4 Applications
MI-DSE was compared to DSE by the evaluation of descriptor ranking and
correlation analysis on 168 compound activity classes. Furthermore, top-ranked
DSE and MI-DSE descriptors were analyzed for their discriminatory potential.
5.4.1 Descriptor Ranking and Correlation Analysis
To investigate whether MI-DSE and DSE prioritize different descriptors, as
would be expected on the basis of our example given in section 5.3, MI-DSE and
DSE calculations were carried out for 168 compound activity classes extracted
from the ChEMBL database that contained at least 50 inhibitors with mini-
mum potency of 1 µM. Compounds were represented by 171 numerical 1D or 2D
descriptors available in MOE, listed in Appendix Table D-1. These descriptors
accounted for a number of diverse properties including physicochemical and
bulk parameters, atom and bond counts, chemical composition, and surface,
topological, or shape properties. Different binning schemes were investigated
by dividing the value ranges of all descriptors into 8, 16, 32, or 64 equally-sized
bins. For each activity class, all descriptor value distributions were compared to
those in a database of 100 000 randomly collected ZINC compounds, MI-DSE
and DSE scores were calculated, and the descriptors were ranked in the order
of decreasing scores. In order to compare DSE- and MI-DSE-based rankings for
an activity class, Spearman correlation coefficients were calculated. The Spear-
man correlation coefficient provides a measure for the correlation between two
data rankings when the values themselves are not of interest, but the relative
order they produce. It can be calculated as the Pearson correlation coefficient of
corresponding ranking positions. As a control for the choice of binning schemes,
DSE-based rankings and MI-DSE-based rankings were first compared among
themselves (Appendix Table D-2). The rankings produced with different num-
bers of bins were highly correlated for the individual methods, reflecting that
descriptor ranking was essentially independent of the utilized number of bins.
We then compared the DSE and MI-DSE rankings and found that, irrespective
of the applied binning scheme, correlations between rankings were in most cases
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not detectable or rather low. The average Spearman rank correlation coefficients
were 0.151, 0.201, 0.262, and 0.341 for 8, 16, 32, and 64 bins, respectively (hence,
with increasing numbers of bins, the rankings became only slightly more simi-
lar). This large-scale comparison over many different compound activity classes
demonstrated that DSE and MI-DSE calculations produced very different de-
scriptor rankings.
5.4.2 Comparison of Top-Ranked DSE and MI-DSE
Descriptors
For each activity class, value distributions for the ten top-ranked DSE and
MI-DSE descriptors calculated on 16 equally-sized bins were represented as
histograms and compared by visual inspection. The comparison of descriptor
value histograms for active and database compounds and resulting DSE and
MI-DSE values clearly showed that MI-DSE calculations prioritized descriptors
capturing compound class-specific information, much more than DSE calcu-
lations. Representative results for two activity classes are shown in Figures
5.4-1 and 5.4-2 (with further information on the descriptor rankings of these
activity classes provided in Appendix Table D-3). For antagonists of the mus-
carinic acetylcholine receptor M2, the most discriminatory descriptor according
to MI-DSE is the formal charge (FCharge) of the molecules. Whereas most
active compounds are positively charged, ZINC molecules are predominantly
uncharged or negatively charged, as shown in Figure 5.4-1. MI-DSE correctly
identifies that the value distributions are mostly disjoint and that the descriptor
carries compound class-specific information. As the descriptor has a low SE for
the ZINC database and DSE calculations are dominated by the value distribu-
tion of the large compound class (vide supra), the descriptor is ranked lowly by
the DSE approach. By contrast, the surface area descriptor SMR_VSA4 is
ranked highly on the basis of DSE calculations, but not MI-DSE calculations.
Figure 5.4-1 reveals that value distributions overlap for active compounds and
the background database. For both sets, descriptor values falling into the first
bin are most frequently observed. However, DSE assigns a high score to this de-
scriptor because the SE calculated for the background database is much higher
than for the activity class (compare equation 5.4). MI-DSE recognizes that the
modes of the two distributions overlap and correctly assigns a considerably
lower score than for the formal charge descriptor.
For a set of carbonic anhydrase II inhibitors, the partial charge descriptor
PEOE_VSA-4 is top-ranked by MI-DSE. Corresponding value distributions
in Figure 5.4-2 illustrate that much higher descriptor values are obtained for ac-
tive molecules and that compounds from the two sets mostly populate different
bins. Albeit the evident discriminatory nature of the descriptor, DSE calcu-
lations yield a negative score because the descriptor values for the carbonic
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anhydrase II inhibitors are more widely spread resulting in a higher SE for
the activity class than for the large background database. Furthermore, Figure
5.4-2 shows value distributions for the adjacency matrix descriptor GCUT_-
SLOGP_0 that is a top-ranked descriptor for carbonic anhydrase II inhibitors
on the basis of both DSE and MI-DSE analysis. This descriptor produces a
comparably high SE value for the database and a low SE value for the activity
class, resulting in a high DSE value, which is mainly determined by the high SE
value for the database. However, the value distributions of this descriptor dis-
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Figure 5.4-1: Descriptor rankings for M2 receptor For the muscarinic acetyl-
choline receptor M2, value distributions for top-ranked descriptors according to MI-DSE or
DSE are shown.
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play only limited overlap, which also results in a high MI-DSE value, consistent
with the class-specific information captured by the descriptor.
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Figure 5.4-2: Descriptor rankings for carbonic anhydrase II For carbonic an-
hydrase II, value distributions for top-ranked descriptors according to MI-DSE and/or DSE
are shown.
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5.5 Conclusions
The identification of descriptors that capture compound class-specific informa-
tion is of high relevance for many chemoinformatics applications. Generally,
compound class-specific information must be assessed by comparing sets of
compounds having a desired property (such as, for example, biological activ-
ity) with data sets where most compounds lack this property. The larger this
reference database is, the more reliable the assessment of class-specific infor-
mation becomes. If only small reference sets are utilized, the analysis is not
meaningful. For the study of biological activity, descriptors that systemati-
cally differ in their value settings between active and database compounds are
highly desired, i.e., descriptors that are activity-relevant. In this chapter, an
information-theoretic approach to reliably assess compound class-specific infor-
mation content of descriptors has been introduced. Importantly, the approach
is not biased by intrinsic differences in the size of activity classes and reference
databases. This has been accomplished by combining the Differential Shannon
Entropy formalism with the mutual information concept. The comparison of
value distributions of descriptors and the resulting (DSE and) MI-DSE values
and descriptor rankings has confirmed the utility of the MI-DSE approach to
identify descriptors containing class-specific information. This newly introduced
approach is straightforward and should be useful for large-scale descriptor anal-
ysis.
Source Information
Sections of the text in this chapter have been taken from [62,99].
Chapter 6
Comprehensive Survey of Single-
and Multi-Target Activity Cliffs
Molecular similarity-analysis is rooted in the similarity-property principle stat-
ing that overall similar molecules should have similar biological activity [4].
Despite the intuitiveness of this principle, it is known that minor structural
modifications of an active molecule can dramatically increase or decrease its
activity, which corresponds to SAR discontinuity. Structurally similar com-
pounds having large differences in potency form so-termed activity cliffs, as
shown in Figure 6.0-1. Therefore, activity cliffs represent the extreme form of
SAR discontinuity [28] and their presence in compound sets is often responsi-
ble for difficulties in deriving QSAR models for activity prediction [12]. Given
their small structural change  large potency effect phenotype, activity cliffs
are also regarded as the most informative SAR feature in bioactivity-annotated
compound data sets. Moreover, the assessment of activity cliffs in compound
series plays an important role for chemical optimization efforts.
Activity cliffs have conventionally been analyzed for compounds active
against individual targets (single-target cliffs). However, for compounds with
activity against multiple targets, multi-target cliffs might also occur [102]. Such
cliffs result from differential potency of a compound pair against two or more
related targets. These targets might be closely related, i.e., members of the same
protein family, or unrelated, if the cliff-forming compounds display polyphar-
macological behavior [65]. Although activity cliffs are intensely studied, anal-
yses are usually focused on identifying activity cliffs in individual compound
sets. We noticed that no systematic assessment of activity cliff distributions
had been carried out so far and that it was unknown how activity cliffs are
globally distributed across available bioactive compounds and protein targets.
Furthermore, it was unclear how frequently multi-target activity cliffs might
actually occur in bioactive compounds. To shed light on these questions, we
have carried out a systematic analysis of single- and multi-target activity cliffs
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12.9 µM 55 nM 
high structural
similarity
low activity
similarity
Figure 6.0-1: Activity cliff Shown are two dopamine transporter inhibitors that are
structurally very similar but show a large difference in their reported IC50 values and therefore
constitute an activity cliff.
formed by public domain compounds annotated with activity against human
protein targets [103], as reported in this chapter. Employed compound data
sets and calculations for similarity-potency comparisons are described in sec-
tion 6.1. Results of our analysis including separate assessments of global and
target family-based activity cliff distributions are presented in section 6.2. The
chapter ends with conclusions in section 6.3.
6.1 Data and Calculations
6.1.1 Data Sets
Two major public domain compound repositories, i.e., PubChem BioAssay and
BindingDB, were analyzed for the occurrence of activity cliffs. As detailed be-
fore, PubChem bioassays contain HTS data, whereas BindingDB predominantly
contains compounds taken from the medicinal chemistry literature, mostly orig-
inating from chemical optimization efforts. The version of BindingDB used in
this analysis has integrated large parts of the ChEMBL compound collection
for defined protein targets.
For our analysis, we extracted small compounds consisting of at least five
heavy atoms and having a molecular weight of not more than 900 Da. An upper
weight threshold was applied because comparisons of large molecules often yield
artificially high similarity values [94]. Only Ki or IC50 values were considered
as activity annotations.
6.1.2 Activity Cliff Calculations
The detection of activity cliffs requires a consistent definition of high structural
similarity and activity dissimilarity. For the calculation of pairwise compound
similarities, molecules were encoded using ECFP4 representations. As a sim-
ilarity threshold for activity cliff formation, an ECFP4 Tc value of 0.55 was
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Figure 6.1-1: Single- and dual-target activity cliffs Shown are four compounds
and their activity profiles. The two compounds shown on the left are serine protease inhibitors.
One of these compounds is active against all three and the other against two of the serine
proteases factor Xa (faXa), thrombin (thr), and trypsin (try). Based on their activity profiles,
these two compounds form a single-target activity cliff (stc) for factor Xa. The cliff is indicated
by an arrow. On the right, two compounds are shown that are active against cathepsins K,
L, and S. One compound is highly potent against all three cathepsins, whereas the other is
only highly potent against cathepsin S but weakly potent against cathepsins K and L. Hence,
these compounds form a dual-target cliff (dtc) for cathepsins K and L, indicated by arrows.
The figure is adapted from [103].
applied since it has been shown previously that this ECFP4 Tc threshold value
identifies compounds with high structural similarity [104]. For comparison, the
calculations were also carried out with another molecular representation, i.e.,
the MACCS fingerprint. The same number of pairs of similar compounds above
the ECFP4 Tc threshold value of 0.55 was obtained for the MACCS Tc calcu-
lations when a threshold value of 0.85 was applied.
For all compounds, an activity profile was generated using a constant rep-
resentation scheme [102]. An activity profile of a compound consisted of binned
activity measurements for all annotated targets. Potency values were assigned to
three different ranges, i.e., weakly potent (pKi ≤ 5; bin label 0), moderately
potent (5 < pKi ≤ 7; bin label 1), or highly potent (pKi > 7; bin label 2).
If multiple measurements were available, a compound was only included in the
analysis if all values fell into the same potency bin. For our analysis, we applied
the definition that an activity cliff was formed by a pair of compounds that ex-
ceeded the defined fingerprint similarity threshold and in which one compound
was highly potent against a given target and the other only weakly potent (i.e.,
representing a 2 vs. 0 potency bin combination against the target). Com-
pounds active against multiple targets can form single- or multi-target activity
cliffs. The latter are termed dual-, triple-, quadruple-target cliffs etc., accord-
ing to the number of targets for which cliffs occur. In Figure 6.1-1, exemplary
compound pairs are shown with their activity profiles that form a single- and
dual-target cliff, respectively.
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To investigate activity cliff frequencies for different target families, the tar-
gets in our analysis were grouped together based on the family organization of
the protein database UniProt. Targets belonging to the large GPCR 1 family
were divided into smaller groups following the protein classification hierarchy
available in ChEMBL.
For our analysis, Perl and Java programs were generated.
6.2 Results
A total of 164 165 unique BindingDB compounds were obtained (approximately
85% of which originated from ChEMBL and were subsequently integrated into
BindingDB) that were reported to be active against 1 355 non-redundant in-
dividual human targets. These compounds yielded 330 526 defined activity an-
notations (i.e., many compounds were active against multiple targets). From
PubChem, 187 confirmatory inhibition assays for human targets were extracted
that contained 21 532 active compounds with 30 805 defined annotations against
98 different targets. We systematically searched these compound data sets for
single- and multi-target activity cliffs.
6.2.1 Global Activity Cliff Distribution
The activity cliff distribution for BindingDB compounds is reported in Table
6.2-1. When, as an approximation, both Ki and IC50 values were considered as
potency annotations, 36 063 single-, 1 654 dual-, and 233 triple-target activity
cliffs were obtained. The number of multi-target cliffs of higher degrees (target
numbers) rapidly declined, although cliffs involving up to seven targets were
detected. Table 6.2-1 also reports the corresponding activity cliff distribution
when only directly comparable Ki values were considered as measurements. In
this case, 10 063 single-, 330 dual-, and 61 triple-target activity cliffs were de-
Table 6.2-1: Activity cliff statistics
activity
type
degree directionality polypharma-
cological
all
1 2 3 4 5 6 7 dir. undir.
Ki/IC50 36 063 1 654 233 43 29 21 2 38 019 26 79 38 045
Ki 10 063 330 61 17 2 0 0 10 469 4 4 10 473
Activity cliff statistics are reported for the Ki/IC50- and Ki-based analyses. degree denotes
the number of targets per activity cliff. all gives the sum of single- and multi-target cliffs.
Under directionality, the number of directed (dir.) and undirected (undir.) multi-target
cliffs is reported. In addition, the number of polypharmacological cliffs (polypharmacologi-
cal) is given.
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tected (i.e., approximately one fourth of the cliffs found when both Ki and IC50
values were considered). Furthermore, 17 cliffs involving four targets and two
cliffs involving five targets were identified. Relating the number of compounds
forming activity cliffs to the total number of compounds in the Ki/IC50- and
Ki-based data sets, we found that 12.5% and 10.9%, respectively, of compounds
were involved in the formation of activity cliffs.
We also determined the total number of compound pairs that could po-
tentially form activity cliffs, i.e., pairs that exceeded the fingerprint similarity
threshold for activity cliffs. When both Ki and IC50 measurements were consid-
ered, 1 530 493 qualifying compound pairs yielded a total of 38 045 (single- and
multi-target) cliffs. Hence, only 2.5% of all qualifying compound pairs formed
activity cliffs and only 5.2% of these compound pairs formed multi-target cliffs.
When only Ki values were considered, 574 851 compound pairs were found that
yielded a total of 10 473 cliffs, i.e., only 1.8% of these pairs formed activity cliffs
and only 3.9% of these were multi-target cliffs. Thus, activity cliffs were only
sparsely distributed among pairs of structurally similar compounds. Control
calculations using the MACCS fingerprint yielded very similar statistics and
are therefore not discussed further.
The active compound pool extracted from PubChem amounted to approx-
imately one seventh of the size of BindingDB. These screening hits had overall
lower potency than BindingDB compounds, as expected, and were structurally
more diverse. When Ki and IC50 values were taken into account, only 13 single-
target and no multi-target cliffs were detected. These 13 activity cliffs involved
only five different targets. Thus, the occurrence of activity cliffs in PubChem
compounds was negligible. Hence, the further analysis of activity cliffs was lim-
ited to the BindingDB compound collection.
6.2.2 Target Family Distribution
We then studied the protein target family distribution of all activity cliffs. The
results for the Ki/IC50- and Ki-based distributions are provided in Table 6.2-2.
For the top ten families of each analysis, ranked according to the total number of
activity cliffs, significant differences in cliff numbers were observed. However, on
a relative scale (with respect to the total number of pairs of similar compounds),
activity cliffs were similarly distributed over these target families. The top ten
families included popular therapeutic targets for which many qualifying active
compound pairs were available. Most activity cliffs were found for ligands of the
short peptide receptor and peptidase S1 families. The family rankings differed
for the Ki/IC50- and Ki-based cliff distributions, but in both cases protease,
kinase, nuclear hormone receptor, and GPCR families were found among the
top ten families. For most highly-ranked families, the percentage of multi-target
cliffs among all activity cliffs was small (i.e., 0% to less than 10%), although
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Figure 6.2-1: Directed and undirected activity cliffs On the left, a compound
pair is shown that forms a triple-target cliff (ttc) for matrix metalloproteases (mmp) 2, 8,
and 13. The potency of one compound is consistently high against all three targets, and the
potency of the other is consistently low, i.e., this cliff is directed. On the right, a compound
pair is shown that forms a triple-target cliff for Aurora serine-threonine kinases A and B
and the tyrosine kinase epidermal growth factor receptor (egfr). In this case, the compounds
show differential target selectivity. One compound is highly potent against Aurora kinases
A and B and weakly potent against the epidermal growth factor receptor kinase, whereas
the other compound displays an inverse activity profile. Accordingly, this triple-target cliff
is undirected. Furthermore, as the three kinases belong to two different target families, a
polypharmacological cliff is formed by the two compounds. The figure is adapted from [103].
there were exceptions. For example, for the AGC serine/threonine kinase and
the peptidase M10A (matrix metalloproteases) families, 24.1% and 17.5% of
all activity cliffs were multi-target cliffs, respectively, and for the peptidase C1
family, 13.0% were multi-target cliffs.
6.2.3 Activity Cliff Directionality
Then we analyzed the directionality of multi-target activity cliffs. In a directed
multi-target cliff pair, the potency of compound A is consistently high for all
targets and the potency of compound B is consistently low. By contrast, in
an undirected multi-target cliff pair, compound A has high potency for at
least one target for which compound B is only weakly potent and vice versa.
Differences in cliff directionality are illustrated in Figure 6.2-1 where exem-
plary directed and undirected triple-target cliffs are shown. Importantly, only
undirected multi-target activity cliffs contain compounds with different target
selectivity. In the Ki/IC50-based distribution, only 26 of 1 982 multi-target cliffs
(1.3%) were undirected, and in the Ki-based distribution, only 4 of 410 (1.0%).
Thus, nearly all multi-target cliffs were directed and activity cliff-forming com-
pounds with different target selectivity were extremely rare.
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Table 6.2-2: Target family distribution of activity cliffs
target family
degree mt
(%)
all
freq.
(%)
#targets
1 2 3 4 5 6 7
Ki/IC50
short peptide receptor 6 657 161 17 1 0 0 0 2.6 6 836 2.6 37
peptidase S1 4 006 68 5 3 1 0 0 1.9 4 083 3.4 21
tyrosine kinase 2 656 192 37 0 0 0 0 7.4 3 085 2.9 29
peptidase A1 1 610 13 6 0 0 0 0 1.2 1 629 2.7 69
prostaglandin G/H synthase 1 585 39 0 0 0 0 0 2.4 1 624 7.6 2
AGC serine/threonine kinase 927 162 71 18 22 21 0 24.1 1 221 4.3 16
peptidase M10A 984 152 32 19 4 0 2 17.5 1 193 2.6 9
CMGC serine/threonine kinase 1 052 75 0 0 1 0 0 6.7 1 128 2.5 12
nuclear hormone receptor 899 113 0 0 0 0 0 11.2 1 012 2.2 17
nucleotide-like ligand receptor 955 26 4 0 0 0 0 3.0 985 1.3 6
Ki
short peptide receptor 3 203 75 9 0 0 0 0 2.6 3 287 2.6 32
peptidase S1 1 732 18 0 3 1 0 0 1.3 1 754 2.4 18
monoamine receptor 677 39 20 2 1 0 0 8.4 739 0.9 24
nucleotide-like ligand receptor 630 30 0 0 0 0 0 4.5 660 0.6 5
carbonic anhydrase 533 15 0 0 0 0 0 2.7 548 3.6 7
peptidase C1 457 58 10 0 0 0 0 13.0 525 9.1 5
G protein-coupled receptor 2 446 0 0 0 0 0 0 0.0 446 3.4 2
lipid-like ligand receptor 406 5 0 0 0 0 0 1.2 411 1.6 12
nuclear hormone receptor 200 8 0 0 0 0 0 3.8 208 1.6 11
TKL serine/threonine kinase 198 0 0 0 0 0 0 0.0 198 28.5 1
The target family distribution of activity cliffs is reported for the Ki/IC50- and Ki-based analyses,
respectively. In each case, the top ten target families are ranked according to the sum of single- and
multi-target cliffs they cover (all). The percentage of multi-target cliffs (mt (%)) among all activity
cliffs is also reported. Furthermore, for each family, the number of compound pairs that form activity
cliffs divided by the number of qualifying pairs of similar compounds and the number of targets for
which activity cliffs occur are reported in the columns freq. (%) and #targets, respectively.
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6.2.4 Polypharmacological Cliffs
In addition, we also searched for what we regard as polypharmacological cliffs,
i.e., multi-target activity cliffs that involved targets belonging to different pro-
tein families. Here, only targets with unambiguous family assignments according
to UniProt or ChEMBL were considered. For the Ki/IC50-based distribution,
we found 79 polypharmacological cliffs that involved a total of 84 compounds.
Seventy-one of these cliffs were dual- and eight triple-target cliffs. For the Ki-
based distribution, we identified only four (dual-target) polypharmacological
cliffs involving seven compounds. Hence, compounds with activity against dif-
ferent target families displayed only limited polypharmacological cliff potential.
6.3 Conclusions
In this chapter, a comprehensive analysis of activity cliffs formed by currently
available bioactive compounds was reported. We have searched for cliffs of large
magnitude that are in general least affected by measurement inaccuracies and
that usually provide focal points of SAR exploration. Furthermore, in our anal-
ysis, we have differentiated between single- and multi-target activity cliffs, stud-
ied the directionality of multi-target cliffs, and also introduced polypharmaco-
logical cliffs that are a special type of a multi-target cliff. In general, single-target
cliffs occurred much more frequently than multi-target cliffs and were similarly
distributed over different target families. We also found that compounds having
different target selectivity only rarely occurred in multi-target cliffs. Although
the percentage of qualifying compound pairs that formed activity cliffs was
only about 2%, on average more than 10% of compounds active against differ-
ent target families were involved in the formation of large-magnitude activity
cliffs. Thus, for an active compound of interest, a thorough search of its struc-
tural neighbourhood is rather likely to reveal activity cliffs from which SAR
determinants might be deduced.
Source Information
Sections of the text in this chapter have been taken from [103].
Chapter 7
Relating Molecular
Transformations to Potency Effects
In lead optimization, the structure of active compounds is changed by small
chemical modifications in the attempt to further improve compound potency
and/or in vitro (and in vivo) properties. Traditionally, the design of analogs
has largely depended on medicinal chemistry expert knowledge, experience,
and intuition [105]. Without doubt, this subjective and expertise-driven ap-
proach has to this date been largely responsible for the success of medicinal
chemistry programs, despite the increasing use of high-throughput technologies
in drug discovery settings. However, attempts have also been made to more
systematically address the process of analog design in order to aid medicinal
chemists in the decision which compounds to synthesize next in the course of
a compound optimization effort [106, 107]. By and large, these attempts have
focused, and continue to focus, on analyzing the wealth of available analog
and structure-property relationship data for diverse targets in order to iden-
tify, and ultimately predict, favorable chemical modifications. For this purpose,
compounds are compared in a pairwise manner in order to identify structural
changes that are subsequently related to changes in compound properties.
In this chapter, three studies are reported that systematically relate chem-
ical replacements to potency changes [108110]. Section 7.1 introduces the con-
cept of matched molecular pairs (MMPs) that provides a consistent structural
reference frame to generalize chemical modifications. Moreover, a computation-
ally efficient algorithm for the identification of MMPs is described. In section
7.2, the application of the MMP concept to systematically analyze the ability
of defined chemical changes to introduce activity cliffs is reported and proper-
ties of structural modifications frequently leading to large potency changes are
discussed. Sections 7.3 and 7.4, on the other hand, report the exploration of
potency-retaining or bioisosteric replacements. Section 7.3 focuses on replace-
ments that act as bioisosteres across different targets and are conservative with
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matched molecular pair molecular transformation
[*:2]N(C)[*:1]>>[*:2]N[*:1]
Figure 7.1-1: Matched molecular pair and molecular transformation Shown
is a pair of compounds that have similar structures and differ only at a localized site. The
fragment exchange relating the compounds to each other is referred to as molecular transfor-
mation and encoded as SMIRKS string [111].
respect to different biological activities. In addition, section 7.4 addresses the
question whether bioisosteric replacements can be found that preferentially act
against a given target family. The chapter closes with a comparison of the
chemical replacements identified in the different studies and a summary of key
observations in section 7.5.
7.1 Matched Molecular Pairs and Molecular
Transformations
An MMP is defined as a pair of compounds that differ only at a single localized
site and are distinguished by a defined substituent or molecular fragment [39].
It follows that two compounds forming an MMP are related to each other by
a specific molecular transformation, such as the addition of a substituent or
the exchange of a ring system. Figure 7.1-1 shows an MMP and the molecular
transformation that converts one compound into the other. Matched molecu-
lar pair analysis (MMPA) generally aims at identifying all MMPs from a set
of compounds and determining associated property changes [112]. MMPA is
highly attractive for medicinal chemistry due to the chemical interpretability
of the results. However, most search algorithms introduced for comprehensively
identifying MMPs in compound sets are computationally expensive and not
applicable to large data sets. For example, this is the case for maximum com-
mon subgraph-based algorithms that carry out pairwise comparisons to find the
largest substructure common to two molecules and then analyze whether differ-
ing fragments constitute a single-point change [107,113]. Only recently, Hussain
and Rea have introduced an efficient algorithm to systematically extract MMPs
from compound data sets [114], thus enabling a large-scale analysis of MMP
distributions.
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Figure 7.1-2: MMP search algorithm The steps of the Hussain and Rea algorithm
leading to the identification of MMPs are illustrated for single and double cuts. Although
molecules 2 and 3 in the single cut example share a common key fragment, the pair is not
accepted as an MMP because the heavy atom counts of the two value fragments differ by
more than eight atoms. The figure is adapted from [108].
7.1.1 Hussain and Rea Algorithm
The first step of the Hussain and Rea algorithm for the identification of MMPs
involves fragmentation of all compounds in a data set. This is accomplished
by marking all non-ring single bonds between two non-hydrogen atoms in a
molecule, followed by systematic deletion of these bonds (single cut) and their
two- and three-bond combinations, called double cuts and triple cuts, respec-
tively. A single cut results in two fragments F1 and F2 that are added to an
index list. Two key-value pairs are built: fragment F1 is added as a key to
the index with F2 as the corresponding value and vice versa. Double cuts
result in a core and two terminal fragments. In this case, the core is considered
the value and the two terminal fragments together constitute the key. Of all
possible triple cuts, only those are considered that result in a single core and
three terminal fragments (i.e., triple cuts that result in two cores and two termi-
nal fragments are not considered). In analogy to double cuts, the core is stored
as the value with the three terminal fragments together as the key. For double
and triple cuts, connectivity information of the fragments is retained. Further-
more, for all generated key-value pairs, source compound information is stored.
Because all compounds sharing a particular key contain the corresponding frag-
ment(s), the pairwise combination of these compounds yields MMPs and the
two value fragments define the structural transformation for each MMP. The
chemical replacement is denoted using the syntax of the reaction transform lan-
82 Chapter 7. Relating Molecular Transformations to Potency Effects
MMP
1*
O
O
-
molecular
transformations
Figure 7.1-3: Structural context of actual substructure exchanges For the
MMP shown on the top, multiple value fragment pairs of different sizes are obtained that
represent alternative structural transformations.
guage SMIRKS [111], which essentially corresponds to the SMILES strings of
the two value fragments connected by >> and is illustrated in Figure 7.1-1.
A schematic outline of the algorithm is provided in Figure 7.1-2. It should be
noted that the algorithm often yields multiple, differently sized fragments that
define the transformation of an MMP. For example, the compounds shown in
Figure 7.1-3 are inter-convertible by a carboxylate to chlorine transformation.
However, another valid transformation for this compound pair is a p-benzoate
to p-chlorophenyl transformation. Hence, for each MMP, transformations de-
scribing the structural context of the actual substructure change to different
extents can be derived. Another strength of the algorithm is that the search
for MMPs is comprehensive and not limited to predefined functional groups or
substrucutres. By utilizing single and multiple cuts, transformations involving
both R-groups and core structures can be assessed.
In the implementation of the algorithm used to carry out the studies re-
ported in this chapter, a combination of two compounds was only considered
an MMP if the heavy (non-hydrogen) atom counts of their distinguishing frag-
ments differed by maximally eight atoms. This criterion was applied to ensure
that compounds forming MMPs did not have large differences in size and is
illustrated in the algorithm scheme in Figure 7.1-2. Furthermore, transforma-
tions relating compounds in a pair were canonicalized such that MMPs could
be grouped by transformations. To be included in our analyses, transformations
had to occur in at least two compound pairs in which the remaining molecular
substructure (that was not involved in the transformation) contained at least
as many heavy atoms as the exchanged fragment, thereby avoiding the identi-
fication of overly large or specific transformations. Moreover, stereochemistry
information of molecules was not considered because this information would
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often be lost during molecular fragmentation. The algorithm was implemented
using Perl and the Scientific Vector Language1.
7.2 Activity Cliff-Introducing Chemical
Replacements
We have been interested in exploring the potential of defined chemical changes
to introduce activity cliffs in compound data sets. In particular, we wished to
determine whether defined chemical transformations exist that display a gen-
eral tendency to introduce activity cliffs across different compound classes and
biological targets. If so, this information might be very helpful to evaluate chem-
ical modifications for compound optimization efforts. To address this question,
we extracted compound potency data from the ChEMBL database (bioassay
repositories such as PubChem BioAssay were not suitable for this analysis,
as demonstrated in the previous chapter), systematically identified MMPs and
molecular transformations, and finally related structural and potency changes
to each other. Defined criteria were applied to identify transformations most
frequently introducing activity cliffs.
7.2.1 Compound Data Sets
From the ChEMBL database, compounds with potency measurements against
human targets were extracted. Whenever available, Ki values were selected
(otherwise IC50 values). For compounds with multiple potency values reported
against the same target, the arithmetic mean was calculated to yield the fi-
nal potency. Furthermore, only measurements with a very high confidence for
direct compound-target interactions were selected. Very large molecules with
more than 45 non-ring single bonds were filtered out prior to MMPA because
their fragmentation would have been computationally demanding. Ligand sets
were assembled for individual targets when at least five active compounds were
available that met our criteria, leading to the selection of a total of 33 497 unique
active compounds organized into 523 target-specific sets containing between 5
and 1 528 ligands. Compounds were grouped by targets and MMPs were sep-
arately identified for each ligand set because molecular transformations were
associated with potency changes that must not be calculated for compounds
with different bioactivities.
1The Scientific Vector Language is an integral part of MOE.
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Figure 7.2-1: Redundancy rules In order to unambiguously define frequent cliff-
forming transformations, rules are applied that relate the size of exchanged fragments and
their number of occurrences in cliff-forming molecule pairs to each other.
7.2.2 Transformation Selection Criteria
For each valid transformation identified by our modified version of the Hussain
and Rea algorithm, corresponding MMPs were assembled and logarithmic po-
tency differences between compounds in each pair were recorded. If an MMP
was present in more than one ligand set, i.e., if it was annotated with potency
values for more than one target, potency differences for all targets were calcu-
lated. In the following, the term potency record refers to the potency difference
calculated for one MMP-target combination. An MMP was considered to form
an activity cliff if the potency values of its compounds differed by at least two
orders of magnitude. In order to identify chemical replacements with a high
propensity to introduce activity cliffs, the following filter criteria were applied:
1) At least 10% of all potency records collected for a transformation repre-
sent activity cliffs (this threshold is approximately five-fold higher than the
general frequency of occurrence of activity cliffs reported in the previous
chapter).
2) The transformation introduces activity cliffs for at least four different tar-
gets.
3) The activity cliffs for the transformation are formed by at least four different
MMPs.
Because several transformations might generate the same MMP, as illustrated
in Figure 7.1-3, we apply the following rules to transformations passing our
three filters, thereby clearly defining cliff-forming transformations and avoiding
redundancies:
i) If several transformations yield the same set of cliff-forming MMPs, then
the largest substructural exchange in terms of heavy atoms is retained. For
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example, if the exchange of a carbonyl against a sulfinyl group (transfor-
mation 1) always occurrs in the context of an amide versus sulfinamide
replacement (transformation 2) in MMPs constituting activity cliffs, only
transformation 2 involving the larger number of heavy atoms is retained,
as illustrated in Figure 7.2-1 (top). The application of this rule (rule 1) en-
sures that potential context dependence of structural changes is taken into
account.
ii) If a transformation accounts for more cliff-forming compound pairs than a
larger substructural exchange and if it includes all cliff-forming compound
pairs of the larger fragment pair, then this transformation is selected in-
stead. For example, if both the exchange of a hydroxyl against an amino
group and the exchange of a carboxyl against an amide group are iden-
tified as activity cliff-introducing transformations, but the more general,
i.e., smaller transformation accounts for more activity cliffs, then only this
transformation is retained, as depicted in Figure 7.2-1 (bottom). This rule
for MMP subset relationships (rule 2) complements rule 1 that is applied
for transformations with identical MMP sets. Hence, the two redundancy
rules were independently applied for different sets of transformations and
not in a sequential manner. Therefore, the structural context dependence
of transformations accounted for through the application of rule 1 was not
removed by rule 2.
As transformations that occurred in different structural contexts (i.e., com-
pound pairs of various chemotypes) were of high interest, for MMPs represent-
ing the same transformation molecular scaffolds were calculated according to
Bemis and Murcko [115]. These scaffolds or molecular frameworks correspond
to all ring systems and atoms on the direct path connecting two ring systems
(linker) in a molecule, as illustrated in Figure 7.2-2. Hence, these scaffolds were
obtained from compounds by removal of all side chains from rings and linkers,
utilizing a Pipeline Pilot implementation.
7.2.3 Results
The major aim of our analysis has been to determine whether chemical changes
exist that generally affect compound potency, i.e., across different compound
classes and targets. For the purpose of our analysis, we have applied the MMP
concept to explore whether defined chemical changes exist that frequently in-
troduce activity cliffs in different ligand sets. For 513 of our 523 ligand sets, at
least one MMP was retrieved. Overall, 323 075 different valid transformations
were identified that corresponded to 149 563 different MMPs (the same MMP
was represented by multiple transformations) and 29 565 unique compounds
(compounds often participated in multiple MMPs).
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Figure 7.2-2: Molecular scaffolds Two compounds and their scaffolds calculated ac-
cording to Bemis and Murcko are shown. Scaffolds are obtained by side chain removal and
correspond to all rings and linkers found in a molecule.
7.2.3.1 Activity Cliff Statistics for Molecular Transformations
We considered transformations to form an activity cliff if compounds in corre-
sponding MMPs displayed an at least 100-fold difference in potency. Initially,
77 052 cliff-forming transformations were detected. For all of these transforma-
tions, the relative frequency with which they introduced cliffs was calculated,
i.e., the total number of cliffs they formed divided by their number of potency
records. Applying frequency-, target-, and compound pair-oriented filters de-
scribed in paragraph 7.2.2, the number of transformations was substantially
reduced to 487. Finally, the application of the two redundancy rules yielded
146 non-redundant frequent cliff formers. SMIRKS representations for these
transformations, which provided the basis for our further analysis, are given in
Appendix Table E-1 and a subset of frequent cliff formers is shown in Figure
7.2-3. The frequency with which they formed activity cliffs ranged from 10%
to 83.3%, with a median frequency of 16.3%. Individual transformations oc-
curred in up to 43 cliff-forming MMPs and 26 ligand sets, respectively. As the
same MMP might form activity cliffs for multiple target, a single transforma-
tion formed a maximum of 47 cliffs. The calculation of corresponding medians
yielded five MMPs, five ligand sets, and eight cliffs.
7.2.3.2 Transformation Characteristics
For the set of frequent cliff formers, fragment pairs can roughly be divided into
two groups, i.e., (i) non-polar fragments of different size and (ii) fragments that
differ in their charge or H-bonding properties. A particular enrichment of frag-
ment pairs was observed where one of the exchanged fragments was negatively
charged. Among these, transformations involving a carboxyl group were preva-
lent. We found that the exchange of a carboxyl group with a variety of other
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Figure 7.2-3:
Frequent cliff
formers Shown
is a representative
subset of structural
transformations that
frequently introduce
activity cliffs.
groups (e.g., halogens, methyl, methoxy, phenyl, or cyano groups) frequently
introduced activity cliffs. Similar but weaker tendencies were also detected for
transformations involving positively charged nitrogens in different structural
environments. Other substructures that were often involved in the formation of
activity cliffs included the carbonyl group and amines. By contrast, although
changes at ortho, meta, and para substituent positions of phenyl rings were
frequently observed, these positional changes rarely introduced activity cliffs.
Moreover, a number of very similar transformations were found to display sub-
stantially different propensities to introduce activity cliffs, as shown in Figure
7.2-4. For example, introducing a fluorine atom at the para position of a phenyl
ring led to an activity cliff in only 5 of 501 cases. However, the relative fre-
quency of cliff formation was found to increase with the size of the halogen
substituent, with iodine substitutions introducing cliffs with a nearly 17% fre-
quency. Furthermore, the introduction of a secondary hydroxyl group showed
a lower cliff frequency than the introduction of a carbonyl oxygen, another
rather unexpected finding. In addition, the exchange of a carbonyl group and
a carboxyl ester group displayed a significantly lower tendency to cause large
potency changes than the exchange of a carbonyl group and an amide moi-
ety. We also observed that distributions of compound potency differences in
MMPs shifted towards high values for transformations that displayed an in-
creasing propensity to introduce activity cliffs, as illustrated in Figure 7.2-5.
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Figure 7.2-4: Transformations with different activity cliff potential Struc-
turally similar transformations are shown together with their relative frequency of cliff for-
mation. If more than two fragments are shown in a box, then the fragment at the top is
exchanged with each of the fragments at the bottom. From left to right, transformations are
arranged in the order of increasing cliff-forming potential. The figure is adapted from [108].
Thus, transformations that frequently introduced activity cliffs also displayed
the tendency to introduce cliffs of large magnitude.
7.2.3.3 Target and Chemotype Distributions of Transformations
In our analysis, transformations that introduced activity cliffs for diverse targets
and in different structural contexts were of most interest. Therefore, we analyzed
whether the 146 identified transformations preferentially introduced activity
cliffs for related targets or different target classes and to what extent frequent
cliff formers introduced activity cliffs in different chemotypes. For the target
distribution analysis, the protein target classification hierarchy of ChEMBL was
adopted and slightly extended to group all targets covered by our ligand sets.
For each of the 146 transformations, the number of targets for which it produced
activity cliffs was determined and divided by the number of different groups
to which these targets belonged. The distribution of all target-to-target group
ratios is reported in Figure 7.2-6 (left). For the majority of transformations that
produced MMPs active against multiple targets, the targets mostly belonged
to different groups, with a median ratio of 1.5 targets per class. Only for a very
few transformations accounting for the right tail of the distribution, a target
group bias was apparent.
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Figure 7.2-5: Potency distributions of selected transformations For four sim-
ilar transformations, distributions of absolute logarithmic potency differences between com-
pounds in corresponding MMPs are shown, and arithmetic means of the potency differences
are reported. The relative frequency of activity cliff formation of these transformations is
given in Figure 7.2-4.
To analyze the chemotype distribution, the ratio of the number of cliff-
forming MMPs and the number of MMPs representing different scaffold pairs
was determined for each frequent cliff former. As shown in Figure 7.2-6 (right),
these results were usually close to one, thus indicating that most transforma-
tions introduced activity cliffs in variable structural environments. Figure 7.2-7
shows examples of cliff-forming MMPs that were defined by the same trans-
formation and contained rather different scaffolds. In each of these compound
pairs, a secondary and tertiary amine was exchanged. These MMPs formed ac-
tivity cliffs against different targets including melanin-concentrating hormone
receptor 1, carbonic anhydrase II, epidermal growth factor receptor, and throm-
bin. For thrombin, the replacement of the tertiary amine by the secondary amine
increased potency by about two orders of magnitude for the compound pair on
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Figure 7.2-6: Target and chemotype distributions of frequent cliff formers
For the set of 146 identified transformations, target-to-target group and MMP-to-scaffold
pair ratios are reported.
the left in Figure 7.2-7 and decreased potency by more than three orders of
magnitude for the compound pair on the right. In light of these findings, we
further investigated the direction of potency changes for transformations induc-
ing multiple activity cliffs for at least one target. We found that 70% of these
transformations displayed only one potency direction for each target. However,
as shown in Appendix Table E-2, there was a clear dependency on the number
of different scaffolds in a set of compound pairs. A transformation that occurred
in different chemotypes active against the same target had a considerably higher
probability to cause large potency changes in different directions.
7.2.4 Summary
We have systematically analyzed chemical transformations in public domain
compound data sets that defined matched molecular pairs and determined the
potential of these substitutions to introduce activity cliffs. Approximately 150
non-redundant transformations were identified that displayed a strong tendency
to introduce cliffs in different chemotypes and across different targets. This gen-
eral tendency was not necessarily expected. However, clear trends emerged for
specific chemical substitutions to globally introduce activity cliffs. By contrast,
in other instances, structurally closely related substitutions displayed only lit-
tle, if any, cliff potential. Hence, concerning the formation of activity cliffs,
privileged substitutions exist.
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Figure 7.2-7: Structurally diverse MMPs Examples of MMPs are shown that are
defined by the same transformation (i.e., the exchange of a secondary against a tertiary
amine), contain different scaffolds, and form activity cliffs for different targets. All compounds
are annotated with their calculated mean potency values. The figure is adapted from [108].
7.3 Bioisosteric Replacements
In addition to the analysis of identified frequent cliff-forming transformations,
we have carried out a systematic search for bioisosteric replacements. In gen-
eral, bioisosteres are defined as groups of atoms with similar structural and
physicochemical properties whose replacement retains the biological activity
of small molecules [116]. In medicinal chemistry, bioisosterism is an intensely
investigated topic [117, 118] because bioisosteric replacements are used to al-
ter molecular properties in a desired way, for example, by improving solubility
and/or metabolic stability or by reducing toxic side effects while not abolishing
the biological activity. In our investigation, we have applied stringent criteria
for bioisosterism. We not only required that chemical replacements retained
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similar biological activity but also comparable compound potency levels across
different target families, thereby focusing on truly tolerated substitutions.
7.3.1 Compound Data Sets
Compound sets for human targets were assembled from the ChEMBL database
following the criteria applied in the search for activity cliff-forming substitu-
tions, complemented by two additional rules: First, measurements containing
threshold values (i.e., reported as > or <) were not considered. In the search
for activity cliff formers, it was essential to include measurements for weakly
active compounds (often carrying the modifier value >) because many ac-
tivity cliffs would have been missed otherwise. However, for the identification
of bioisosteric replacements yielding compounds with similar potency levels,
potency differences between pairs of compounds must be clearly resolved, mak-
ing measurements with threshold values unsuitable for this analysis. Second, if
multiple measurements were available for the same compound-target pair and
individual potency values differed by more than one order of magnitude, all
measurements were disregarded. The selection procedure led to the extraction
of 30 368 different compounds organized into 472 target-specific sets with at
least five ligands each. All targets used in our study were grouped into target
families using the sequence-based family annotation of the UniProt database
and the classification hierarchy of the ChEMBL database.
7.3.2 Transformation Selection Criteria
MMPs were calculated for all ligand sets using our modified version of the
Hussain and Rea algorithm and transformations were associated with potency
changes as described in paragraph 7.2.2. To identify transformations that are
bioisosteric replacements, we applied the following filter criteria:
1) At least 30 potency records are associated with the transformation.
2) MMPs defined by the transformation are found for targets of at least two
different families.
3) If the target family for which most potency records are available is removed
from the analysis, at least 15 measurements remain.
4) Not more than 1/15 of all potency records are larger than one, i.e., maxi-
mally 6.67% of all potency changes induced by the transformation are larger
than one order of magnitude.
5) In the case that more than 50% of all potency records are observed for one
target family, the fraction of potency records greater than one magnitude
observed for the other target families only is not larger than 2/15.
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With these filters, we aimed at identifying transformations that were fre-
quently observed for different target families but rarely introduced large potency
changes. Filter 1 was applied to base the analysis on a meaningful statistical
ground, whereas filters 1, 3, and 5 prevented that the analysis was biased toward
a single target family for which the transformation was frequently observed, as
had been the case for a very few identified frequent cliff formers. Filter 4 is the
actual bioisostere filter in that it identifies those transformations that con-
sistently generate compound pairs with very similar potency levels. In analogy
to the rules for structural context dependence and MMP subset relationships
applied to cliff-forming transformations, we formulated the following two rules
to avoid redundancies:
i) Rule 1: if the MMP sets described by two or more transformations are
identical, only the largest transformation is retained as it provides most
information about the structural exchange. This rule was applied prior to
our selection criteria and was used to reduce the number of transformations
subjected to filters 1-5.
ii) Rule 2: all those transformations whose MMP sets are subsets of MMP sets
of other bioisosteric replacements are excluded. This rule was applied after
filters 1-5 to further reduce the resulting set of bioisosteric replacements.
7.3.3 Results
On the basis of our search strategy, transformations were regarded as poten-
tial bioisosteric replacements if they were consistently represented by multiple
MMPs with moderate potency differences for targets of more than one family
and, in addition, if the corresponding potency records were not significantly
biased by a single target family. Potency variations as a consequence of trans-
formations were largely (but not exclusively) limited to an order of magnitude.
This range is consistent with the basic idea of bioisosterism because a replace-
ment resulting in a 100- or 1 000-fold reduction in compound potency would
hardly be regarded as bioisosteric. On the other hand, a ten-fold increase in
potency as a consequence of a replacement would certainly be considered a
favorable bioisosteric effect. Furthermore, it should be noted that fragments
replaced by transformations meeting our requirements may not always be true
bioisosteres because they constitute an unimportant part of the molecule, i.e.,
one cannot be sure that they are involved in critical interactions with the target.
7.3.3.1 Transformation and Potency Difference Statistics
For 460 of our 472 ligand sets, at least one MMP was identified. The corre-
sponding 460 targets belonged to 141 different target families, with the number
of targets per family ranging from 1 to 35. Redundancy rule 1 reduced the
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Figure 7.3-1: Potency difference distributions Distributions of absolute logarith-
mic potency differences are reported as histograms for all matched molecular pairs (left) and
matched molecular pairs that were defined by a transformation with at least 30 potency
records (right). The figure is adapted from [109].
original set of 276 920 identified different transformations to 55 399 candidate
transformations, which provided the pool for the application of our bioisostere
selection criteria. For this set of 55 399 transformations, the number of potency
records for a single transformation ranged from 2 to 2 360. For compound pairs
defined by these transformations, absolute logarithmic potency differences were
calculated for all targets and the distribution of these potency records is shown
in Figure 7.3-1 (left). The distribution roughly follows an exponential distribu-
tion. Thus, compounds of the majority of MMPs showed only small differences
in potency and only few MMPs showed large potency differences. The median
absolute logarithmic potency difference was 0.542 for compounds forming an
MMP.
7.3.3.2 Identified Replacements
In order to identify bioisosteric replacements that were observed for members
of multiple target families, filters 1-5 were applied. Of the 55 399 considered
transformations, only 1 721 transformations had at least 30 potency records
associated with them. Hence, filter 1 already reduced the number of transfor-
mations to approximately 3% of the original volume. However, we considered a
minimum of 30 potency records required for a statistically meaningful analysis.
A total of 1 585 transformations were observed in the ligand sets of different
protein families and passed filter 2. However, for 153 transformations, potency
records were predominantly reported for one target family with less than 15
records remaining for other families, such that these transformations failed filter
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3. For the MMPs described by the remaining 1 432 transformations, a distribu-
tion of absolute logarithmic potency differences was calculated and is displayed
in Figure 7.3-1 (right). In comparison to the distribution for the complete set
of transformations shown on the left in Figure 7.3-1, the overall shape of the
distribution is similar, however, the median potency difference is shifted to the
left (0.428) indicating a slight tendency to cover smaller potency differences for
frequently found transformations. We determined that 19.6% of all calculated
potency differences were larger than one order of magnitude. This frequency
could be used to estimate the amount of false positive bioisosteres identified
by our analysis. For a transformation that introduces potency changes of more
than one order of magnitude with this mean frequency and for which only 30
measurements are available, the probability that it is identified as a bioisostere
given our criteria was smaller than 5%. This demonstrates that a cutoff of 30
measurements enabled a statistically meaningful analysis.
Our bioisostere filter reduced the set of 1 432 transformations to 132 re-
placements. Hence, in many instances, too many potency records available for
a transformation violated the potency criterion. Only 1 of these 132 transfor-
mations did not meet the final selection criterion, but the second redundancy
rule for subset relationships further reduced the number to 96 transformations
that described bioisosteric replacements accepted in the context of our anal-
ysis. SMIRKS representations for these bioisosteric replacements are provided
in Appendix Table E-3 and are annotated with their number of corresponding
potency records (ranging from 30 to a maximum of 439 records). Individual
bioisosteric replacements occurred in up to 282 different MMPs and were found
in 132 ligand sets belonging to 48 target families. The calculation of correspond-
ing medians yielded 27 MMPs, 25.5 targets, and 13.5 target families.
We have also determined whether the identified bioisosteric replacements
occurred in different chemotypes by calculating the ratio of the number of
MMPs and the number of MMPs representing different scaffold pairs for each
transformation. In most cases, the MMP-to-scaffold pair ratios were close to
one, hence indicating that most bioisosteric replacements indeed occurred in
different chemotypes.
7.3.3.2.1 Comparison to Known Bioisosteric Replacements Among
our set of 96 non-redundant bioisosteric replacements, we found a number of
previously described bioisosteres [117, 118], as illustrated in Figure 7.3-2. The
halogen substitutions bromine versus chlorine or iodine and the exchange of
piperazine and piperidine are examples of classical isosteres, as defined by
Erlenmeyer [119], i.e., atoms or molecules in which the outer electron shells are
considered identical. In addition, previously reported non-classical bioisosteres
were also identified, including, for example, the substitution of iodine for a nitro
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Figure 7.3-2: Tra-
ditionally known
bioisosteres Classi-
cal and non-classical
bioisosteres identified in
our analysis are shown.
The figure is adapted
from [109].
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or methoxy group, the exchange of a cyclopropyl and isopropyl group, and the
substitution of a dimethylamine for a methoxy group.
7.3.3.2.2 Preferred Structural Environments Several other commonly
accepted bioisosteric replacements were only found in specific structural envi-
ronments, as illustrated in Figure 7.3-3. For example, the exchange of a fluorine
atom and hydroxyl group, which are for long known as isosteres according to
Grimm's Hydride Displacement Law [120], was only accepted as a bioisostere
when these substituents were attached to an acyclic carbon atom. Similar struc-
tural restrictions were also observed for replacements of chlorine by fluorine,
and methyl, trifluoromethyl, and hydroxyl groups, the replacement of a nitro
or trifluoromethyl group by bromine, and the exchange of a methoxy group and
fluorine. Furthermore, the exchange of an O and an S linker only qual-
ified as a bioisosteric replacement when one of the attached moieties was a
4-substituted phenyl ring.
Because only single bonds between non-hydrogen atoms were deleted to
fragment bioactive compounds for MMPA, it was not possible to identify a
transformation that replaced a single hydrogen atom. Instead, the substitution
of hydrogen atoms by other functional groups was detected as part of transfor-
mations involving multiple heavy atoms that provided additional information
about the structural context of a substitution. Figure 7.3-3 shows several such
transformations where the actual exchange is the replacement of a hydrogen
atom by a fluorine or chlorine atom or a methyl or methoxy group.
Furthermore, a subset of our 96 bioisosteric replacements consisted of struc-
tural isomers, as shown in Figure 7.3-4. Most of these replacements defined
ortho/meta or meta/para regioisomers. By contrast, bioisosteric ortho/para re-
gioisomers were not found.
7.3.3.2.3 Excluded Bioisosteric Replacements A number of commonly
accepted bioisosteric replacements were not identified. For example, the sub-
structure pairs shown in Figure 7.3-5 are generally regarded as bioisosteres and
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Figure 7.3-3: Structural context dependence Commonly accepted bioisosteric re-
placements that only met our transformation selection criteria when occuring in specific
structural environments are reported. The figure is adapted from [109].
we investigated the reasons for their exclusion on the basis of our selection crite-
ria. The phenyl versus 2-thienyl, 2-furanyl, and 2-pyridyl exchanges frequently
occurred across different target families but failed to pass our bioisostere filter
because the fraction of potency records within one order of magnitude ranged
from 75.7% to 86.3%. Furthermore, we analyzed five known bioisosteric replace-
ments of carboxylate whose substitution with other groups had been found to
frequently introduce activity cliffs, as reported in the previous section. For the
substitutions of phosphonate and sulfonate for carboxylate, too few potency
records were available to meet our selection criteria. However, the limited num-
ber of available potency records revealed a substantial difference between these
two replacements. For the carboxylate versus phosphonate replacement, only
29.2% of the potency records were within one order of magnitude, whereas
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Figure 7.3-4: Structural isomers Molecular transformations that describe constitu-
tional isomers and qualified as bioisosteric replacements in our analysis are shown. The figure
is adapted from [109].
93.3% of the potency records for the carboxylate versus sulfonate replacement
were within one order of magnitude. The replacements of a primary amide, hy-
droxamate, and tetrazolate by carboxylate occurred more frequently, but were
often accompanied by potency changes larger than one order of magnitude,
for example, in 68% of all cases for hydroxamate. In addition, the hydroxamate
versus carboxylate exchange was essentially limited to matrix metalloproteases.
Overall, exchanges of the divalent linkers S, O, NH, and C, which were
also frequently observed, retained similar potency levels in about 75% to 85%
of all cases. A similar percentage was observed for the replacement of carbonyl
by sulfinyl and sulfonyl groups. However, the sulfinyl to carbonyl transforma-
tion was only annotated with ten potency records and much less frequent than
the sulfonyl versus carbonyl exchange. Furthermore, the three replacements of
the amide group shown in Figure 7.3-5 clearly failed to meet our bioisostere
criterion, with approximately every fourth potency record being larger than
one order of magnitude. Thus, in these cases, previously reported bioisosteres
were not selected by our analysis because too few potency measurements were
available or the replacements were associated with rather large changes in po-
tency. Of course, for compound optimization efforts, such replacements might
well be attractive, but their bioisosteric nature should be considered with some
caution.
7.3.3.2.4 Extending the Current Spectrum of Bioisosteres Half of
our bioisosteric replacements were previously unobserved. A subset of these
replacements is shown in Figure 7.3-6. For example, rather surprisingly, an
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Figure 7.3-5: Non-accepted substitutions Replacements that were excluded on the
basis of our selection criteria are shown and annotated with their number of potency records
and the percentage of records falling within one order of magnitude. If more than two frag-
ments are shown in a box, the fragment at the top is exchanged with each of the fragments
at the bottom. The figure is adapted from [109].
ortho-fluoro-substituted and various meta-substituted phenyl rings, but not the
unsubstituted phenyl moiety, were found to be bioisosteres of 2- or 3-thienyl
groups. In addition, pyrrolidine, but not the probably more intuitive piperidine,
was identified as a bioisostere of morpholine. Furthermore, the 3-methoxyphenyl
and benzodioxol rings were also found to be bioisosteric. Moreover, the cy-
clopentyl ring was not only identified as a bioisostere of the cyclobutyl group
but also of isobutyl and propyl groups. Several bioisosteric replacements in Fig-
ure 7.3-6 also reveal that the introduction of an ether group was permitted in
different structural environments. Thus, about half of the bioisosteres identified
in our analysis further extend the spectrum of generally accepted bioisosteric
replacements.
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Figure 7.3-6: Extended spectrum of bioisosteric replacements Previously only
little-considered or unobserved bioisosteric replacements are shown. The figure is adapted
from [109].
7.3.4 Summary
On the basis of systematically generated MMPs, we have identified a set of non-
redundant transformations that defined potential bioisosteric replacements, i.e.,
conservative substitutions of chemical groups that are tolerated by biological
targets but have the potential to modulate other compound properties in a
desired way. Transformation selection criteria were applied that captured what
we considered to be key aspects of bioisosterism. These criteria emphasized
the availability of many potency records associated with defined transforma-
tions, limited potency differences in MMPs representing a given replacement,
and observed activity of candidate replacements across different target families.
On the basis of these criteria, a number of previously reported replacements
were not considered to be bioisosteric because currently available compound
data were too sparse to draw statistically sound conclusions or the replace-
ments were accompanied by large changes in compound potency. Another key
observation has been that many commonly accepted bioisosteric replacements
depended on a specific structural environment. We identified a set of 96 non-
redundant bioisosteric replacements that consistently met our selection criteria
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and were well-supported by currently available data. Approximately half of
these bioisosteres were thus far only little-considered or unobserved. This re-
vised and further extended set of bioisosteric replacements should be useful for
many medicinal chemistry applications.
7.4 Target-Family Directed Bioisosteric
Replacements
Bioisosteric replacements discussed thus far have been general, i.e., they have
been considered to be bioisosteric across different targets. In compound opti-
mization, one typically considers bioisosteres on the basis of this premise. A
question that has not yet been investigated, but that is also of high relevance
for medicinal chemistry applications, is whether or not bioisosteric replacements
can be found that preferentially act against a given target family. Considering
the individual structural constraints that must be met to yield specific target-
ligand interactions, it would perhaps not be unlikely that such replacements ex-
ist. In order to address this question we have adapted the previously described
transformation selection criteria to the search for bioisosteres in individual tar-
get families, using the same compound data sets as in the search for general
bioisosteric replacements.
7.4.1 Compound Data Sets
We used the sets of target-specific MMPs identified in our search for general
bioisosteric replacements. As only target families with MMP sets for at least
three targets were considered in our analysis, only 432 of the original 460 MMP
sets were retained. The corresponding 432 targets belonged to 40 different target
families, with the number of targets per family ranging from 3 to 35. The 432
sets accounted for 22 631 different compounds forming 107 669 MMPs defined
by 255 845 (in part redundant) transformations.
7.4.2 Transformation Selection Criteria
Molecular transformations were separately analyzed for each target family. For
each transformation found in compound sets of a target family, all correspond-
ing MMPs were assembled and the following search protocol for bioisosteric
replacements in target families was applied:
1) At least 20 potency records are associated with the transformation.
2) MMPs defined by the transformation are found for at least two targets and
contain at least five different scaffold pairs.
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3) If the target or the scaffold pair for which the largest number of potency
records are available is removed from the analysis, at least ten potency
records have to remain.
4) Not more than 1/15 of all potency records are larger than one, i.e., maxi-
mally 6.67% of all potency changes induced by the transformation are larger
than one order of magnitude.
5) In the case that more than 50% of all potency records are observed for
one target or scaffold pair, the fraction of potency records greater than one
magnitude observed for the other targets or scaffold pairs, respectively, is
not larger than 2/15.
Filter 2 focuses the search on transformations that occur in different structural
contexts. In the search for frequent cliff formers and general bioisosteric re-
placements, chemotype diversity was retrospectively assessed for the final set
of selected transformations but not included in the search criteria. However, on
the basis of individual target families, biases of potency record distributions to-
wards single scaffolds are much more likely to occur and were therefore directly
prevented by our modified search criteria. Rules for avoiding redundancies in
transformations were adopted from paragraph 7.3.2.
7.4.3 Results
We aimed at the identification of bioisosteric replacements at the level of a target
family. Transformations met the search requirements if they were consistently
represented by multiple MMPs with moderate potency differences for more
than one target, if they occurred in different structural environments, and if
the corresponding potency records were not significantly biased by a single
target or scaffold pair. Importantly, due to the general sparseness of currently
available activity annotations, one would not be able to conclude with certainty
that replacements meeting these selection criteria would be true bioisosteres for
all targets belonging to a family or that they could not act on a target belonging
to another family. It is important to note that one can only extract information
that currently available compound data provide. Therefore, replacements that
ultimately met our criteria for only one target family were classified as target
family-directed (rather than family-specific) bioisosteres.
7.4.3.1 Preselected Transformations
A pool of 255 845 transformations provided the starting point for our analysis.
After the application of our selection criteria, only 79 non-redundant trans-
formations remained. The selection procedure traced transformations back to
16 target families. However, for a subset of transformations, multiple family
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Figure 7.4-1: Bioisosteres directed at multiple target families The 16 bioisos-
teric replacements that were identified for multiple target families are shown and anno-
tated with their family assignments. Three replacements that were also identified as gen-
eral bioisosteres across multiple target families are highlighted in red. The figure is adapted
from [110].
assignments were obtained. We found more than one family assignment for a
total of 15 transformations that are shown in Figure 7.4-1. These transforma-
tions involved replacements of small functional groups (e.g., halogen atoms and
methyl and methoxy groups), aliphatic linkers of different length, and phenyl
rings with different substituents. Most of these transformations were assigned
to two target families and, in a few instances, also to three or four. The extreme
case has been a rather generic replacement of a meta- versus para-substituted
phenyl ring, which was bioisosteric for ligands of six target families. Three of
the 15 transformations had also passed the filter criteria in our previous search
for transformations acting as bioisosteres across different target families and
are highlighted in red boxes in Figure 7.4-1.
7.4.3.2 Identified Replacements
After removal of these 15 transformations, a total of 64 transformations re-
mained that met our single target family constraint and hence qualified as
target family-directed bioisosteres. These 64 bioisosteric replacements were di-
rected against 11 target families. Table 7.4-1 reports the distribution of bioisos-
teric replacements over these families. A total of 22 replacements were found
in ligands active against the nucleotide-like ligand receptor family, which rep-
resented the largest number, followed by the short peptide receptor, tyrosine
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Table 7.4-1: Distribution of target family-directed bioisosteres
target family abbr. #bioisosteres #targets
nucleotide-like ligand receptor NLR 22 5
short peptide receptor SPR 17 35
tyrosine kinase TK 7 30
peptidase M10A M10A 4 9
peptidase S1 S1 3 17
monoamine receptor MAR 3 34
carbonic anhydrase CA 3 9
nuclear hormone receptor NHR 2 18
AGC serine/threonine kinase AGC 1 14
peptidase C1 C1 1 6
lipid-like ligand receptor LLR 1 20
Target families for which family-directed bioisosteres were identified are listed in the col-
umn target family and are abbreviated (abbr.). For each family, the number of directed
bioisosteres (#bioisosteres) and the number of targets in the family (#targets) are re-
ported.
kinase, and peptidase M10A families with 17, 7, and 4 bioisosteric replacements,
respectively. Interestingly, while seven bioisosteric replacements were found for
inhibitors of tyrosine kinases, only a single bioisostere was detected for inhibitors
of AGC serine/threonine kinases. In two more cases including the lipid-like lig-
and receptor and the peptidase C1 families, only a single qualifying replacement
was identified. In Figure 7.4-2, all 64 target family-directed bioisosteric replace-
ments are shown. Four transformations identified for a single target family in
this study were also included in the set of 96 replacements acting as bioisosteres
across multiple target families and are highlighted in red boxes. This finding
underlines the known sparseness of available compound activity data and im-
plies that these transformations would likely have been identified as bioisosteres
for additional target families if enough potency records had been available for
their ligands. However, as further discussed below, replacements that might,
at first glance, look rather generic are indeed target family-directed because of
significant potency differences associated with them in different families.
As shown in Figure 7.4-2, chemically different and differently sized replace-
ments were observed for individual protein families. Qualifying replacements
involved not only functional groups, but exchanges of linker fragments or substi-
tuted ring systems were also frequently found. Thus, for practical compound op-
timization, some target family-directed bioisosteres involving well-defined func-
tional groups might be of higher interest than others, such as linker fragments,
although these fragments also met all formal requirements for bioisosterism.
Figure 7.4-3 shows a subset of these preferred bioisosteres that would have also
qualified for one to five other target families if potency changes of more than
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Figure 7.4-2: Target family-directed bioisosteric replacements All 64 single
target family-directed bioisosteric replacements are shown and annotated with their family
assignment. Abbreviations are used according to Table 7.4-1. Four replacements that were
also identified as general bioisosteres across multiple target families are highlighted in red
boxes. The figure is adapted from [110].
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one order of magnitude would have been permitted in our analysis. As an ex-
ample, we consider the methyl to trifluromethyl replacement that was found
to be directed against the nucleotide-like ligand receptor family. This substi-
tution was also frequently observed for monoamine receptors, tyrosine kinases,
short peptide receptors, lipid-like ligand receptors, and sodium neurotransmit-
ter symporters. However, for these families, the replacement often induced large
potency differences. For these families, potency changes of more than one order
of magnitude were observed with frequencies of 21.1, 18.5, 15.6, 13.3, and 9.7%,
respectively. Hence, in these cases, the methyl to trifluromethyl substitution
did not qualify as a bioisostere. Nevertheless, although their bioisosterism with
respect to the secondary target families might in part be questionable due to
large potency alterations, the replacements shown in Figure 7.4-3 can also rep-
resent attractive candidates for the optimization of compounds active against
these families if potency changes are tolerated or even explicitly desired in the
current stage of the optimization process.
7.5 Conclusions
In this chapter, we have adapted the matched molecular pair formalism to com-
prehensively retrieve molecular transformations from publicly available bioac-
tive compound sets. A strength of the MMP-based approach is that it requires
no preconceived chemical notion of groups that might be of interest, but rather
systematically detects all substructure exchanges that are defined by single
transformations. In addition, structural contexts of actual substructure modi-
fications are taken into consideration. In our analyses, chemical replacements
were systematically related to resulting potency changes. Sections 7.2 and 7.3
reported the identification of substructure exchanges with a general propensity
to introduce activity cliffs or produce compounds with similar potency levels.
Care was taken not to bias the analyses towards individual chemotypes or tar-
get families. From vast available chemical transformation space, including both
R-group and core substructure changes, compendiums of activity cliff-forming
and bioisosteric replacements were assembled that showed clearly distinguish-
ing characteristics. For example, frequent cliff formers often described structural
exchanges that led to compounds with different charges or notable differences
in size. By contrast, the bioisosteric replacements that we identified mainly con-
sisted of substructures of similar size and charge, in accordance with the general
definition that bioisosteres should have similar structural and physicochemical
properties. A notable amount of our identified bioisosteric replacements led to
pairs of compounds with different numbers of H-bond acceptors, but changes in
the number of H-bond donors were only rarely observed. Our set of frequent cliff
formers, which is the first and only collection of this kind reported so far, and
our revised and further extended set of bioisosteric replacements should be use-
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Figure 7.4-3: Comparisons across different target families Target family di-
rected replacements are shown that would have qualified as bioisosteres for more than one
target family if potency changes larger than one order of magnitude had been accepted. The
qualifying target family is abbreviated in green and other families that did not meet the
potency criterion are shown and annotated with the relative frequency with which the trans-
formation introduced potency changes larger than one order of magnitude. Abbreviations are
used according to Table 7.4-1. SNF stands for the sodium neurotransmitter symporter family.
The figure is adapted from [110].
ful for many medicinal chemistry applications and have important implications
for screening library design.
Furthermore, the results presented in section 7.4 suggest that the currently
available repertoire of bioisosteric replacements is further extendable through
a systematic analysis of bioisosteres at the level of target classes and that a
subset of bioisosteres is indeed preferentially directed against individual target
families. A differentiation of transformations on the basis of their observed ac-
tivity profiles is anticipated to be helpful in the establishment of a classification
scheme for bioisosteric replacements and of great aid in compound optimization
efforts.
In general, systematic compound data analysis approaches, as reported
herein, are expected to become increasingly relevant for the analysis of structure-
activity relationships in the future as available compound collections further
grow in size.
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Source Information
Sections of the text in this chapter have been taken from [108110].
Chapter 8
Structure-Activity Relationship
Patterns in Series of Analogs
In addition to the approaches to study structure-activity relationships presented
so far, computational visualization methods have been introduced that help
to extract SAR information from compound data sets [31]. Different methods
have been developed to analyze large and diverse compound data sets including
HTS data [15, 121]. The extraction of SAR information from large compound
sets represents one of two major tasks in SAR analysis. The other task is com-
pound optimization during later stages of medicinal chemistry efforts. In this
case, the focus shifts from larger data sets to individual compound series where
SAR exploration primarily aims at the analysis and design of analogs of active
compounds with further improved properties. Therefore, computational meth-
ods are required that are very sensitive to small structural modifications and
analyze SARs with a high resolution at the level of individual substitution sites.
The conventional and still most widely used data structure for the analysis
of analog series are R-group tables that contain the core structure common to a
series of analogs and rows displaying the substituents of individual compounds
and the associated potency measurements. User-friendly extensions of R-group
tables have been introduced, such as SAR maps [25] that arrange analogs in
rectangular matrices of cells where each cell represents a unique combination
of R-groups at two substitution sites. Cells are then color-coded according to
a specific molecular property, usually compound potency against a given tar-
get. Only a subset of a series is displayed if analogs display variations at more
than two substitution sites. Heat maps were also used to display mean po-
tency changes resulting from the exchange of a pair of substituents at a given
site [122]. Similarly to SAR maps, multiple views of the same series of analogs
are required to display SAR information for more than one substitution site.
Another recently introduced data structure of graphical analog analysis is the
combinatorial analogue graph (CAG) [42] that systematically organizes substi-
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tution sites and their combinations in a tree-like structure and identifies their
contributions to SAR discontinuity. Hence, CAGs view analog series differently
from R-group tables because they pinpoint substitution sites in the common
core structure where R-groups introduce significant changes in potency. How-
ever, CAGs do not provide an immediate access to functional groups at these
positions (discussed in more detail in Chapter 9).
Other than R-group tables, their extensions, and CAGs, there are currently
no graphical SAR analysis methods for analogs available. In particular, SARs
between R-group combinations at different sites are difficult to monitor. There-
fore, we have developed a graphical data structure that goes beyond the capac-
ities of previously published visualization methods by explicitly using R-group
combinations and their (subset) relationships as an organizing principle [123].
The design of this graph structure that emphasizes relationships between differ-
ent R-group combinations and is termed directed R-group combination (DRC)
graph (DRCG) is introduced in this chapter. As detailed in section 8.1, R-group
combinations are systematically extracted from a given analog series, associated
with potency information of all analogs containing a specific combination, and
organized according to consistently numbered substitution sites. Interpretable,
information-rich SAR patterns emerging from this data structure are described
in section 8.2 and exemplary applications to four different analog series are
reported in section 8.3. The chapter ends with a summary of key aspects in
section 8.4.
8.1 Methodology
The newly designed graph structure represents entire series of analogs in a
consistent manner, regardless of their size and complexity of substitution pat-
terns. The approach is specifically tailored towards a systematic exploration
and intuitive interpretation of SAR features involving different R-groups and
their combinations. Analogs and their potency information are systematically
organized on the basis of R-group combinations that are present in a series.
8.1.1 R-group Deconvolution and Signature Formation
Initially, the maximum common subgraph (MCS) of compounds comprising an
analog series is determined and all non-hydrogen atoms of the MCS are labeled
with numeric identifiers, as illustrated in Figure 8.1-1 (top) for a model series
of five analogs. The MCS is then used as the invariant molecular core structure
for R-group deconvolution of all analogs. For this purpose, the MCS is mapped
onto each analog and the numeric identifiers are transferred to matching atoms.
Variable R-groups are identified and unambiguously assigned to corresponding
substitution sites for all analogs by extracting groups that are not part of the
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alignment and marking them with the numeric identifier(s) of the matching
atom(s) to which they are attached. The list of all identified R-groups is used as
the signature of the molecule. If multiple mappings of the MCS onto a compound
are possible because it contains symmetry elements around rotatable bonds, all
mappings and resulting signatures are determined, as illustrated for molecules
C, D, and E in Figure 8.1-1 (middle). In this example, the three molecules
contain a chlorine atom at the ortho position of the phenyl ring that can be
assigned to substitution sites 2 or 4.
In the next step, R-group combinations that are shared by multiple com-
pounds are systematically detected by extracting signature subsets from all
analogs. Hence, if an analog contains R-groups at n substitution sites, all pos-
sible signature subsets with R-groups for n− 1 to 1 substitution sites are gen-
erated, as illustrated for molecule E in Figure 8.1-1 (middle). The original
signature and all signature subsets are then added as separate keys to an index
table and assigned to the source compound (Figure 8.1-1, bottom). Hence, all
analogs belonging to a particular key share the R-group combination defined
by the key. If alternative mappings of the MCS onto given analogs of a series
are possible, corresponding keys in the index might describe the same R-group
pattern for an identical set of compounds with alternatively numbered substi-
tution sites. These keys are identified and combined into a single entry (Figure
8.1-1, bottom).
The R-group decomposition, signature (subset) formation, and index struc-
ture generation routines were implemented in Java using the OpenEye chemistry
toolkit.
8.1.2 DRCG Design and Visualization
In order to capture subset relationships between keys in the index table (i.e., sets
of R-groups at specific substitution sites), a directed acyclic graph is generated,
as illustrated in Figure 8.1-2.
8.1.2.1 Graph Structure
Keys correspond to nodes in the DRCG. Each node is associated with the set of
molecules that contain the specified R-group combination (and are thus linked
to the same key in the index table). Nodes are connected via directed edges
to all other nodes that are obtained by removing R-groups from exactly one
substitution site of the original set. Thus, nodes connected by directed edges
are involved in parent-child relationships and all molecules that are associated
with a parent node are also associated with a child node. However, a child node
might contain additional analogs.
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Figure 8.1-1: R-group combinations A model analog series of five compounds is
shown (top) together with its MCS. Compounds A-E are annotated with their logarithmic
potency, i.e., pKi values. Signatures, i.e., sets of R-groups, are extracted from all compounds
(middle). For molecule E, the generation of signature subsets is illustrated. R-group combi-
nations are then added to an index structure and associated with the analogs in which they
occur (bottom). For clarity, only a section of the complete index structure is shown. R-group
combinations that are obtained by symmetry-related mappings are combined into a single
entry. The figure is adapted from [123].
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A child node associated with exactly the same set of molecules as its par-
ent node is removed, which reduces the complexity of the graph by omitting
redundant information. This is the case if a smaller R-group combination al-
ways occurs in the context of a larger one. If node removal eliminates the only
existing pathway between a parent and a grandchild (i.e., another node con-
nected to the child), an edge is inserted that directly connects the parent to its
grandchild. The graph structure is iteratively updated after each node removal.
The process ends when all redundancies are eliminated. The original unpro-
cessed graph structure for the model analog series in Figure 8.1-1 is shown
in Figure 8.1-2a. Because all edges from the top to the bottom of the graph
are directed (and follow the same direction), arrows are generally omitted for
clarity. Nodes that convey redundant information and are removed from the
graph during processing are shown in yellow. The processed graph is depicted
in Figure 8.1-2b.
8.1.2.2 Node Types
In the processed graph, two types of nodes are distinguished: nodes that are
associated with a single compound are drawn as circles while nodes that repre-
sent R-group combinations in multiple analogs are drawn as squares. The size
of an analog subset assigned to a square-shaped node is indicated by its frame
thickness that increases with the number of compounds.
The different node types are interpreted as follows: the R-group combi-
nation represented by a circular node corresponds to the signature (i.e., the
complete list of R-groups) of the single molecule that is assigned to the node.
Hence, the combination of the signature and MCS defines the molecular struc-
ture of the associated compound. However, the signature of a molecule is only
associated with a circular node if the corresponding set of R-groups does not oc-
cur in any other analog of the series. If the signature of a compound corresponds
to a subset of R-groups in other analogs, these analogs are combined and repre-
sented by a square-shaped node. Following our terminology, this compound is
then masked by the square-shaped node. In order to identify a masked com-
pound in the graph, it is symbolized as a rectangle in the lower-right quadrant
of the node (Figure 8.1-2b).
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Figure 8.1-2: Graph structure (continued) Schematic illustrations of the graph
structure are presented that highlight different design elements. (a) An unprocessed graph is
displayed that contains nodes for all substituent combinations found in the model data set
shown in Figure 8.1-1. Nodes are associated with all analogs containing the given R-group
combination. An exemplary parent-child relationship between two R-group sets and the cor-
responding directed edge are indicated on the right. Nodes that carry redundant information
because they are associated with the same analog subset as a parent node are highlighted in
yellow. (b) The processed graph is shown after (i) removal of redundant nodes, (ii) introduc-
tion of different node types, and (iii) scaling of node frames according to compound numbers.
For two nodes, the masked compounds B and C are labeled in purple. (c) The graph is
displayed with (i) a color-code accounting for (mean) compound potencies and (ii) scaling
of color-filled node areas according to potency variations. For clarity, node labels and com-
pound information are not shown. Instead, groups of nodes are labeled with the corresponding
substitution site combinations. The figure is taken from [123].
8.1.2.3 Compound Potency Information
All circular nodes are colored according to the potency of the corresponding
compounds and the square-shaped nodes are colored according to the mean po-
tency of the associated analogs using a uniform continuous color gradient from
green (lowest potency in the data set) to red (highest potency), as illustrated in
Figure 8.1-2c. A rectangle symbolizing a masked compound is colored accord-
ing to its potency (analogous to circular nodes). Square-shaped nodes are often
not completely color-filled, for the following reason: if multiple compounds are
associated with a node, the area of the node that is colored reflects the standard
deviation of potency values. Thus, a node that is completely colored corresponds
to a standard deviation of zero, i.e., all associated molecules have the same po-
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tency value. For standard deviations larger than zero and smaller than one,
the color-filled area continually decreases to half of the original diameter and is
then kept constant for standard deviations equal to or larger than one (Figure
8.1-2c). Hence, decreasing color-filled node areas indicate increasing compound
potency variations.
As shown in Figure 8.1-2, nodes are arranged in layers that reflect decreas-
ing numbers of substitution sites, i.e., parents are always positioned above their
children. Furthermore, within the same layer, nodes representing R-groups at
exactly the same substitution sites are grouped together and arranged in order
of increasing potency from left to right.
8.1.2.4 Interactive Analysis
R-groups represented by nodes are stored as canonical SMILES strings that
serve as node labels. Nodes are associated with tooltips to display R-group
structures, report the number of compounds assigned to a node as well as their
mean potency, and the potencies of any masked compounds. The graph layout
can also be interactively edited. The graph design was implemented using the
Java package JUNG.
8.2 SAR Patterns
The DRC graph structure is designed to extract SAR information from R-
group patterns in analog series. An important feature of the approach is that
any series of analogs can be studied in context, regardless of the number of
substitution sites that occur (or the number of compounds). Furthermore, the
systematic and hierarchical organization of analogs on the basis of combinations
of all R-groups that are available in a series and the analysis of relationships
between different sets of R-groups also sets this methodology apart from cur-
rently available approaches to study analog series, such as R-group tables and
their extensions. In particular, the multiple R-group analysis scheme reveals
(i) critical substitution sites, (ii) (un)favorable substituents, (iii) additive and
non-additive effects on compound potency as a consequence of multi-site sub-
stitutions, (iv) optimization pathways gradually increasing compound potency,
and (v) suggestions for analog design. Thus, as shown in the following, the
potential of the DRCG approach goes much beyond conventional analysis of
analog series.
The DRCG structure contains several well-defined SAR patterns, i.e., sub-
graphs that reveal immediately interpretable SAR information. These graph
components are schematically depicted in Figure 8.2-1 and are rationalized as
follows:
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 SAR pattern 1 : R-group combinations that exclusively occur in highly po-
tent compounds are identified by square-shaped nodes filled with red color
that, ideally, have a thick frame indicating that the R-group combination
has been explored in many different compounds that are consistently highly
potent.
 SAR pattern 2 : critical substitution sites or combinations of sites where
structural modifications lead to large differences in potency occur as hor-
izontal node patterns in the graph. In this case, differently colored nodes
are grouped together within the same node layer, hence representing dif-
ferent combinations of R-groups at the same substitution sites spanning a
wide potency range. It follows that this pattern also provides an immediate
access to favorable and unfavorable R-group combinations.
 SAR pattern 3 : if the nodes forming the horizontal pattern 2 are all con-
nected to the same child node in the subsequent layer, the structural mod-
ifications responsible for large potency variations can be traced back to a
single substitution site.
 SAR pattern 4 : a gradual increase in potency resulting from a stepwise
addition of R-groups to a starting compound is detected as vertical pattern.
Following the path from a node in inverse edge direction (i.e., bottom-up
towards its ancestors) leads to increasingly potent analogs.
 SAR pattern 5 : a parent node that is connected to multiple less potent child
nodes indicates that its potency results from the interplay of the different
R-group sets associated with the child nodes. The substituent sets of the
child nodes are disjoint unless they share a common ancestor. The interplay
between different substitution sites and R-groups might result in additive
or non-additive effects on compound potency.
 SAR pattern 6 : under the assumption that favorable R-group effects on
compound potency are not compensatory (i.e., that positive effects at two or
more sites do not combine in a negative way), compound design suggestions
can be easily made on the basis of the DRCG structure. Attractive analogs
with presumably high potency can be derived from nodes that represent
favorable R-group combinations within the same layer and are connected
to a shared less potent child node in the next layer. Thus, starting from
the same R-group combination, the introduction of additional R-groups at
different substitution sites leads to analogs with increased potency. It follows
that new analogs can be immediately suggested that combine the original R-
group set with all potency-increasing R-groups introduced at distinct sites.
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3
horizontal pattern for nodes with an identical child node in the next layer:
modification at single substitution site results in compounds spanning 
a wide potency range
4
vertical pattern: stepwise addition of substituents gradually increases
potency
5
combination of substituent sets yields a more potent
compound
?
overlapping disjoint 
substituent sets
6 compound design suggestion by combining favorable sets of 
substituents with a common child in next layer
Figure 8.2-1: SAR patterns Subgraph patterns that capture SAR information in a
defined manner are shown and explained. The figure is taken from [123].
If SAR information is contained in a series of analogs, it will consistently
emerge in the form of the intuitive SAR patterns described above. Therefore,
searching a DRCG of any analog series for these characteristic SAR patterns
enables the extraction of SAR information, if available in a data set.
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8.3 Applications
In the following, four examples of analog series are discussed that contain in-
terpretable SAR information inferrable from DRCG representations.
8.3.1 Compound Data Sets
Four analog series of different composition containing between 31 and 54 com-
pounds were assembled from the ChEMBL database. Compounds active against
the human melanocortin receptor 4, norephineprine transporter, and dopamine
D1 receptor were extracted. From compounds forming each activity class, Bemis
and Murcko scaffolds were extracted and molecules sharing the same scaffold
(and activity) were combined into an analog set. Series comprising 30 or more
analogs were subjected to DRCG analysis.
8.3.2 Melanocortin Receptor 4 Antagonist Series 1
The first series of melanocortin receptor 4 antagonists consists of 32 analogs
with potencies ranging from pKi 5.2 to 8.9. For this series, a conventional R-
group table is provided in Appendix Table F-1 and its DRCG representation
is shown in Figure 8.3-1a. Because analogs sharing the same substitution sites
are grouped together, the graph reveals that most analogs in this series are
characterized by two different substitution site combinations, i.e., sites 0 and 5
(lower horizontal pattern in Figure 8.3-1a) and sites 0, 3, and 5 (upper horizontal
pattern). In both cases, R-groups at site 0 vary whereas groups at site 5 or sites
3 and 5 are invariant. This is captured by the graph structure because removal
of the substituents at site 0 yields the same child for all nodes of a group, i.e.,
child nodes annotated with site combinations 3 5 and 5, respectively. The
labels of these nodes reveal that the invariant R-groups at positions 3 and 5 are
chlorine atoms. Analogs forming both horizontal patterns are arranged in order
of increasing potency. In both instances, traversing nodes and associated R-
groups from the left to the right reveals that aliphatic amine moieties attached
to site 0 via an amide bond or carbamide derivatives are preferred substituents.
Exemplary analogs are depicted in Figure 8.3-1b.
Because R-groups at site 0 are highly variable, only three of the analogs in
the upper horizontal pattern are derived from others by addition of a chlorine
atom to position 3. However, from the vertical pathways involving these analog
pairs (highlighted in blue in Figure 8.3-1a) it can be inferred that a chlorine
atom at site 3 increases compound potency. The leftmost compound in the
upper horizontal pattern is accessible via two edges because an analog that
differs from this compound by the absence of the chlorine substituent at site 5
is also available in the data set. The analog without the chlorine at position 5
is also less potent: we can thus conclude that chlorine atoms at sites 3 and also
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5 make positive contributions to compound potency, which is also reflected by
the framed, red-filled node representing this R-group pair.
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Figure 8.3-1: DRCG for melanocortin receptor 4 antagonists (series 1)
(a) The MCS of a series of 32 analogs is shown at the top and substitution sites are labeled
with numeric atom identifiers. For two nodes, substituent combinations are provided. Char-
acteristic SAR patterns are numbered according to Figure 8.2-1 and highlighted as follows:
patterns 1 and 3, blue node background; pattern 4, blue edges (on the right); pattern 5, com-
bination of blue and turquoise edges (left). (b) Exemplary analogs from horizontal patterns
are shown. The remaining nodes are colored gray. The figure is taken from [123].
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By comparison with Appendix Table F-1 it is evident that the DRCG struc-
ture provides easy access to SAR information contained in this series that would
be much harder to extract from an R-group table. In particular, the analysis of
multi-site R-group effects would require a comparison of an analog with all oth-
ers in the R-group table. Furthermore, in the graph structure, a set of R-groups
is not only associated with the potency of the analog it defines but also with
the mean potency of all compounds in which this R-group combination occurs.
For example, the node that represents chlorine at position 5 in Figure 8.3-1a
(bottom right) provides the information that this substitution alone yields only
a weakly potent compound (masked in this node), whereas its combination with
other R-groups at other sites generally produces compounds with increased po-
tency. This type of information conveyed by the DRCG representation helps to
identify R-groups that act favorably in combination with others.
8.3.3 Melanocortin Receptor 4 Antagonist Series 2
The DRCG of another structurally distinct series of 54 melanocortin recep-
tor 4 antagonists covering a pKi range from 5.1 to 8.4 is shown in Figure
8.3-2a. The complete graph reveals that all analogs in this series are substi-
tuted at three or more different sites. A region formed by increasingly po-
tent analogs is highlighted. In these analogs, two different combinations of R-
groups at substitution sites 2, 16, and 22 are frequently found (corresponding
to the two nodes with 2 16 22 annotation at the bottom of the highlighted
pattern). Figure 8.3-2b focuses on another combination that consistently pro-
duces highly potent analogs. This combination is formed by a 2-methylpropyl-
3-(dimethylamino)propanamide group at position 0 and a chlorine atom at site
22. Analog A in Figure 8.3-2b that contains only these two substituents is cur-
rently untested (as stated above, all known analogs of this series carry R-groups
at three or more sites). The hypothetical analog A is also associated with the
node representing this R-group combination in the displayed graph structure.
Edges forming pathways to all compounds that contain this R-group combi-
nation are highlighted in blue in Figure 8.3-2b. Furthermore, all analogs that
contain the same R-group at site 0 but lack the chlorine substituent at site 22
are reached following the turquoise edges that lead to a cluster of weakly potent
compounds highlighted on the right of the graph. However, these compounds
are also set apart from the other analogs in the set by the presence of an R-
group at site 21, such that it cannot be concluded whether the disruption of the
interplay of substituents at sites 0 and 22 or the presence of a substituent at
site 21 is detrimental to compound potency. Two analogs B and C are marked
in the graph that contain the 2-methylpropyl-3-(dimethylamino)propanamide
group at position 0 and identical R-groups at sites 4 and 16, as indicated by a
shared child node. One of these analogs contains an additional chlorine atom at
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site 22 and is highly potent whereas the other contains a chlorine atom at site
21 and is only weakly potent. Therefore, it would be suggested to test another
hypothetical compound D (also shown in Figure 8.3-2b) that does not contain
any of the chlorine substituents, which might confirm the potency-decreasing
effect of a chlorine substituent at site 21 or the potency-increasing effect of a
chlorine atom at site 22.
Overall, most potent compounds are obtained when substitution sites 0, 2,
16, and 22 are simultaneously occupied, as highlighted in Figure 8.3-2a. Many
analogs with this site combination contain an isopropyl group at position 16, a
chlorine atom at position 22, and a methyl or trifluoromethyl group at position
2, as shown in Figure 8.3-2c. The R-group at site 0 is generally large and has
limited structural variability, as illustrated at the top of Figure 8.3-2c, which
displays the subgraph associated with these highly potent analogs.
Compounds associated with nodes B and E in Figure 8.3-2b share the
same R-groups at overlapping substitution sites (sites 0, 16, and 22; shared
child node) and have consistently high potency. Hence, it would be interesting
to combine these favorable R-group sets by generating a new analog F that is
shown in Figure 8.3-2b.
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Figure 8.3-2: DRCG for melanocortin receptor 4 antagonists (series 2)
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Figure 8.3-2: DRCG for melanocortin receptor 4 antagonists (series 2) (con-
tinued) For a series of 54 analogs, the complete graph and SAR information-rich subgraphs
are shown. (a) The MCS of all analogs is shown with relevant numeric atom identifiers. A sub-
graph associated with highly potent compounds and two substituent combinations frequently
found in these analogs are highlighted (SAR pattern 1, blue background). (b) Starting from a
favorable combination of two R-groups at substitution sites 0 and 22 (SAR pattern 1), edges
leading to highly potent compounds containing this combination are shown in blue. A cluster
of weakly potent compounds is highlighted (blue background) that contains only one of these
two R-groups (displayed substituent at site 0) and additional R-groups at other sites. The
path to this cluster is indicated using turquois edges. A compound design suggestion based
on SAR pattern 6 is indicated by dashed pink edges. Six nodes are labeled with the identi-
fiers of compounds (A-F) defined by the corresponding substituent combinations. Structures
and, if available, potency information for these compounds are provided at the bottom. (c)
The subgraph corresponding to the highlighted SAR pattern in (a) is shown together with
R-group information for nodes. The figure is adapted from [123].
8.3.4 Norepinephrine Transporter Inhibitor Series
The DRCG of a series of 41 norepinephrine transporter inhibitors spanning a
potency range of approximately three orders of magnitude is shown in Figure
8.3-3. The graph representation reveals that substitution sites 0 and 5 have
predominantly been explored in this series. Recurrent R-groups among analogs
include a trifluoromethyl group at position 5 and a dimethyl rest at position 0.
Interestingly, the introduction of one of these R-groups in isolation only gener-
ates a weakly potent compound, but their simultaneous introduction leads to a
more than additive increase in potency, yielding one of the most potent analogs
in this series (masked compound labeled A in Figure 8.3-3). The highlighted
horizontal pattern for the combination of substitution sites 0 and 5 shows that
the introduction of different R-groups at both sites has large effects on com-
pound potency. Moreover, as revealed by the weakly potent compounds on the
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right in Figure 8.3-3, the introduction of additional substituents at the meta
positions of the phenyl ring displays a strong tendency to decrease potency.
For example, when adding a trifluoromethyl group to the most potent analog
of this series (B in Figure 8.3-3) at site 8 (yielding analog C) or site 6 (analog
D), potency is reduced by more than two orders of magnitude. In general, the
relationships between di- and trisubstituted analogs in the DRCG of this series
indicate that the addition of R-groups at sites other than atom positions 0 and
5 does not lead to notable increases in potency.
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pKi range:  6.0 – 8.9
A
0 5
B
C D
0 65 7
0 5 7 0 5 9 0 5 8 0 5 6
5 0
DCBA
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Figure 8.3-3: DRCG for norepinephrine transporter inhibitors The MCS ex-
tracted from a series of 41 analogs is shown with numeric atom identifiers. For three nodes,
substituent combinations are shown. In addition, four nodes are labeled with the identifiers
of compounds (A-D) defined by the corresponding substituent combinations. Structures and
potency information for these compounds are provided at the bottom. SAR patterns are
highlighted: pattern 2, blue node background; pattern 5, blue edges. In addition, detrimental
effects of R-group combinations on compound potency are indicated using turquoise edges.
The figure is adapted from [123].
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8.3.5 Dopamine D1 Receptor Antagonist Series
The DRCG of a series of 31 dopamine D1 receptor antagonists that span a
comparably narrow pKi range from 6.8 to 8.8 is shown in Figure 8.3-4a. As
revealed by the highlighted horizontal pattern, the introduction of different
chemical groups at the meta position of the terminal phenyl ring (designated
with numeric identifier 21 in the graph) leads to largest potency fluctuations
within this series. At the left and right of this pattern, the trifluoromethyl and
methyl group are identified as least and most favorable R-group at this site,
respectively. In addition, considerable potency increases are observed for all
analogs having an R-group at the ortho position of the phenyl ring (site 20). Two
vertical patterns are highlighted in Figure 8.3-4a where the subsequent addition
of R-groups leads to stepwise increases in potency. Both pathways begin at the
same analog that carries a chlorine substituent at site 11 and is only moderately
potent (analog A). The addition of a fluorine atom at position 20 then leads
to a potency increase of approximately one order of magnitude (analog B).
Another order of magnitude is gained by adding a trifluoromethyl group at the
other ortho position in the ring (site 24, analog C). Similar potency changes are
detected for the stepwise addition of two methoxy groups at the corresponding
positions (analogs D and E). However, as depicted in more detail in Figure 8.3-
4b, potency changes of larger magnitude are observed for compounds F and G
that are also derived from analog A. In these cases, both the introduction of a
chlorine atom at the ortho position or a methyl group at the meta position of the
terminal phenyl ring increase compound potency by two orders of magnitude.
Hence, it would be attractive suggesting two additional analogs that combine
these favorable substitutions (i.e., hypothetical molecules H and I in Figure
8.3-4b) in order to further increase compound potency within this series.
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Figure 8.3-4: DRCG for dopamine D1 receptor antagonists For a series of 31
analogs, the complete graph and a subgraph illustrating compound design suggestions are
shown. (a) The MCS with relevant numeric atom identifiers is shown. Nodes are labeled with
compound identifiers. Structures and pKi annotations are displayed for compounds A-E.
Characteristic SAR patterns are highlighted: pattern 3, blue node background; pattern 4,
blue edges. (b) Compound design suggestions (H, I) are made based on SAR pattern 6. The
figure is adapted from [123].
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8.4 Conclusions
In this chapter, we have introduced a new graphical SAR analysis concept
specifically developed for the study of analog series and for compound design.
Instead of individual compounds, systematically derived R-group combinations
provide the basis for the construction of the DRCG structure, which is a central
feature of the approach. The graphical representation contains a number of de-
sign elements that emphasize available SAR information. From the hierarchical
organization of R-group combinations and corresponding analog sets, character-
istic subgraphs emerge that represent well-defined SAR patterns. If analog se-
ries are characterized by the presence of multiple substitution sites and R-group
combinations, it is usually difficult to rationalize SARs by comparing individ-
ual analogs and their potency values in R-group tables or subsets of analogs
with modifications at pairs of substitution sites. By contrast, in DRCGs, entire
analog series are consistently represented, regardless of the numbers of analogs
and substitution sites, and emerging SAR patterns reveal interpretable SAR
information. Importantly, subset relationships between R-group combinations
emerge from this data structure such that potency changes resulting from the
removal (addition) of a substituent from (to) a given R-group combination can
be monitored.
Source Information
Sections of the text in this chapter have been taken from [123].
Chapter 9
Selectivity Determinants in Series
of Analogs
Lead optimization traditionally has a strong single-target focus. In fact, the
premise that specific (and exclusive) interactions of a compound with an in-
dividual target are a prerequisite for desired biological efficacy represents a
paradigm that has for long been a cornerstone of drug discovery research [63].
However, with increasing evidence of polypharmacological behavior of biolog-
ically active compounds, these views are beginning to be revised [65]. It is
now better understood that many pharmaceutically relevant compounds act
on multiple targets and promiscuous multi-target interactions are known to be
favorable in several instances, for example, for the treatment of cancer using
protein kinase inhibitors [64].
However, target-specific compounds continue to be of critical importance,
considering that adverse drug reactions, which often result from a lack of molec-
ular specifity, are estimated to be the fourth leading cause of death in western
countries [124]. Furthermore, high selectivity is required to combat pathogenic
infections, for example, when targeting bacterial enzymes for which human or-
thologs exist. Consequently, if one intends to focus on an individual target,
one usually attempts to render compounds with multi-target activity target-
selective through chemical optimization efforts. For this purpose, multi-target
structure-activity relationships (mtSARs) are studied and compared, which rep-
resents a rather complicated task for classical analog design strategies. In or-
der to achieve target selectivity, or specificity, one ultimately needs to identify
functional groups that are selectivity determinants, which is often difficult. To
study SARs in a consistent manner, we have developed a methodology for mt-
SAR analysis [125] that combines information about 2D pharmacophore feature
similarity and compound potency distributions within compound series with
combinatorial analogue graphs (CAGs) that are specifically tailored toward
the detection of critical, i.e., activity-determining substitution sites in analog
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series [42]. For the study of mtSARs, we revised the CAG data structure to
provide better access to types of substitutions responsible for apparent SAR
discontinuity and to facilitate side-by-side comparisons of CAGs for multiple
targets. The enhanced data structure is capable of extracting available mtSAR
information from compound data sets and differentiate it in a target-directed
manner, as demonstrated in this chapter. Section 9.1 describes methodologi-
cal details of our approach and emphasizes modifications that were made to
the original CAG implementation it was built on. In section 9.2, it is shown
how the introduced analysis scheme can be used to derive preference orders for
selectivity-conferring substitution patterns and SAR rules. Section 9.3 reports
two exemplary applications of the methodology to publicly available compound
data. Concluding remarks are found in section 9.4.
9.1 Methodology
The CAG data structure was designed to analyze SARs of analog series and is
generated on the basis of three operations: R-group decomposition, similarity
assessment, and SAR discontinuity evaluation [42].
9.1.1 CAG Data Structure
For each analog series, the MCS shared by all analogs is determined using
Pipeline Pilot. The MCS is then used as the invariant core structure for R-
group decomposition to determine corresponding substitution sites in analogs
and assign sets of substituents to these sites. For all possible pairs of com-
pounds, substitution sites that carry different R-groups are determined and
compound pairs are grouped into subsets according to the substitution site
combination S at which they differ, as shown in Figure 9.1-1. Symmetrically
substituted molecules are not firmly associated with only one possible mapping
onto the MCS, but a symmetrically substituted compound is compared with all
remaining compounds in the analog series, and each compound pair is mapped
such that the number of identical substituents shared by the two molecules is
maximal. If several mappings are possible for a compound pair based on this
selection criterion, all mappings are retained and the compound pair is assigned
to multiple subsets. Furthermore, subsets containing pairs of compounds that
show differences at more than three substitution sites are discarded. Then, the
degree of discontinuity found for compound pairs in each subset is assessed by
using the SAR Index discontinuity score [29], a numerical function that mon-
itors the presence of activity cliffs in compound classes and yields high values
for sets of molecules that contain structurally similar compounds with large po-
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tency differences. For each subset, a raw discontinuity score is calculated for all
compound pairs i and j that differ at the given substitution site combination S
discraw = mean{(i,j)|i,j differ at S}
(
|Pi − Pj| × sim(i, j)
)
(9.1)
where Pi and Pj denote the negative decadic logarithm of potency values of
compounds i and j and sim(i,j ) corresponds to a similarity function. Raw dis-
continuity scores are converted into Z-scores by using the sample mean and
standard deviation of scores obtained for analog pairs in target family-specific
reference sets. Z-scores are then mapped onto the value range [0,1] by calculat-
ing the cumulative probability for each score under the assumption of a normal
distribution. Because scores are not specific for a single activity class but nor-
malized with respect to reference compounds from a target family, the magni-
tude of scores can be directly compared for related targets. A high discontinuity
score indicates the presence of activity cliffs in compound data sets. As scores
are calculated for subsets of compound pairs that differ only at well-defined
substitution sites, they reflect the SAR discontinuity introduced by individual
substitutions or combinations of substitutions and highlight atom positions in
the MCS where minor structural modifications lead to considerable potency
changes.
To provide immediate access to critical substitution sites, the results of
R-group decomposition and discontinuity calculations are visualized in a CAG,
as shown in Figure 9.1-2. A CAG is a graph that consists of nodes and edges
connecting individual nodes. Here, nodes correspond to subsets of compounds
varying at specific substitution sites identified by node labels. Edges indicate
that compound pairs in connected subsets share modifications at the same sub-
stitution sites (e.g., site 1, 1 and 2 (1-2), and 1-2-3). Thus, CAGs hierarchically
organize analog series according to substitution sites. Nodes are color-coded
according to discontinuity scores using a continuous color spectrum from green
(low discontinuity score) to red (high discontinuity score). The discontinuity
score for the root node is calculated by taking only those compound pairs into
account that differ in no more than three substitution sites. CAGs are calculated
and displayed using the statistical computing language R [42].
As shown in Figure 9.1-2, the graph structure allows the straightforward
identification of SAR hotspots (red nodes), i.e., substitution sites where
changes are most likely to introduce SAR discontinuity and produce compounds
with large differences in potency. Furthermore, CAGs enable the identification
of SAR holes, i.e., combinations of substitution sites, that have not yet been
explored. Hence, useful suggestions which compounds to synthesize next and
how to complement a current series can be derived from considering relation-
ships between SAR holes and hotspots. In the analysis of mtSARs, a side-by-
side comparison of CAGs is useful to identify commonalities or differences in
SAR hotspots for related targets. However, based on the original CAG data
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Figure 9.1-1: CAG subset formation Four compounds and their MCS are shown.
Pairs of compounds are built that differ either at substitution site 2 or at sites 1, 2, and 3.
Compound pairs are grouped accordingly.
structure, it is generally difficult to determine which type of substitutions are
responsible for introducing discontinuity and, consequently, SAR rules toward
target selectivity are difficult to formulate.
9.1.2 Adaptation to Multi-Target SAR Analysis
The most critical modifications made to the original CAG data structure to fa-
cilitate the analysis of mtSARs address the encoding of structural variation and
the similarity assessment of molecules. Previously, pairwise compound similar-
ity was calculated as conventional whole-molecule similarity based on MACCS
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Figure 9.1-2: Combinatorial analogue graphs CAG representations for six and 35
analogs active against the protein targets cyclin-dependent kinase 4 (cdk4) and cytochrome
P450 3A4 (cyp P450 3A4), respectively, are shown. For the cdk4 inhibitors, substituents of
the individual compounds and the assignment of compound pairs to corresponding nodes are
reported. SAR holes in the CAG representation for cyp P450 3A4 are circled in blue. The
figure is adapted from [31].
structural keys and the Tanimoto coefficient. In the revised CAG data structure
for mtSARs, to directly assess chemical variations of substituents, we compare
molecules on the basis of substituent pharmacophore feature similarity. There-
fore, substituents are assigned to pharmacophore feature classes by following
the scheme of Harper et al. [126]. First, substituents are classified based on
whether they are acyclic or contain an aromatic or aliphatic ring structure
(three constitutional classes). Then, a substituent is further assigned to one of
the six classes positively charged, negatively charged, donor, acceptor,
donor and acceptor, or featureless. Combining these six classes with the
three constitutional classes yields 18 possible pharmacophore feature categories
that are listed in Table 9.1-1. For the purpose of our analysis, the classification
scheme was further extended by an additional class: no substituent. Because a
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Table 9.1-1: Substituent pharmacophore feature classes
pharmacophore feature class abbr. pharmacophore feature class abbr.
acyclic positively charged Ac-P aliphatic ring positively charged Al-P
acyclic negatively charged Ac-N aliphatic ring negatively charged Al-N
acyclic donor Ac-D aliphatic ring donor Al-D
acyclic acceptor Ac-A aliphatic ring acceptor Al-A
acyclic donor and acceptor Ac-DA aliphatic ring donor and acceptor Al-DA
acyclic featureless Ac aliphatic ring featureless Al
aromatic ring positively charged Ar-P no substituent (-)
aromatic ring negatively charged Ar-N
aromatic ring donor Ar-D
aromatic ring acceptor Ar-A
aromatic ring donor and acceptor Ar-DA
aromatic ring featureless Ar
The 19 pharmacophore feature classes used for encoding substituents and their abbreviations
(abbr.) are listed.
given substituent might formally be assigned to more than one feature class, the
following order of priority is applied according to Harper et al. [126] to unam-
biguously define the class membership of each substituent: positively charged
> negatively charged > donor or acceptor. Since pharmacophore features
have different degrees of similarity, different edit distances or costs are asso-
ciated with feature replacements, as reported in Table 9.1-2. These costs are
defined in analogy to the weights used by Harper et al. for calculating an edit
distance for pairs of reduced graphs [126]. For comparison of two analogs, costs
are summed for all operations needed to convert one analog into the other,
which yields the distance between the compounds. Similarity is then calculated
as the complement of the edit distance, as shown in Figure 9.1-3. Hence, for an
analog series with n substitution sites, the similarity between two compounds
i and j is calculated as follows:
sim(i, j) = 1−
n∑
s=1
cost(Ris, R
j
s) (9.2)
where Ris and R
j
s denote the pharmacophore classes of compounds i and j at
substitution site s (s = 1, . . . , n). As costs for a single substitution range from
0 to 0.2, similarity values for compounds that differ only at one substitution
site lie between 0.8 and 1, those for compounds that differ at two sites between
0.6 and 1 and those for compounds that differ at three sites between 0.4 and
1. A similarity value of one means that all substituent exchanges always occur
within the same pharmacophore class.
Analog series generally display a high degree of whole-molecule similar-
ity. Therefore, using pharmacophore feature edit distances instead of Tanimoto
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Table 9.1-2: Pharmacophore feature substitution matrix
Class (-) Ac-P Ac-N Ac-D Ac-A Ac-DA Ac Ar-x Al-x
(-) 0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Ac-P 0 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Ac-N 0 0.2 0.2 0.2 0.2 0.2 0.2
Ac-D 0 0.2 0.1 0.2 0.2 0.2
Ac-A 0 0.1 0.2 0.2 0.2
Ac-DA 0 0.2 0.2 0.2
Ac 0 0.2 0.2
Ar-x 0.1 0.2
Al-x 0.2
Costs are reported for substitutions of pharmacophore features. Feature classes are abbrevi-
ated according to Table 9.1-1, except that all aromatic and aliphatic substituents are com-
bined here into two classes Ar-x and Al-x, respectively, because all Ar-x/Al-x substitutions
are assigned the same costs. Costs reported apply only to feature class mismatches, i.e., the
substitution cost of an aromatic positively charged group to an aromatic negatively charged
group is 0.1, but the cost for the replacement of one aromatic positively charged group by
another one is zero.
similarity puts more emphasis on small structural modifications that lead to
high differences in potency. Furthermore, it is now possible to directly relate
apparent SAR discontinuity to underlying pharmacophore feature exchanges,
as further explained in the following.
9.2 Derivation of SAR Rules
The introduction of pharmacophore feature transformations for pairs of com-
pounds makes it possible to group compounds according to defined changes in
substituents and infer systematic SAR trends for subsitution site combinations
that can be compared for the targets under study and exploited in the design
of target-selective compounds.
9.2.1 Substituent Preference Orders
Figure 9.2-1 summarizes how the SAR of an analog series against an individual
target is analyzed. Analogs in CAG representations only differ at given substitu-
tion sites and thus the local discontinuity scores account for SAR contributions
of R-groups at these sites. Compounds representing SAR hotspots are most rel-
evant for further analysis, as illustrated for node 2 in Figure 9.2-1. The encoding
of substituents as defined pharmacophore features makes it possible to group
compounds according to changes in substituents that are required to transform
one molecule into the other. For example, the first operation shown in Figure
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pKi 7.8pKi 6.5
N
NH
Br
OH
site mutation cost (edit distance)
1 Ac → Ac 0
2 (-)  → Ac-DA 0.2
3 Ar → Ac 0.2
∑ 0.4
O
N
MCS
similarity 1 – distance(i,j)
∆pKi pKi( i) – pKi( j)
discraw sim(i,j) x ∆pKi( i,j)
1 – 0.4 = 0.6
7.8 – 6.5 = 1.3
0.6 x 1.3 = 0.78
Figure 9.1-3: Similarity calculation Substituents are assigned to classes of pharma-
cophore features and pairwise compound similarity is calculated based on pharmacophore
feature edit distances of different substituents.
9.2-1 is the introduction of a featureless aromatic group ((-)→ Ar) at substitu-
tion site 2. One exemplary compound pair falling into this substitution category
is shown at the top. The introduction of the featureless aromatic group leads to
an increase in potency (the potency difference is given on a logarithmic scale).
For all other compound pairs falling into this substitution category, potency
changes are recorded and the process is repeated for all other observed substi-
tution categories. The negative sign for the operation listed in the third row
in Figure 9.2-1, i.e., substitution of a featureless acyclic group by a featureless
aromatic group (Ac→ Ar), indicates that the substitution decreases potency.
Node-specific records are easily interpretable and allow several conclusions to
be drawn:
1. Records mirror how thoroughly substitution sites have been explored and
which pharmacophore features have been investigated.
2. They identify substitutions causing most significant changes in potency.
3. Given that the same type of pharmacophore transformation is consistently
associated with similar potency changes, they enable the derivation of pref-
erence orders of pharmacophore features for given substitution sites.
Such preference orders are of prime importance to explore and exploit mtSARs
because the comparison of preference orders makes it possible to formulate
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pKi 6.7
pKi 7.2
pKi 6.5
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Figure 9.2-1: Analysis of pharmacophore feature-dependent potency
changes For each substitution site or combination of sites that is assigned a high disconti-
nuity score, compound pairs are grouped according to the substitutions required to transform
one analog into the other and potency changes observed for these substituent exchanges are
recorded. Based on the direction (increase or decrease) and magnitude of potency changes,
preference orders for pharmacophore features at individual substitution sites or combination
of sites can be derived. The figure is adapted from [125].
SAR rules for the design of target-selective compounds. The derivation of a
preference order is also illustrated for the compound series in Figure 9.2-2:
the introduction of an aliphatic H-bond acceptor and a featureless aromatic
group leads to increased potency. The potency change is larger for the aromatic
substituent and hence indicates a higher preference for this pharmacophore
class. However, it is not the most preferred feature at this site because the
comparison of featureless acyclic and aromatic groups reveals that an acyclic
group is even more favorable. Taken together, these observations result in the
following preference order that prioritizes substitutions at site 2: featureless
acyclic group > featureless aromatic group > aliphatic H-bond acceptor > no
substituent.
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uPA
factor Xa
Figure 9.2-2: Identification of selectivity determinants Preference orders for
specific chemical modifications at a given substitution site are compared. In this case, an
aliphatic H-bond acceptor is the most preferred substituent for inhibitors of enzyme 1 (uroki-
nase) but the least favorable for enzyme 2 (factor Xa). Consequently, the introduction of
a substituent corresponding to this pharmacophore feature is likely to increase the potency
ratio for enzyme 1 over 2. The figure is adapted from [125].
9.2.2 Design of Target-Selective Compounds
After separate analyses of SARs of an analog series for multiple targets, SAR
hotspots can be compared across these targets. If targets have different SAR
hotspots or if they share critical substitution sites but differ in their preference
order of substituents, rules for the optimization of compound potency and selec-
tivity can be derived. The latter case is illustrated in Figure 9.2-2 for an analog
series active against two serine proteases, urokinase (uPA) and factor Xa. Pref-
erence orders of pharmacophore features at substitution site 2 are displayed for
both enzymes. Pharmacophore features having comparable effects on potency
are grouped together and are not separated by >. In this example, compar-
ing the preference orders reveals that an aliphatic H-bond acceptor is the most
preferred substituent at site 2 for uPA, whereas this substituent is least pre-
ferred for factor Xa. Hence, the introduction of an aliphatic H-bond acceptor
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increases the potency ratio for uPA over factor Xa, which can be exploited to
render analogs selective for uPA.
9.3 Applications
By studying mtSARs, we ultimately address the question of compound selectiv-
ity. For compounds active against multiple targets, we aim to understand SAR
characteristics for each individual target, compare these SARs, and differenti-
ate between conserved and non-conserved SAR rules, which can be explored
to search for selectivity determinants. Thus, the study of mtSARs leads to
an analysis of structure-selectivity relationships (SSRs). A major goal of SSR
analysis is the derivation of structural/substitution rules for designing target-
selective compounds. The utility of CAGs to identify SSR determinants and
make compound design suggestions is exemplified in two applications on the
serine protease family.
9.3.1 Compound Data Sets
Ten analog series with reported inhibitory activity against the human serine
proteases factor Xa, thrombin, trypsin, and uPA were extracted from Bind-
ingDB. All analog series were annotated with potency information (Ki or IC50)
for at least two related targets. Similarity and discontinuity calculations were
carried out for all analog series and the resulting values provided the basis
for discontinuity score normalization (see paragraph 9.1.1). In the following,
exemplary results are reported and discussed for two analog series of serine
protease inhibitors consisting of 18 and 14 compounds, respectively. The two
discussed serine protease inhibitor series are active against human uPA, fac-
tor Xa, and trypsin. Only compounds with potency values reported against all
three proteases were taken from BindingDB. In order to assess predictions of
potency-increasing and target selectivity-conferring substitutions, the database
was searched for analogs with dual protease annotations that were not included
in the analyzed series and hence not utilized to derive target selectivity rules.
It was examined whether analogs contained predicted selectivity determinants.
9.3.2 Serine Protease Inhibitor Series 1
Figure 9.3-1 shows CAG representations for serine protease inhibitor series 1
consisting of 18 analogs active against human uPa, factor Xa, and trypsin.
Calculation of the MCS yields a core structure with three substitution sites.
Comparison of the individual CAGs in Figure 9.3-1 clearly shows that the SAR
characteristics of this series against its three targets differ. Especially com-
pounds with variations at site 2 but also site 3 are assigned a high discontinuity
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uPA
2.2 nM – 2.9 µM
factor Xa
13 nM – 60 µM
trypsin
37 nM – 9.5 µM
18 compounds
Figure 9.3-1: CAG representations for serine protease inhibitors (series 1)
The maximum common subgraph of a series of 18 serine protease inhibitors is shown and the
CAG representations of these analog sets for the three enzymes uPA, factor Xa, and trypsin.
The CAG topology is conserved because the same analog series is represented. Comparison
of these CAGs indicates the presence of different SAR characteristics. The figure is adapted
from [125].
score for uPA, whereas site 1 produces discontinuity exclusively for factor Xa.
For trypsin, SAR discontinuity and node heterogeneity is much reduced in com-
parison to the other two enzymes. The overall degree of discontinuity is also
reflected by the root node that combines all compound pairs differing at up to
three substitution sites and yields a considerably lower score for trypsin than
for the other two proteases. For uPA, any substituent at site 2 improves com-
pound potency, in some instances by more than two orders of magnitudes. The
priority ordering for this site is featureless acyclic group > featureless aromatic
group > aliphatic H-bond acceptor, as reported in Table 9.3-1. Interestingly,
similar preferences are also observed for factor Xa and trypsin, but the ob-
served potency increases are smaller. At site 3, the substitution having largest
impact on potency for uPA is the introduction of a featureless acyclic group
that decreases potency by more than one magnitude. This type of substituent
also decreases the potency against trypsin, albeit to a much lesser extent. For
factor Xa, substitution site 1 constitutes a prominent SAR hotspot. The intro-
duction of a featureless acyclic group at this site consistently decreases potency
by more than one or two magnitudes. Combinations of substitution sites with
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Table 9.3-1: Preference orders
analog series target site 1 site 2 site 3
uPA Ac > (-) > Ac' Ac > Ar >
Al-A >> (-)
Ac-A >
Ac-P|Ac-A'|(-) >>
Ac|Ac-N
factor Xa (-) >> Ac Ac > Ar > Al-A|(-) Ac-P > Ac-A >
Ac-A'|(-)|Ac|Ac-N
trypsin (-) > Ac Ac|Ar > Al-A > (-) Ac-A >
Ac-P|Ac-A'|(-) >
Ac|Ac-N
uPA Ac > (-)|Ac' Al-A > Ac-A|Ar >
Ac|(-)
inconclusive
factor Xa (-) > Ac (-)|Ac-A|Ar|Ac >
Al-A
inconclusive
trypsin (-) > Ac Ac-A|Al-A|Ar >
Ac > (-)
Ac-A|Ac >
Ac-N|(-)|Ac-P
The table reports preference orders of pharmacophore features for individual substitution
sites in two series of serine protease inhibitors for the three targets uPA, factor Xa, and
trypsin. Abbreviations of pharmacophore feature classes are given according to Table 9.1-1.
`>>' indicates that the average potency difference observed for substituents belonging to
two pharmacophore classes is more than one order of magnitude, whereas `|' indicates that
potency values observed as a consequence of feature class substitution are comparable. In
cases where notable potency differences for substitutions within the same feature class occur,
the class P is divided into P and P' to account for intra-class potency differences and placed
twice in the preference order.
high discontinuity scores for uPA or factor Xa were also examined. For site
combinations, SAR discontinuity was generally introduced by the same types
of substitutions that caused discontinuity at the individual sites.
9.3.2.1 Key substitutions
Taken together, the analysis of protease inhibitor series 1 revealed the presence
of differential SAR characteristics for the three target enzymes and indicated
that high potency for uPA would be achieved by a combination of a featureless
acyclic group at site 2 and an acyclic H-bond acceptor at site 3. However, a
compound representing this combination of pharmacophore features was not
present in the data set. Moreover, on the basis of preference ordering, an unoc-
cupied substitution site 1 in combination with a featureless acyclic substituent
at site 2 and a positively charged group at site 3 would represent the most pre-
ferred combination of substituents for achieving high potency against factor Xa.
However, a compound having this substitution pattern was also not available
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faXa 10.1 µM
uPA 33.8 nM
faXa 70 nM
uPA 200 nM
faXa 100 nM
try    450 nM
faXa 2.4 µM
uPA 2.9 µM
try       4.9 µM
Figure 9.3-2: Verification of selectivity determinants identified for series 1
BindingDB analogs not included in the analyzed compound data set were used to evaluate
predicted selectivity determinants. Here, three additional protease inhibitor analogs are dis-
played and their potency values are compared to those of the least substituted analog in this
series. Selectivity-conferring substituents are encircled. faXa stands for factor Xa and try for
trypsin. The figure is adapted from [125].
in the data set, indicating that the series might not have been explored to its
full potential for factor Xa and uPA.
9.3.2.2 Target Selectivity Rules
Rules for the design of target-selective compounds were also derived. On the
basis of our analysis, the following rules were formulated: the most important
modification to increase selectivity for uPA or trypsin over factor Xa was the
introduction of a featureless acyclic group at site 1. However, for trypsin, this
type of modification also decreased potency, albeit to a much lesser extent than
for factor Xa, thereby leading to a relative increase in selectivity over factor Xa
at the expense of potency. The selectivity for uPA over the other two enzymes
was further increased by the introduction of a featureless acyclic or aromatic
group at site 2. By contrast, the selectivity for factor Xa or trypsin over uPA
was increased by introducing a featureless acyclic group at site 3.
In order to assess these predictions, we searched BindingDB for analogs with
matching substitution patterns. Three inhibitors were identified that were not
contained in series 1 because they were annotated only with potency information
for two of the three targets. These compounds confirmed the predictions and are
shown in Figure 9.3-2 with their potency values. The compound at the upper
left is selective for uPA, as we would expect considering the halogen substituent
(featureless acyclic group) at site 1. The aliphatic H-bond acceptor at site 2 also
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14 compounds
uPA
31.5 nM – 6 µM
factor Xa
440 nM – 32 µM
trypsin
2 µM – 42 µM
Figure 9.3-3: CAG representations for serine protease inhibitors (series 2)
The maximum common subgraph of a series of 14 serine protease inhibitors is shown and the
CAG representations of these analog sets for the three enzymes uPA, factor Xa, and trypsin.
The figure is adapted from [125].
makes a contribution to selectivity. The compound at the upper right contains
a featureless acyclic group at site 3, which favors selectivity for factor Xa over
uPA. However, this effect is counter-balanced by the introduction of a featureless
acyclic group at site 2 that increases potency for uPA more than for factor Xa.
Hence, the net effect of simultaneously introducing these two substituents is
only a small increase in selectivity for factor Xa over uPA. The third compound
at the lower right contains an aromatic ring at site 2 and a negatively charged
substituent at site 3. However, consistent with our prediction that substitutions
at these sites would not be critical for distinguishing between factor Xa and
trypsin, this compound is approximately ten-fold more potent for both targets
than the unsubstituted molecule (lower left) but also non-selective.
9.3.3 Serine Protease Inhibitor Series 2
In Figure 9.3-3, CAG representations for serine protease inhibitor series 2 are
shown. The MCS of series 2 is very similar to the one of series 1 in Figure
9.3-1; the indole moiety in series 1 is replaced with a benzimidazole in series 2.
However, the CAG representations for these two series differ notably. CAG root
nodes for series 2 are assigned much lower discontinuity scores than for series 1,
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faXa 11 µM
uPA 9.5 µM
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uPA 2.7 µM
try        17 µM
Figure 9.3-4: Verification of selectivity determinants identified for series 2
Three additional protease inhibitor analogs are displayed and their potency values are com-
pared to those of the least substituted analog in this series. Selectivity-conferring substituents
are circled. faXa stands for factor Xa and try for trypsin. The figure is adapted from [125].
consistent with the presence of a comparably narrow potency range in series 2.
Similar to series 1, substitution site 2 in series 2 is most important for activity
against uPA and is involved in all substitution site combinations with high
discontinuity scores. However, Table 9.3-1 reporting the preference orders for
series 1 and 2 shows that substitution site 2 in series 2 has a preference order that
substantially differs from series 1. In this case, the introduction of an aliphatic
H-bond acceptor is most preferred. Its introduction is also favorable for trypsin,
albeit to a lesser extent, but unfavorable for factor Xa. By contrast, substitution
site 1 represents an SAR hotspot in both series 1 and 2 for factor Xa. At this
site, potency losses are caused by the introduction of a featureless acyclic group.
However, for the benzimidazole derivatives, induced potency changes are much
smaller than for the indole derivatives. The introduction of a featureless acyclic
group at site 1 is unfavorable for trypsin but does not significantly affect the
potency of uPA.
In contrast to series 1, the data for series 2 do not provide insights as to how
one would improve the selectivity for trypsin or factor Xa over uPA. Instead,
two possibilities emerge to increase selectivity for uPA, i.e., by introducing a) a
featureless acyclic group at site 1 and b) an aliphatic H-bond acceptor at site
2. Again, we searched for analogs that were not included in our analysis and
found three inhibitors that were only annotated with potency information for
human factor Xa and uPA, shown in Figure 9.3-4. As predicted, compounds
with a featureless acyclic group at site 1 or an aliphatic H-bond acceptor at
site 2 show a higher selectivity for uPA than the unsubstituted molecule. By
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contrast, an additional analog with a substituent at site 3 (bottom right) shows
no change in selectivity.
9.4 Conclusions
Multi-target SARs are often complex and difficult to analyze. However, decod-
ing of such SARs is critically important for identifying determinants of com-
pound selectivity. In the past, different SARs have in some instances been com-
pared using QSAR techniques to ultimately make predictions of compounds
active against a specific target. Such predictions made using different QSAR
models could then be compared in attempts to differentiate SAR characteris-
tics [127,128]. Only recently, first attempts have been made to design molecular
graph representations that identify selectivity cliffs resulting from potency dif-
ferences of compounds against pairs of targets [129] or multi-target activity
cliffs of different magnitude [102]. Nevertheless, it is fair to say that a more
systematic analysis of mtSARs using computational means is currently still in
its infancy.
We have introduced a computational approach to study mtSARs that relies
on a data structure generated by consistent R-group decomposition, assessment
of analog similarity on the basis of pharmacophore feature edit distances, and
correlation with potency data. An intuitive and easy graphical access to these
data is provided by CAGs that hierarchically organize analog series accord-
ing to substitution sites. Comparison of these graph representations for multi-
ple targets immediately identifies individual SAR hotspots and reveals target-
dependent differences in SAR characteristics of analog series. Then, compound
pairs corresponding to SAR hotspots are analyzed and preference orders for
pharmacophore feature substitutions are derived, which is a key aspect of the
approach presented herein. From these preference orders, simple and intuitive
rules for the design of target-selective compounds can often be deduced, as
demonstrated in the reported applications. Selectivity predictions made on the
basis of mtSAR analysis have been confirmed through searching for relevant
analogs not included in our analysis.
Source Information
Sections of the text in this chapter have been taken from [125].

Chapter 10
SAR Transfer
The chemical lead optimization process involves the simultaneous improvement
of multiple properties, such as compound potency, selectivity, oral availability,
or metabolic stability. There are many possible complications along the path
to developing clinical candidates and it is not uncommon that a compound se-
ries displaying an otherwise promising SAR hits a roadblock, perhaps due to
metabolic liabilities or unwanted side effects, which then prevents its further de-
velopment. In these situations, it would be highly desirable to reutilize available
SAR information and apply learned SAR rules to an alternative chemotype that
shows similar SAR characteristics. Accordingly, one would search for alterna-
tive molecular core structures (scaffolds) where corresponding chemical substi-
tutions yield comparable SAR trends (consistent with a conserved mechanism
of action) but circumvent liabilities associated with the original chemotype.
However, an SAR transfer represents a rather challenging task. Importantly, it
goes far beyond the identification of alternative scaffolds displaying a specific
biological activity [116] because it requires the identification or generation of
corresponding analog series with equivalent SAR characteristics. As shown in
Chapter 9 by the comparison of substituent preference orders for the two serine
protease inhibitor series, even for very similar scaffolds, different SAR trends
can be observed. Hence, SAR transfer events are not expected to be abundant
and easy to identify.
In addition to replacing one chemical series by another, SAR transfer also
has other facets. For example, if parallel compound series with varying degrees
of chemical exploration (e.g., different numbers of analogs, different potency
levels) would be available, one might learn more about SAR progression than
on the basis of a single series. In addition, it might be possible to suggest potent
analogs for one series based on another, whose other lead-relevant properties
could then be compared.
Figure 10.0-1 illustrates an SAR transfer scenario that emphasizes both
the alternative series and learning aspects. Compound series 1 and 2 in Fig-
ure 10.0-1 contain distinct core structures and consist of analogs with pairwise
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Figure 10.0-1: SAR transfer series The principal idea of SAR transfer is illustrated.
Two structurally related model analog series are shown. The ring systems that distinguish the
two corresponding scaffolds are highlighted in red in a compound of each series. Compounds
in both series that carry the same substituents and only differ in the exchanged rings are
aligned vertically, i.e., they form pairs of corresponding analogs. The alignment organizes
compounds (labeled with their pKi values) in the order of increasing potency from left to
right. For potency-based ordering, one series serves as a reference. In this case, the two ordered
series display a steady potency progression and potency differences (shown in blue) between
analogs are comparable for both series, although the absolute potency values of corresponding
compounds differ. Hence, the two analog series represent a prototypic SAR transfer.
corresponding R-group patterns that show a comparable increase in potency.
Thus, the SARs of series 1 and 2 are essentially interchangeable and the two
series represent a prototypic SAR transfer model. Moreover, series 1 contains
a potent analog that has no counterpart in series 2 and hence the correspond-
ing analog might be suggested for synthesis. Although chemotype replacement
might be considered the primary task of SAR transfer, the comparative learning
aspect is also attractive for SAR exploration and exploitation.
Although SAR transfer is of high practical relevance in medicinal chem-
istry and a frequently discussed topic, comprehensive literature searches did
not reveal computational methods available to aid in this process. Therefore,
as a first step in this direction, we designed a data mining method to iden-
tify chemical series with SAR transfer potential [130]. This chapter presents
the methodological concept of our computational approach in section 10.1 and
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reports exemplary applications in section 10.2. Applications comprise (i) the
identification of chemical series with SAR transfer potential if one analog se-
ries is available as a starting point and (ii) the detection of all SAR transfer
events that occur in compound databases. A summary of major findings and
an outlook for future work is given in section 10.3.
10.1 Methodology
Because the prediction of an SAR mimic from first principles would be very
difficult, we have approached SAR transfer from a data analysis perspective.
We started from a typical, practically relevant SAR transfer situation where a
series of analogs with multiple structural modifications and increasing potency
was available as a starting point and aimed to identify SAR transfer series
through compound database searching. For this purpose, we designed an ap-
proach consisting of three different stages that were implemented in Java using
the OpenEye chemistry toolkit and are introduced in the following.
10.1.1 Identification of Alternative Scaffolds
Initially, from a known series of active analogs, in the following also termed
template series, the common scaffold is extracted. Single atoms forming ex-
ocyclic double bonds to ring atoms (mostly carbonyl oxygens) are considered
part of a scaffold and not removed. Then, a database search is carried out to find
related but chemically distinct scaffolds (Figure 10.1-1). Candidate scaffolds are
permitted to differ from the original scaffold by the replacement of one contigu-
ous ring system (i.e., consisting of one or more rings). There are no restrictions
on ring sizes or composition. Hence, depending on the exchanged ring systems,
corresponding scaffolds might display different degrees of (dis)similarity. Scaf-
folds with changes in one ring structure are identified using a variant of the
MMP search algorithm of Hussain and Rea presented in Chapter 7. In this
adaptation, all contiguous ring systems in a scaffold are separately removed
by deleting all connecting bonds between the ring system and the remaining
structure. Connectivity information for the resulting fragments is retained by
marking the attachment points. For two scaffolds that only differ by a single
ring, removal of the exchanged ring structures leads to identical key fragments
and this scaffold pair can be identified from an index table, as described in
Chapter 7. If an alternative scaffold is identified for the template scaffold, all
compounds represented by this scaffold are retrieved (Figure 10.1-1). These
analogs constitute a target series.
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Figure 10.1-1: Database search for alternative scaffolds A scaffold representing
a template series is used to search a database for scaffolds that differ by the replacement of
exactly one ring system. Two target scaffolds meeting this structural criterion are highlighted
in blue. For one of these scaffolds, all analogs are assembled representing a target series. In
this example, both the template and the target series contain six analogs. These compounds
are consecutively names A-L. The pKi value of each analog is reported. The figure is adapted
from [130].
10.1.2 Identification of Corresponding Analogs
For analogs in the template series, matching compounds in the target series are
identified. For this purpose, all compounds represented by the two scaffolds are
fragmented by removing the distinguishing ring and attached R-groups. The
removed fragment is then further decomposed into the invariant ring structure
and the R-groups, which are marked with the numeric identifier of the ring
atom to which they were attached. Hence, each molecule of a series can be un-
ambiguously represented by the combination of the residual substructure after
ring removal and the set of R-groups. Corresponding compounds of two analog
series are required to have identical residual substructures and R-groups. These
R-groups are used to define corresponding substitution sites in the exchanged
ring systems, as shown in Figure 10.1-2. Especially if R-groups are found for
exchanged rings of different size, substitution site correspondences are not clear
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and, therefore, all possible pairwise mappings of positions in exchanged rings
are explored and alternative mappings are compared, as illustrated in Figure
10.1-2. In order to identify series/mappings showing SAR transfer, all com-
pound pairs complying with the same R-group mapping are assembled into two
matching series.
10.1.3 Potency-Based Compound Ordering and SAR
Transfer Score
For all compounds represented by a given scaffold within a matching series, the
mean potency is determined and potency values are rescaled with respect to the
mean, i.e., zero-centered relative potency values for all analogs are calculated
by subtracting the mean from actual compound potency values (in pKi units).
In order to meet SAR transfer criteria, template and target series can differ in
their absolute potency values but potency differences between ordered analogs
in each series should be similar so that corresponding structural modifications
entail similar potency effects. The comparison of relative potency values for
paired analogs is a straightforward way to account for potency progressions
within the two series. If compounds forming a pair are always assigned the same
relative potency, substitutions consistently cause the same potency changes,
leading to complete SAR transfer for the two matching series.
10.1.3.1 Color-Coded Analog Pair Alignments
To facilitate the comparison of relative potency values for a target and template
series and for a visual inspection of SAR transfer potential, color-coded analog
pair alignments are utilized, as shown in Figure 10.1-3. From top to bottom,
corresponding compound pairs are ranked in the order of decreasing potency of
the target series and displayed as colored nodes connected by an edge. A uni-
form color code is applied to account for the potency difference of a compound
from the mean. The color code represents a continuous spectrum from green
(over yellow) to red to account for potency differences from the mean within
the range from -1.5 (green) to 1.5 (red) pKi units. Potency differences falling
below or above this range are represented in green and red, respectively. Color
matches along the ranking indicate whether corresponding replacements have
similar effects on potency progression within the analog series. SAR transfer
is characterized by paired nodes that are consistently assigned the same color
along the alignment. By contrast, if corresponding analogs have differently col-
ored nodes, substitutions have different relative potency effects. If this occurs
for only a few pairs of analogs within larger series, SAR transfer is locally in-
complete. If no corresponding color patterns are observed, the SARs of the two
series are distinct and not transferable.
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Figure 10.1-2: Pairwise analog assembly Top left: Corresponding compounds in the
template and target series are identified by removing the distinguishing ring system. Identical
R-groups at the exchanged ring structures determine substitution site correspondences (e.g.,
3:3) for each pair of corresponding compounds. Top right: All possible compound pairs
retrieved for the template and target series from Figure 10.1-1 are reported and mappings of
ring substituent positions are provided. The hyphen (-) indicates the absence of substituents
at the exchanged rings. Bottom: All different mappings of ring positions are systematically
explored for SAR transfer. Therefore, all compound pairs that comply with a mapping are
assembled into so-called matching series (highlighted in green for the mapping 2:2,3:4).
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10.1.3.2 Score Calculation
For a quantitative assessment of SAR transfer potential, absolute differences
between rescaled potencies of all compound pairs in matching series are calcu-
lated, as demonstrated in Figure 10.1-3. The maximal difference between two
compounds in a pair is utilized as an SAR transfer score because it describes
the largest observed deviation of matching series from an ideal SAR transfer
scenario. Accordingly, a score of zero corresponds to perfect SAR transfer with
identical potency progressions between ordered pairs of analogs in matching
series, whereas high scores indicate a substantial discrepancy in potency pro-
gression.
10.2 Applications
We first tested the methodology by searching for alternative analog series using
a known series as template and then aimed at a systematic detection of all SAR
transfer events in BindingDB.
10.2.1 SAR Transfer Detection for Selected Analog
Series
Compounds annotated with Ki values against human targets were extracted
from BindingDB. For different activity classes, compound series consisting of
multiple analogs were selected as template series and the remaining active com-
pounds were searched for potential target series that contained corresponding
compounds with comparable potency progression. In the following, four exam-
ples for successful SAR transfer detection for the targets dopamine D3 receptor,
thrombin, factor Xa, and carbonic anhydrase I are reported.
10.2.1.1 Dopamine D3 Receptor Antagonists
Figure 10.2-1 reports search results for a template series consisting of eight
analogs of dopamine D3 receptor antagonists. Three target series with different
SAR transfer potential were detected.
In Figure 10.2-1a, the template (left) and target (right) series are related
by the exchange of a benzofuran versus an indole moiety. The target series
also consists of eight analogs. In the template and target series, five and six
analogs, respectively, are unsubstituted at the exchanged ring and form four
corresponding pairs in the alignment, as shown in Figure 10.2-1a. Among these
pairs, a clear SAR transfer is observed, indicated by very similar node colors
for compounds forming each pair.
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Figure 10.1-3: Analog pair alignment For the mapping 2:2,3:4 (compare Figure
10.1-2), all pairs of analogs are assembled into two matching series. Corresponding compounds
of the target (right) and template (left) series are vertically aligned and represented by nodes
connected by an edge. From top to bottom, analog pairs are ranked in the order of decreasing
potency of the target series. The mean potency for the four aligned compounds from each
series is determined, and for each compound, the potency difference from the mean (relative
potency) is calculated. The compounds are annotated with their relative (bold) and abso-
lute potency values. Nodes are color-coded by relative potency using a continuous spectrum
from green (via yellow) to red. Green indicates lowest and red highest relative potency in a
series. Edges are labeled with differences between rescaled potencies of corresponding com-
pounds (connected nodes), and maximal differences representing the SAR transfer score are
highlighted in light blue.
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In the second target series shown in Figure 10.2-1b, which consists of three
analogs, the benzofuran moiety is replaced by a benzothiophene ring. Here,
three corresponding pairs are also formed for unsubstituted exchanged rings. In
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Figure 10.2-1: Template and target series for dopamine D3 receptor an-
tagonists
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Figure 10.2-1: Template and target series for dopamine D3 receptor an-
tagonists (continued) (a-c) Alignments with three different target series are shown for
a template series consisting of dopamine D3 receptor antagonists. In each case, compounds
belonging to the template series are shown on the left and the target series is shown on the
right. Corresponding compound pairs are ranked in the potency order of the target series.
Node colors are determined on the basis of centered potency differences according to Figure
10.1-3. Gray nodes indicate missing analogs. For each compound, its pKi value is reported.
In the compound pair at the top of each alignment, the exchanged ring structures are col-
ored red. R-groups at the highlighted exchanged rings are colored blue. The figure is adapted
from [130].
contrast to the first target series, no SAR transfer is observed for the second
target series, due to inconsistent potency progression. Whereas a 3,4-dichloro-
substituted phenyl ring leads to the most potent analog in the template series,
a 4-chloro-substituted phenyl ring is preferred in the target series. Hence, al-
though the core structures of the template and the two target series are almost
identical and differ only by a single heteroatom, only two of the three series
show a similar SAR. This observation is also reflected by calculated SAR trans-
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fer scores that amounted to 0.15 and 0.54 for the alignments of the template
series with target series 1 and 2, respectively.
Figure 10.2-1c shows a rudimentary yet structurally qualifying match with
only two pairs of analogs for the alignment of the template series with the third
target series. In this case, the central saturated ring moiety is exchanged and
the two rings carry a hydroxyl substituent. Although node colors are similar for
the two aligned compound pairs, the alignment conveys comparably little SAR
transfer information and it would certainly be inappropriate to deduce SAR
transfer based on similar potency effects for only one structural modification.
At least, the alignment does not exclude the possibility of an SAR transfer for
the two series.
10.2.1.2 Thrombin Inhibitors
Figure 10.2-2 shows a thrombin inhibitor template series consisting of eight
analogs and the single target series we identified. The target series contains
five analogs, all of which form pairs with template compounds. The template
and target series are related by the exchange of a tetrazole versus a triazole
ring. The alignment reveals clear SAR transfer character. In addition, the two
most potent template compounds have no counterparts in the target series.
In light of the observed potency progression, the corresponding analogs would
be expected to have higher potency than the currently most potent triazole-
containing compound, hence providing a prototypic example for alignment-
based compound suggestions and the comparative learning aspect associated
with SAR transfer analysis.
10.2.1.3 Factor Xa Inhibitors
We also searched for target series using a large template series of 88 factor Xa
inhibitors. In this case, a small target series containing only six analogs was de-
tected. These series were related by the exchange of phenyl and pyridyl rings.
Four pairs of corresponding analogs could be aligned (Figure 10.2-3). The align-
ment shows that the relative potency of corresponding compounds is similar and
SAR transfer is observed along all compound pairs. In the most potent paired
analogs, the variable core rings contain a fluorine-methyl-fluorine substituent
pattern and the two phenyl rings are meta-substituted with carbamimidoyl
groups. A comparison to the most weakly active compounds reveals that both
series benefit from the exchange of an aminomethyl by a carbamimidoyl group
at the meta position of a phenyl ring. Hence, when the substitution pattern of
the central ring is kept constant, structural changes at the phenyl ring lead to
similar potency progression in both series. Remaining highly potent compounds
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Figure 10.2-2: Template and target series for thrombin inhibitors Shown is
a template series consisting of thrombin inhibitor analogs (left) and a single target series
(right). The representation is according to Figure 10.2-1. The figure is adapted from [130].
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Figure 10.2-3: Template and target series for factor Xa inhibitors Shown is
a template series consisting of factor Xa inhibitor analogs (left) and a single target series
(right). The representation is according to Figure 10.2-1. The figure is adapted from [130].
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of the template series (a representative example is shown in Figure 10.2-3) also
contain this fluorine-methyl-fluorine ring substituent pattern. Thus, on the ba-
sis of these findings, additional compound design suggestion could be made for
the target series.
10.2.1.4 Carbonic Anhydrase I Inhibitors
In Figure 10.2-4, search results are shown for another large template series of
sulfonamide-containing carbonic anhydrase I inhibitors (51 analogs). Here, a
target series with 39 analogs was identified. In this case, a phenyl and a thia-
diazole ring are exchanged that carry the critical sulfonamide substituent. For
matching compounds in the target series, this substituent can be transferred to
the ortho, meta, or para position of the exchanged phenyl ring and we inves-
tigated all three possibilities for SAR transfer. The best alignment consisting
of eight analog pairs was obtained for transferring sulfonamide substituents to
the meta position of the phenyl ring, as illustrated in Figure 10.2-4. In this
alignment, SAR transfer is locally incomplete because the relative potencies of
a weakly potent analog pair differ for the two series, as indicated by the color
code. For the remaining analog pairs, potency progression is comparable. Thus,
the alignment represents an example of partial SAR transfer. Importantly, SAR
transfer is observed for the more potent compounds and several potent analogs
in both series have no counterparts in the alignment (a few representative ex-
amples are shown in Figure 10.2-4), thus providing another opportunity for
comparative learning from two series and the design of other potent analogs.
10.2.2 Systematic SAR Transfer Detection
We then systematically searched for possible SAR transfer events in BindingDB
to address the question how frequently SAR transfer is observed for chemical
series that differ by the replacement of a single ring system.
10.2.2.1 Compound Data Sets
All ring-containing compounds with available Ki values for human targets were
extracted from BindingDB. For all molecules with multiple potency measure-
ments against the same target, the arithmetic mean was calculated to yield
a final potency value unless reported Ki values spanned a potency range of
more than one order of magnitude. In this case, the target activity was ex-
cluded from the analysis. A total of 53 760 different qualifying compounds were
selected and organized into 708 target-specific compound data sets. In each
ligand set, compounds were grouped by scaffolds containing at least two ring
systems. Compounds represented by single ring scaffolds were discarded.
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Figure 10.2-4: Template and target series for carbonic anhydrase I in-
hibitors Shown is a template series consisting of carbonic anhydrase I inhibitor analogs
(left) and a single target series (right). For clarity, only a part of the global series alignment
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transfer. The figure is adapted from [130].
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10.2.2.2 SAR Transfer Score Distribution
For the general assessment of SAR transfer potential, we searched for all scaf-
fold pairs meeting the single ring exchange criterion in the compound data
sets extracted from BindingDB. All possible matching series in a ligand set
were identified (in this case, template and target series are not distinguished).
Then, all possible mappings of R-group positions in matching series were sepa-
rately considered for score calculation, i.e., for each possible analog alignment
the maximal difference of rescaled potency values for corresponding compounds
was calculated. In order to focus the search on series that displayed a compara-
ble potency progression over multiple compounds, we only retained alignments
containing at least three compound pairs. Furthermore, analogs in at least one
of the matching series must span a potency range of more than one order of
magnitude.
On the basis of these criteria, 306 matching scaffold pairs were identified in
93 target sets. Because some scaffold pairs occurred in multiple sets, a total of
405 different scaffold pair-target combinations were obtained. For the general
assessment of SAR transfer potential, the matching series yielding the lowest
SAR transfer score for a scaffold pair-target combination were selected among
alternative mappings.
We found that matching series consisted on average of 4.15 corresponding
compound pairs. Figure 10.2-5 shows the score distribution observed for the 405
compound pair alignments. Scores between 0.2 and 1.0 were most frequently
obtained, with a mean score of 0.69. However, the right tail of the distribution
indicates that very high scores also occurred in some instances, i.e., for some
matching series the exchange of a single ring structure led to dramatic SAR
discrepancies. In order to investigate whether the number of transferred ring
positions had an influence on the SAR transfer potential of a matching scaffold
pair, statistics were separately generated for different numbers of mapped R-
group sites. Table 10.2-1 reveals that matching series without R-groups at the
exchanged rings were most frequently observed and that these series displayed
the tendency to yield low scores, consistent with high SAR transfer potential.
Furthermore, we observed the trend that with increasing numbers of R-groups
at exchanged rings the scores also increased.
10.2.2.3 SAR Transfer Series
Visual inspection of many analog alignments suggested that a score lower than
or equal to 0.3 typically represented matching series showing SAR transfer.
For example, for the series shown in Figures 10.2-1a, 10.2-2, and 10.2-3 scores
of 0.15, 0.12, and 0.24 were obtained, respectively. Hence, we applied a score
threshold of 0.30 to search for SAR transfer series. A total of 61 SAR transfer
series were identified in BindingDB that occurred in 39 different target sets and
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Figure 10.2-5: SAR transfer score distribution The distribution of SAR transfer
scores is reported for 405 compound pair alignments extracted from BindingDB. Thresholds
for SAR transfer and non-transfer series are displayed. The figure is adapted from [130].
contained 59 different scaffold pairs. As shown in Table 10.2-2, 70% of these
SAR transfer series did not carry R-groups at the exchanged ring systems.
10.2.2.4 Similar Chemical Series With Distinct SARs
Finally, we also identified matching series without SAR transfer potential.
Therefore, a lower score cutoff of 0.80 was applied. In this case, 135 match-
ing series were identified where the exchange of a ring system resulted in very
different potency progression. Hence, matching series with limited or no SAR
transfer potential were more frequently found than SAR transfer series. In-
terestingly, about 65% of matching series with scores larger than or equal to
0.80 comprised compounds with R-groups at the exchanged ring systems (Table
10.2-2). Perhaps surprisingly, the number of matched compound pairs did not
correlate with a decreasing SAR transfer potential of two series.
10.3 Conclusions
This chapter introduced a computational approach to search for SAR transfer
series, a task of considerable practical relevance in medicinal chemistry, and
systematically analyze SAR transfer events in databases. Despite the inher-
ent complexity of the problem, the underlying computational methodology is
straightforward and much emphasis was put on the chemically intuitive nature
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Table 10.2-1: Global assessment of SAR transfer potential
#R-sites #occurence score #pairs
0 186 0.60 4.04
1 134 0.75 4.11
2 57 0.64 4.37
3 27 1.01 4.63
4 1 1.23 4.00
The 405 compound alignments extracted from BindingDB are grouped by the number of ring
positions (R-sites) mapped for corresponding compounds from different analog series. For
each group, its absolute frequency of occurrence (#occurence), average SAR transfer score
(score), and average number of aligned compound pairs (#pairs) are reported.
Table 10.2-2: SAR transfer and non-transfer series
#R-sites
#occurence
SAR transfer series non-transfer series
0 43 49
1 11 58
2 6 12
3 1 15
4 0 1
The 61 SAR transfer series and 135 non-transfer series are grouped by the number of ring
positions (R-sites) mapped for corresponding compounds from different analog series. For
each group, its absolute frequency of occurrence (#occurence) is reported.
of the approach. Interpretability of the results was ensured by the introduction
of analog pair alignments that are simple to analyze and provide a basis for
comparative SAR analysis. Furthermore, if SAR transfer is observed and in-
dividual compounds exist in one analog series that do not have counterparts
with corresponding R-groups in the other, new analogs can be readily suggested,
i.e., analog pair alignment information can be translated into compound design.
Several representative examples have been discussed and a statistical analysis of
SAR transfer events has been presented, which also included the identification
of structurally corresponding analog series with differing potency progression.
Our systematic analysis revealed that, in many instances, the replacement of a
single ring system results in a chemical series with distinct SAR characteristics.
In our approach, partial core structure replacements were considered for the
purpose of SAR transfer analysis, with no restrictions on the size, complexity,
and composition of exchanged ring systems. However, the reported method can
also be easily modified to account for scaffold or substructure replacements
other than our preferred ring transformation.
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Source Information
Sections of the text in this chapter have been taken from [130].

Chapter 11
Summary and Conclusions
In this thesis, computational methods that address the analysis of SARs
from very different perspectives have been discussed. Presented approaches in-
cluded machine-learning techniques for orphan and potency-directed screening,
information-theoretic concepts for descriptor profiling, large-scale data mining
of compound databases, and graphical SAR analysis. SARs were elucidated at
multiple levels of detail and the major results are summarized in this chapter.
First, support vector machine search strategies for the prediction of ligands
for orphan targets have been presented and were retrospectively evaluated in
simulated virtual screening trials. In the analysis of search results, implications
of our findings for prospective applications were evaluated and discussed. It was
demonstrated that ligand prediction for orphan targets using SVMs and various
target-ligand kernels was significantly influenced by nearest neighbor effects.
Ligand information provided by nearest neighbors of orphan targets dominated
SVM performance, much more so than the inclusion of protein information in
multi-task learning strategies. As long as ligands of closely related neighbors of
orphan targets were available for SVM learning, orphan target ligands could be
well predicted, regardless of the type and sophistication of the kernel function
that was used. Therefore, simplified strategies for SVM-based ligand prediction
for orphan targets were suggested. The identification of targets that are closely
related to the orphan target and for which known ligands are available should
be a major objective in orphan screening campaigns.
We then extended the current spectrum of SVM approaches for different
chemoinformatics applications by the introduction of potency-directed SVM
searching. In comparison to conventional SVM ranking, the potency-oriented
SVM linear combination and the multi-task learning strategy using the newly
designed structure-activity kernel achieved an enrichment of highly potent hits
at high ranking positions. One of the attractive features of potency-directed
LC and SAK calculations was that high recall rates of active compounds were
obtained and searches were not limited to exclusive recognition of highly potent
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compounds. Furthermore, benchmarking of the strategies on HTS data sets
highlighted their utility for hit identification.
Concepts from information theory were adapted to assess the amount of
compound class-specific information captured by numerical descriptors. Differ-
ent approaches based on the Shannon entropy concept were presented and the
utility of the novel MI-DSE approach to identify descriptors containing activity-
relevant information was confirmed.
Data mining approaches that explore prespecified properties of available
bioactive compounds on a large scale and extract knowledge from the data
were presented. First, a large-scale analysis of currently available bioactive com-
pounds was carried out to present a systematic survey of single- and multi-target
activity cliffs. It was shown that only approximately 2% of all pairs of struc-
turally similar compounds sharing the same biological activity form activity
cliffs. However, on average, approximately one of ten active compounds is in-
volved in the formation of one or two single-target cliffs of large magnitude.
Perhaps unexpectedly, activity cliffs were found to be similarly distributed over
different protein target families. Moreover, only approximately 5% of all activ-
ity cliffs were multi-target cliffs, and only very few of these cliffs were formed
by compounds having different target selectivity. After this global frequency
analysis of activity cliffs, we asked the question whether large-magnitude po-
tency changes were predominantly induced by specific structural modifications.
Indeed, a systematic analysis of activity-cliff inducing chemical replacements
on the basis of matched molecular pairs identified 146 replacements, including
both R-group and core substructure changes, that displayed a general tendency
to form activity cliffs. This means that introduced activity cliffs were formed
in the structural context of diverse scaffolds and in compounds active against
many different targets.
Bioisosteric replacements with a high propensity to produce compounds
with limited potency alterations could also be identified. A compendium of
96 molecular transformations retaining potency across diverse targets and 64
modifications being conservative for single target families was assembled.
Graphical methods for the analysis of congeneric compound series were
presented that aimed at the extraction of interpretable SAR rules applicable
to the design of new compounds. The DRC graph structure was introduced
to extend conventional analysis of analogs using R-group tables and provide
more differentiated SAR information. Conventional approaches suffer from the
limitation that SARs between R-group combinations at different sites cannot
be analyzed in a straightforward and consistent manner. Therefore, subset re-
lationships between different R-group combinations were utilized as organizing
principle in the design of the DRCG. It was shown that this organization scheme
results in graph components that represent well-defined SAR patterns. Analysis
of these patterns provides an immediate access to critical substitution sites, fa-
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vorable and unfavorable R-groups, or non-additive potency effects of multi-site
substitutions. Furthermore, the data structure makes it possible to design new
analogs by combining favorable R-group combinations derived from different
compounds.
Then, a methodological framework for the study of mtSARs and identifi-
cation of selectivity determinants was described. Active analogs were organized
in CAGs that were adapted for mtSAR analysis by comparing and grouping
compounds on the basis of pharmacophore feature exchanges. Generating this
data structure for multiple targets makes it possible to determine preference
orders for chemical modifications that improve target selectivity.
Finally, a combined data mining and visualization approach for the detec-
tion of SAR transfer from one chemical series to another was presented. The
methodology enables the identification of alternative analog series with different
core structures, corresponding substitution patterns, and comparable potency
progression. Scaffolds can be exchanged between these series and new analogs
suggested that incorporate preferred R-groups. The application of the approach
to a systematic assessment of SAR transfer potential in publicly available com-
pound data revealed a limited number of SAR transfer events and also confirmed
that SARs of chemically related series are often substantially different.
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Appendix A
Software and Databases
Software and databases used in this thesis are listed in alphabetical order in
Tables A-1 and A-2, respectively.
Table A-1: Software
EMBOSS European Molecular Biology Open Software Suite
description EMBOSS is a software analysis package for molecular biology and
bioinformatics applications including, for example, sequence align-
ment, rapid database searching with sequence patterns, and protein
motif identification.
provider European Bioinformatics Institute, Hinxton, UK
URL http://emboss.sourceforge.net/
Java
description Java is an object-oriented programming language.
provider Oracle Corporation, Redwood City, CA, USA
URL http://www.oracle.com/technetwork/java/
JUNG Java Universal Network/Graph Framework
description JUNG is a software library providing a common and extendible lan-
guage for the modeling, analysis, and visualization of data repre-
sentable as a graph or network.
provider Danyel Fisher, Tom Nelson, and Joshua O'Madadhain
URL http://jung.sourceforge.net/
MOE Molecular Operating Environment
description MOE is an interactive computing and molecular modeling tool writ-
ten in the Scientific Vector Language, a self-contained programming
system developed by the Chemical Computing Group. MOE provides
applications for the calculation of numerical property descriptors and
implementations of numerous fingerprint formats including MACCS
structural keys and the TGD fingerprint.
provider Chemical Computing Group Inc., Montreal, QC, Canada
URL http://www.chemcomp.com/
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Table A-1: Software (continued)
OEChem TK OpenEye Chemistry Toolkit
description OEChem TK is a programming library for chemistry and chemoinfor-
matics that is, inter alia, wrapped for Java.
provider OpenEye Scientific Software Inc., Santa Fe, NM, USA
URL http://www.eyesopen.com/oechem-tk/
Perl
description Perl is a scripting language.
provider Larry Wall
URL http://www.perl.org/
Pipeline Pilot
description Pipeline Pilot is a scientific informatics platform that provides com-
ponents for the creation of workflow protocols enabling data analyses
and a variety of chemoinformatics applications, e.g., fingerprint and
scaffold calculations.
provider Accelrys Inc., San Diego, CA, USA
URL http://www.accelrys.com/products/scitegic/
PROFEAT Protein Feature Server
description PROFEAT is a web server for computing commonly used features of
proteins and peptides from amino acid sequence.
provider Bioinformatics & Drug Design Group, Computational Science Depart-
ment, National University of Singapore, Singapore
URL http://bidd.cz3.nus.edu.sg/cgi-bin/prof/protein/profnew.cgi/
PSIPRED
description The PSIPRED server is a web server for protein secondary structure
prediction.
provider Bioinformatics Group, Departments of Computer Science, University
College London, UK
URL http://bioinf.cs.ucl.ac.uk/psipred/
R The R Project for Statistical Computing
description R is a programming language and software environment for statistical
computing and graphics.
provider R Development Core Team, R Foundation for Statistical Computing,
Vienna, Austria
URL http://www.r-project.org/
SSEA Secondary Structure Element Alignment
description SSEA is a web server for computing either local or global alignments
of protein secondary structures.
provider Biocomputing UP, Department of Biology, University of Padua, Italy
URL http://protein.bio.unipd.it/ssea/
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Table A-1: Software (continued)
SVMlight
description SVMlight is an implementation of support vector machines for classi-
fication, regression, and ranking problems.
provider Thorsten Joachims
URL http://svmlight.joachims.org/
TopMatch-web
description TopMatch-web is a web server for the alignment and superposition of
protein structures.
provider Division of Bioinformatics, Department of Molecular Biology, Univer-
sity of Salzburg, Austria
URL http://topmatch.services.came.sbg.ac.at/
Table A-2: Databases
BindingDB
description BindingDB is a database of approximately 800 000 measured binding
affinities, in particular for interactions between proteins considered to
be therapeutically relevant and drug-like small molecules (see Chap-
ter 2).
provider Skaggs School of Pharmacy and Pharmaceutical Sciences, University
of California, San Diego, CA, USA
URL http://www.bindingdb.org/
ChEMBL
description ChEMBL is a database reporting bioactivity data and calculated prop-
erties for more than one million drug-like small molecules (see Chap-
ter 2).
provider European Bioinformatics Institute, Hinxton, UK
URL https://www.ebi.ac.uk/chembl/
CutDB
description The CutDB is a collection of documented proteolytic events for nat-
ural proteins in vivo or in vitro, with each entry in the database cor-
responding to a combination of a protease, a protein substrate, and a
cleavage site.
provider Burnham Institute for Medical Research, La Jolla, CA, USA
URL http://cutdb.burnham.org/
MDDR MDL Drug Data Report
description The MDDR is a database containing more than 150 000 biologically
active compounds assembled from patent literature, meetings, con-
gresses, and journals.
provider Symyx Software, San Ramon, CA, USA
URL http://www.symyx.com/
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Table A-2: Databases (continued)
MEROPS
description The MEROPS database provides a structure-based classification of
peptidases and is an information resource for proteins and small
molecules that inhibit them.
provider Wellcome Trust Sanger Institute, Cambridge, UK
URL http://merops.sanger.ac.uk/
PDB Protein Data Bank
description The PDB is a central repository for 3D structural data of proteins and
nucleic acids obtained by NMR spectroscopy or X-ray crystallography.
provider European Bioinformatics Institute, Hinxton, UK; Osaka University,
Japan; Research Collaboratory for Structural Bioinformatics, USA
URL http://www.pdb.org/
PubChem BioAssay
description The PubChem Bioassay database contains 500 000 descriptions of as-
say protocols and provides over 130 million bioactivity outcomes. More
than 1 600 assays are confirmatory, hence providing quantitative po-
tency measurements.
provider National Center for Biotechnology Information, Bethesda, MD, USA
URL http://pubchem.ncbi.nlm.nih.gov/
SCOP Structural Classification of Proteins
description The SCOP database provides a (mostly manually curated) classifica-
tion of protein structural domains based on amino acid and structure
similarities.
provider Laboratory of Molecular Biology, Cambridge, UK
URL http://scop.mrc-lmb.cam.ac.uk/scop/
UniProt Universal Protein Resource
description UniProt is a central repository of protein sequence and functional
annotation.
provider European Bioinformatics Institute, Hinxton, UK; Protein Information
Resource, Georgetown University Medical Center, DC, USA; Swiss
Institute of Bioinformatics, Lausanne, Switzerland
URL http://www.uniprot.org/
ZINC
description ZINC is a database of over 14 million commercially available com-
pounds provided in 3D formats.
provider Shoichet Laboratory, Department of Pharmaceutical Chemistry, Uni-
versity of California, San Francisco, CA, USA
URL http://zinc.docking.org/
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Appendix B
Orphan Screening  Additional
Information
A comment on the general validity of target kernel functions used in our simu-
lated orphan screening trials reported in Chapter 3 is provided.
Tables B-1 and B-2 report average recovery rates for individual targets of data
set 1 using the strategies SVM TLK and SVM LC, respectively. Corresponding
results for individual targets of data set 2 are provided in Tables B-3 and B-4.
Average recovery rates for homology-based SVM on individual targets of data
set 2 are given in Table B-5.
Table B-6 reports average recovery rates for the SVM strategies SVM TLK and
SVM LC that are obtained for individual targets of data set 1 when ligands of
the nearest neighbor target are excluded from training.
A Note on the Validity of Kernel Functions
Some of our target kernel functions introduced in the context of orphan screen-
ing are not generally valid kernel functions because they are not necessarily
positive semi-definite for all protein sets (i.e., for a given set of proteins, an
all-versus-all matrix of scores might have some negative eigenvalues). To over-
come this problem, one can convert a symmetric into a positive semi-definite
matrix by subtracting from the diagonal of the matrix its smallest negative
eigenvalue [131]. However, for the analysis presented in this thesis, this conver-
sion was not required because all score matrices were positive semi-definite for
our data sets.
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Table B-1: Search results for ligand prediction using SVM TLK (set 1)
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ace2 5.7 5.2 4.4 3.9 5.2 3.5 0.0 0.9 0.4 4.4 1.3
cal2 2.3 5.7 6.6 2.3 5.2 2.5 19.1 27.5 26.1 13.6 25.2
cas3 6.7 6.7 8.9 8.1 6.6 8.7 7.4 8.3 8.3 6.3 6.2
catD 21.2 22.2 34.6 27.5 46.0 31.7 37.2 39.5 24.5 24.3 24.8
catL 8.5 9.3 11.0 8.6 8.6 8.8 11.6 17.7 10.8 10.4 13.6
mgcp 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
metap2 1.7 1.2 1.7 1.6 1.4 1.6 1.6 1.5 1.1 1.7 0.7
mmp2 3.3 17.4 16.2 4.0 15.4 8.7 14.9 20.3 34.2 39.6 41.9
mmp8 9.1 30.9 28.2 10.0 20.9 17.3 23.6 27.3 42.7 48.2 46.4
ren 3.0 18.7 9.5 5.0 14.1 9.7 30.5 12.2 26.0 17.9 25.6
thr 17.5 29.2 27.5 18.9 13.4 27.2 13.7 27.5 29.1 29.4 28.9
try 19.6 37.9 30.4 20.4 14.4 34.8 28.3 35.2 41.7 38.5 41.7
average 8.2 15.4 14.9 9.2 12.6 12.9 15.7 18.2 20.4 19.5 21.4
TGD
ace2 10.4 16.5 11.3 10.9 14.8 13.0 0.4 7.8 6.1 10.9 10.4
cal2 9.3 6.6 9.3 6.4 7.7 6.1 11.6 12.7 11.1 10.7 15.5
cas3 14.9 14.4 17.4 16.0 20.4 15.0 19.0 21.2 21.5 21.6 20.8
catD 36.0 38.2 41.2 36.3 42.5 39.9 43.7 42.9 43.4 40.5 42.3
catL 6.3 6.2 6.3 6.3 6.3 6.2 7.0 7.5 7.4 6.2 7.3
mgcp 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
metap2 11.5 7.6 11.4 11.2 9.7 11.7 5.1 2.7 10.4 5.5 11.7
mmp2 4.9 33.0 15.4 5.5 16.8 8.7 10.9 18.6 49.6 57.3 60.5
mmp8 10.0 37.3 26.4 12.7 28.2 15.5 22.7 34.6 54.6 57.3 57.3
ren 17.5 43.5 33.8 22.9 39.6 30.6 43.0 40.4 44.7 43.5 44.2
thr 19.5 25.1 22.7 20.3 19.3 23.5 25.9 27.5 28.2 27.0 28.2
try 27.3 38.1 32.9 27.5 24.6 35.2 29.6 43.9 45.6 46.0 46.4
average 14.0 22.2 19.0 14.7 19.2 17.1 18.2 21.7 26.9 27.2 28.7
Recovery rates (in %) for all targets in data set 1 are reported for selection sets of 100
compounds averaged over ten independent trials per target. Target abbreviations are used
according to Table 3.4-1.
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Table B-2: Search results for ligand prediction using SVM LC (set 1)
u
n
if
or
m
n
ee
d
le
w
at
er
P
R
O
F
E
A
T
sp
ec
tr
u
m
S
S
E
A
G
O
cl
ea
va
ge
S
C
O
P
T
op
m
at
ch
M
E
R
O
P
S
MACCS
ace2 3.5 3.9 3.0 3.5 4.8 3.5 2.2 1.7 0.4 4.4 1.3
cal2 7.3 5.2 7.1 7.5 8.0 7.1 14.1 14.6 22.7 9.8 22.7
cas3 7.1 6.6 7.5 7.0 6.0 7.5 6.3 6.9 7.1 5.6 5.6
catD 28.8 28.2 34.3 29.7 46.6 29.9 36.5 35.7 27.9 37.9 27.5
catL 9.0 8.9 8.9 9.0 8.6 9.2 11.9 14.5 11.8 10.0 12.9
mgcp 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
metap2 1.2 1.2 1.3 1.3 1.2 1.3 1.7 1.4 1.0 1.4 0.6
mmp2 2.6 13.1 5.6 3.0 9.0 3.6 7.1 7.2 27.7 29.6 39.4
mmp8 4.6 25.5 8.2 4.6 12.7 4.6 13.6 11.8 35.5 41.8 44.6
ren 4.1 18.3 7.9 4.5 14.3 7.9 12.3 16.6 29.4 17.6 29.9
thr 11.2 28.2 16.3 12.1 11.4 16.4 28.4 21.4 29.8 28.7 29.8
try 15.6 37.1 21.5 15.4 14.0 22.7 20.2 29.6 43.9 41.0 43.7
average 7.9 14.7 10.1 8.1 11.4 9.5 12.9 13.5 19.8 19.0 21.5
TGD
ace2 15.2 16.5 15.2 15.2 16.5 15.7 15.2 10.9 10.9 13.5 13.5
cal2 13.6 8.4 12.7 11.8 10.0 12.3 17.7 17.7 10.9 11.8 16.1
cas3 20.1 16.1 20.5 20.0 21.8 19.5 22.2 23.3 23.1 22.2 21.0
catD 34.6 38.0 39.2 34.5 42.6 38.2 42.8 45.5 44.3 41.4 44.0
catL 6.6 6.6 6.6 6.6 6.7 6.7 6.4 7.3 7.8 6.6 7.4
mgcp 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
metap2 7.5 5.3 7.5 7.8 8.0 7.6 7.5 2.5 9.8 4.1 10.7
mmp2 4.4 23.5 7.1 4.9 11.2 5.5 8.6 6.3 39.1 37.2 53.0
mmp8 11.8 28.2 18.2 11.8 22.7 12.7 16.4 20.0 52.7 54.6 53.6
ren 21.8 45.0 31.8 23.8 39.8 29.6 36.7 40.5 46.4 45.7 45.9
thr 19.5 24.9 21.4 19.8 19.9 21.7 27.0 25.9 27.7 26.6 28.0
try 19.4 35.2 25.6 20.8 22.3 25.2 24.8 35.4 44.8 41.5 45.2
average 14.5 20.6 17.1 14.7 18.5 16.2 18.8 19.6 26.5 25.4 28.2
Recovery rates (in %) for all targets in data set 1 are reported for selection sets of 100
compounds averaged over ten independent trials per target. Target abbreviations are used
according to Table 3.4-1.
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Table B-3: Search results for ligand prediction using SVM TLK (set 2)
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cal1 38.1 49.5 52.0 50.0 50.5 51.7 49.5 53.2 52.2 53.2 51.0
cal2 32.7 65.7 55.5 44.1 63.0 50.9 52.7 58.9 65.7 63.0 67.1
cas1 6.9 10.0 12.5 10.6 16.3 15.6 19.4 20.0 16.9 20.0 18.8
cas3 6.6 19.5 12.3 7.4 15.6 12.4 9.1 21.4 24.4 21.2 24.0
catB 37.5 35.8 40.0 35.8 39.2 34.2 30.0 39.2 25.0 29.2 23.3
catK 13.7 18.5 16.7 16.3 19.4 16.1 17.8 17.3 16.6 17.3 17.7
catL 22.7 24.4 24.1 23.6 26.0 25.9 23.2 24.3 24.0 24.8 23.4
catS 11.8 24.1 11.0 14.0 23.6 17.6 16.3 14.5 21.9 21.3 23.9
faXa 3.6 9.7 7.7 4.7 8.4 7.9 8.2 9.2 10.4 10.2 10.5
thr 7.3 25.9 19.9 8.8 15.6 19.2 24.7 21.0 28.3 25.9 29.0
try 16.0 44.3 33.0 19.6 23.8 35.1 29.8 41.9 45.1 40.6 47.4
average 17.9 29.8 25.9 21.4 27.4 26.0 25.5 29.2 30.0 29.7 30.5
TGD
cal1 21.0 30.7 27.3 22.7 31.0 25.1 28.1 27.3 31.2 30.7 29.8
cal2 14.3 44.3 19.8 16.4 47.7 20.7 20.5 20.9 40.0 26.1 48.4
cas1 16.3 20.0 19.4 16.3 29.4 21.3 24.4 33.8 31.9 35.0 33.8
cas3 18.0 30.1 24.4 19.0 27.3 24.3 22.7 34.9 35.9 33.5 35.9
catB 35.0 35.8 34.2 35.0 33.3 33.3 37.5 34.2 29.2 35.0 31.7
catK 8.3 11.8 9.9 8.8 11.6 9.0 9.4 10.8 11.5 11.3 11.7
catL 9.3 10.3 8.9 9.5 10.8 9.5 9.7 10.3 10.4 10.6 9.9
catS 3.9 3.7 3.8 3.7 3.7 3.4 3.6 3.2 3.6 3.4 3.7
faXa 7.4 7.7 7.6 7.3 7.6 7.7 7.8 7.7 8.1 7.9 7.9
thr 28.0 30.4 30.0 28.6 29.8 29.8 31.6 30.4 31.1 30.7 31.2
try 47.4 50.9 50.8 47.9 47.2 50.6 50.9 53.0 52.8 50.9 52.8
average 19.0 25.1 21.5 19.5 25.4 21.3 22.4 24.2 26.0 25.0 27.0
Recovery rates (in %) for all targets in data set 2 are reported for selection sets of 100
compounds averaged over ten independent trials per target. Target abbreviations are used
according to Table 3.4-2.
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Table B-4: Search results for ligand prediction using SVM LC (set 2)
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cal1 45.7 48.5 51.2 48.6 49.3 50.0 50.0 50.7 50.0 52.0 50.2
cal2 42.5 67.5 55.7 48.0 63.2 52.5 65.0 65.7 78.6 69.8 74.3
cas1 8.8 6.3 10.0 9.4 12.5 11.3 19.4 20.0 21.3 20.6 21.3
cas3 7.5 16.3 10.2 7.8 14.3 10.3 10.3 17.8 22.7 17.9 22.7
catB 40.0 36.7 40.8 40.8 40.8 39.2 33.3 41.7 35.0 38.3 29.2
catK 17.8 19.2 18.3 18.0 19.3 18.4 19.8 18.7 18.0 18.9 18.1
catL 23.8 25.6 23.8 23.6 26.3 24.5 21.8 21.9 23.0 24.3 24.0
catS 13.2 23.0 12.8 13.9 22.3 15.7 16.9 14.1 21.1 19.4 22.6
faXa 2.6 8.2 4.5 2.9 7.2 4.6 4.6 6.2 10.2 9.6 10.2
thr 7.0 23.2 11.7 7.5 14.2 11.7 27.0 13.8 28.5 26.1 28.5
try 13.8 44.0 23.6 14.9 22.6 24.7 22.1 34.0 48.5 44.0 48.5
average 20.2 29.0 23.9 21.4 26.5 23.9 26.4 27.7 32.4 31.0 31.8
TGD
cal1 22.4 31.2 26.8 24.4 31.2 25.9 28.1 28.1 30.5 30.2 30.7
cal2 19.6 46.8 20.9 20.5 50.0 23.2 26.4 21.8 39.8 24.8 50.2
cas1 19.4 21.9 22.5 20.6 30.6 23.1 26.9 36.9 38.8 36.9 38.8
cas3 19.0 29.3 22.8 19.6 27.1 22.3 24.9 33.6 36.0 32.9 36.0
catB 34.2 37.5 32.5 33.3 35.8 33.3 39.2 34.2 35.8 36.7 35.8
catK 10.1 12.3 10.9 10.4 11.8 10.4 11.6 12.6 13.8 12.6 12.2
catL 10.0 11.0 10.0 10.0 11.4 10.0 9.9 10.6 11.2 11.0 10.7
catS 3.0 3.0 3.1 2.9 3.1 2.8 3.4 2.6 3.3 3.0 3.0
faXa 6.6 7.5 7.0 6.7 7.4 7.0 7.4 7.3 7.9 7.7 7.9
thr 28.2 30.5 29.8 28.5 29.9 29.8 31.9 30.3 31.3 31.0 31.3
try 41.7 48.7 46.0 42.5 45.5 46.2 44.9 48.1 50.9 50.0 50.9
average 19.5 25.4 21.1 19.9 25.8 21.3 23.1 24.2 27.2 25.2 28.0
Recovery rates (in %) for all targets in data set 2 are reported for selection sets of 100
compounds averaged over ten independent trials per target. Target abbreviations are used
according to Table 3.4-2.
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Table B-5: Search results for ligand prediction using homology-based SVM
(set 2)
MACCS TGD
NN targeta alla NN targeta alla
100b 1000b 100b 1000b 100b 1000b 100b 1000b
cal1 46.8 62.2 46.8 62.2 29.8 40.2 29.8 40.2
cal2 61.8 76.8 61.8 76.8 49.3 65.5 49.3 65.5
cas1 21.3 51.9 21.3 51.9 36.9 69.4 36.9 69.4
cas3 21.6 41.2 21.6 41.2 36.0 54.2 36.0 54.2
catB 10.0 39.2 13.3 63.3 13.3 35.8 21.7 49.2
catK 14.0 42.9 16.7 47.7 8.0 22.4 8.9 33.2
catL 14.5 36.4 22.2 64.3 7.0 26.3 9.5 26.6
catS 14.0 41.5 24.8 60.7 3.5 18.0 4.3 32.6
faXa 8.7 31.7 10.5 39.0 7.6 48.7 8.1 53.0
thr 9.6 33.3 28.1 71.6 23.6 70.9 31.2 82.0
try 12.5 29.1 44.7 67.6 34.0 72.3 51.9 87.7
average 21.3 44.2 28.3 58.8 22.6 47.6 26.1 54.0
a Reference target(s). b Set size. Recovery rates (in %) are reported for all targets in data
set 2 averaged over ten independent trials per target. Searches are either carried out using
only the ligands of the nearest neighbor (NN) target as positive training class or using the
pooled ligands of all members of the orphanized target's subfamily (column all) as positive
training class. For simulated orphan targets of the calpain and caspase families, reference
sets for both settings are identical because only one reference target belonging to the same
subfamily exists in the test system. Target abbreviations are used according to Table 3.4-2.
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Table B-6: Search results for ligand prediction using SVM TLK and LC in
the absence of nearest neighbor information
MACCS TGD
SVM LCa SVM TLKa SVM LCa SVM TLKa
100b 1000b 100b 1000b 100b 1000b 100b 1000b
ace2 4.4 17.8 4.4 15.7 14.4 36.5 13.5 40.0
cal2 3.2 49.6 2.7 41.8 13.0 32.5 10.7 30.0
cas3 7.0 35.8 7.5 36.3 21.3 48.5 20.8 48.1
catD 15.9 54.3 20.6 60.8 28.6 65.5 27.5 64.2
catL 7.5 26.3 8.5 25.8 5.8 12.6 5.8 11.5
mgcp 0.0 1.1 0.0 1.1 0.0 0.0 0.0 0.0
metap2 0.8 7.3 0.9 6.1 11.1 38.8 12.2 40.8
mmp2 0.4 5.6 0.3 4.7 4.6 23.1 4.7 23.9
mmp8 0.0 6.4 0.0 6.4 5.5 24.6 6.4 23.6
ren 1.3 14.2 1.2 16.9 4.9 44.2 4.5 44.5
thr 4.5 29.7 4.1 29.2 14.5 43.3 13.8 41.1
try 5.0 25.4 4.6 24.4 9.8 44.8 10.8 49.2
average 4.2 22.8 4.6 22.4 11.1 34.5 10.9 34.7
a Strategy. b Set size. Recovery rates (in %) are reported for all targets in data set 1 averaged
over ten independent search trials per target. For all orphan targets, the nearest neighbor
target and its ligands were excluded from training. All searches were carried out with the
MEROPS target kernel. Target abbreviations are used according to Table 3.4-1.
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Appendix C
Potency-Directed LBVS 
Additional Information
Search results for potency-directed SVM calculations using the MACCS finger-
print are provided.
Figure C-1 reports cumulative recall curves for potency-balanced reference sets
and the three different SVM strategies introduced in Chapter 4.
Figure C-2 shows SVM performance for database selection sets of constant size.
Figure C-3 compares control calculations using highly potent reference com-
pounds only to an advanced SVM strategy (SVM SAK) developed for potency-
directed LBVS.
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Figure C-1: Cumulative recall curves for potency-balanced reference sets
For each bioassay, cumulative recall curves are shown for all active compounds and the highest
potency categories (C1 and C2) and different SVM strategies using the MACCS fingerprint.
Recall curves represent the average of ten independent trials using different reference sets.
Potency-balanced reference sets consist of compounds spanning the entire potency range in
a data set. The figure is adapted from [76].
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Figure C-2: Support vector machine performance for database selection
sets of constant size Recovery rates are shown for the MACCS fingerprint, potency-
balanced reference sets, and database selection sets of 1 000 compounds. The results are
averaged over ten independent trials per data set. The figure is adapted from [76].
197
010
20
30
40
50
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
all
0
10
20
30
40
50
60
70
80
90
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
C1
0
10
20
30
40
50
60
70
80
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
C2
50
re
c
o
v
e
ry
 r
a
te
 [
%
]
all
60
re
c
o
v
e
ry
 r
a
te
 [
%
]
C1
70
re
c
o
v
e
ry
 r
a
te
 [
%
]
C2
886
887
0
10
20
30
40
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
0
10
20
30
40
50
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
0
10
20
30
40
50
60
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
20
30
re
c
o
v
e
ry
 r
a
te
 [
%
]
all
40
50
60
70
re
c
o
v
e
ry
 r
a
te
 [
%
]
C1
50
60
70
80
re
c
o
v
e
ry
 r
a
te
 [
%
]
C2
894
0
10
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
0
10
20
30
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
0
10
20
30
40
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
10
re
c
o
v
e
ry
 r
a
te
 [
%
]
all
10
20
30
40
re
c
o
v
e
ry
 r
a
te
 [
%
]
C1
10
20
30
re
c
o
v
e
ry
 r
a
te
 [
%
]
C2
1030
0
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
0
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
0
0 1000 2000 3000 4000 5000
re
c
o
v
e
ry
 r
a
te
 [
%
]
selection set size
1Cat 2Cat Pooled SAK
Figure C-3: Control calculations using highly potent reference compounds
For each bioassay, recall curves are shown for all active compounds and the two highest po-
tency categories (C1 and C2). Compound recall is monitored for different SVM strategies us-
ing MACCS as fingerprint representation averaged over ten independent trials. The following
strategies are compared: standard SVM with reference compounds from potency category 1
(`1Cat'), 1 and 2 (`2Cat'), and all categories (`Pooled') and SVM SAK. SAKsimple is shown
for sets 887 and 894, SAKsquared for sets 886 and 1030. The figure is adapted from [76].
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Appendix D
Class-Specific Descriptors 
Additional Information
An explanation for the value range [0,1] of the MI-DSE method introduced in
Chapter 5 is given.
The 171 descriptors used in our large-scale comparison of DSE- and MI-DSE-
based rankings are listed and grouped by descriptor type in Table D-1.
Table D-2 analyzes the influence of different binning schemes on DSE- and MI-
DSE-based descriptor rankings. For both methods, descriptor rankings using 8,
16, 32, or 64 bins in the histogram calculation are systematically compared on
168 activity classes extracted from the ChEMBL database and average Spear-
man rank correlation coefficients are reported.
For the targets carbonic anhydrase II and muscarinic acetylcholine receptor M2,
the ten top-ranked descriptors based on DSE and MI-DSE are listed in Table
D-3.
MI-DSE value range
The mutual information MI(D,C )can be equivalently expressed as
MI(D,C) = H(D)− H(D|C) = H(C)− H(C|D) (D.1)
Since only two classes A and B are being compared, the maximal entropy
that can be obtained for H(C ) assuming equal probabilities of Pr(C = A) =
Pr(C = B) = 0.5 is one (i.e., H(C) = log2(2)). From equation D.1 it follows
that MI(D,C) ≤ H(C), and therefore MI-DSE produces values in the range
from zero to one.
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Table D-1: MOE descriptors
type descriptors
physical properties apol, bpol, density, FCharge, logP(o/w), logS, mr, SlogP, SMR,
TPSA, vdw_area, vdw_vol, Weight
subdivided surface
areas
SlogP_VSA0, SlogP_VSA1, SlogP_VSA2, SlogP_VSA3,
SlogP_VSA4, SlogP_VSA5, SlogP_VSA6, SlogP_VSA7,
SlogP_VSA8, SlogP_VSA9, SMR_VSA0, SMR_VSA1,
SMR_VSA2, SMR_VSA3, SMR_VSA4, SMR_VSA5,
SMR_VSA6, SMR_VSA7
atom counts and
bond counts
a_aro, a_count, a_heavy, a_IC, a_ICM, a_nB, a_nBr, a_nC,
a_nCl, a_nF, a_nH, a_nI, a_nN, a_nO, a_nP, a_nS, b_1rotN,
b_1rotR, b_ar, b_count, b_double, b_heavy, b_rotN, b_rotR,
b_single, b_triple, chiral, chiral_u, lip_acc, lip_don, rings,
VAdjEq, VAdjMa
adjacency and dis-
tance matrix de-
scriptors
balabanJ, BCUT_PEOE_0, BCUT_PEOE_1, BCUT_PEOE_2,
BCUT_PEOE_3, BCUT_SLOGP_0, BCUT_SLOGP_1,
BCUT_SLOGP_2, BCUT_SLOGP_3, BCUT_SMR_0,
BCUT_SMR_1, BCUT_SMR_2, BCUT_SMR_3, diameter,
GCUT_PEOE_0, GCUT_PEOE_1, GCUT_PEOE_2,
GCUT_PEOE_3, GCUT_SLOGP_0, GCUT_SLOGP_1,
GCUT_SLOGP_2, GCUT_SLOGP_3, GCUT_SMR_0,
GCUT_SMR_1, GCUT_SMR_2, GCUT_SMR_3, petitjean,
petitjeanSC, radius, VDistEq, VDistMa, wienerPath, wienerPol
pharmacophore fea-
ture descriptors
a_acc, a_acid, a_base, a_don, a_hyd, vsa_acc, vsa_acid,
vsa_base, vsa_don, vsa_hyd, vsa_other, vsa_pol
Kier&Hall connec-
tivity and kappa
shape indices
chi0, chi0_C, chi0v, chi0v_C, chi1, chi1_C, chi1v, chi1v_C, Kier1,
Kier2, Kier3, KierA1, KierA2, KierA3, KierFlex, zagreb
partial charge de-
scriptors
PEOE_PC+, PEOE_PC-, PEOE_RPC+, PEOE_RPC-,
PEOE_VSA+0, PEOE_VSA+1, PEOE_VSA+2,
PEOE_VSA+3, PEOE_VSA+4, PEOE_VSA+5,
PEOE_VSA+6, PEOE_VSA-0, PEOE_VSA-1, PEOE_VSA-2,
PEOE_VSA-3, PEOE_VSA-4, PEOE_VSA-5, PEOE_VSA-6,
PEOE_VSA_FHYD, PEOE_VSA_FNEG,
PEOE_VSA_FPNEG, PEOE_VSA_FPOL, PEOE_VSA_FPOS,
PEOE_VSA_FPPOS, PEOE_VSA_HYD, PEOE_VSA_NEG,
PEOE_VSA_PNEG, PEOE_VSA_POL, PEOE_VSA_POS,
PEOE_VSA_PPOS, Q_PC+, Q_PC-, Q_RPC+, Q_RPC-,
Q_VSA_FHYD, Q_VSA_FNEG, Q_VSA_FPNEG,
Q_VSA_FPOL, Q_VSA_FPOS, Q_VSA_FPPOS,
Q_VSA_HYD, Q_VSA_NEG, Q_VSA_PNEG, Q_VSA_POL,
Q_VSA_POS, Q_VSA_PPOS
For more detailed information on the descriptors, see:
http://www.chemcomp.com/journal/descr.htm.
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Table D-2: Spearman rank correlation coefficients
MI-DSE DSE
8 bins 16 bins 32 bins 64 bins 8 bins 16 bins 32 bins 64 bins
8 bins 1 0.935 0.890 0.841 1 0.919 0.869 0.798
16 bins 1 0.967 0.922 1 0.956 0.895
32 bins 1 0.973 1 0.961
64 bins 1 1
Table D-3: DSE- and MI-DSE-based descriptor rankings
Descriptors (DSE) Descriptors (MI-DSE)
carbonic anhydrase II
GCUT_SLOGP_0 (0.66) PEOE_VSA-4 (0.76)
chiral_u (0.53) vsa_don (0.73)
PEOE_VSA-1 (0.42) SMR_VSA4 (0.72)
BCUT_SLOGP_0 (0.35) SlogP_VSA1 (0.65)
SMR_VSA2 (0.33) GCUT_SLOGP_0 (0.63)
SlogP_VSA4 (0.29) vsa_pol (0.53)
a_aro (0.26) a_nS (0.49)
SMR_VSA3 (0.22) GCUT_SLOGP_1 (0.49)
chiral (0.20) PEOE_VSA-3 (0.42)
BCUT_SMR_3 (0.19) TPSA (0.41)
muscarinic acetylcholine receptor M2
GCUT_SMR_0 (1.01) FCharge (0.82)
BCUT_PEOE_3 (0.89) a_base (0.80)
SMR_VSA4 (0.88) GCUT_SMR_0 (0.77)
SlogP_VSA1 (0.78) BCUT_SLOGP_0 (0.73)
BCUT_SMR_0 (0.73) BCUT_PEOE_3 (0.69)
BCUT_SMR_3 (0.71) GCUT_PEOE_0 (0.69)
BCUT_SLOGP_0 (0.70) BCUT_SMR_0 (0.64)
GCUT_PEOE_0 (0.70) GCUT_PEOE_3 (0.62)
vsa_acc (0.60) BCUT_SMR_3 (0.56)
PEOE_VSA+5 (0.56) BCUT_PEOE_0 (0.55)
For the top-ranked descriptors based on DSE (Descriptors (DSE)) and MI-DSE (Descrip-
tors (MI-DSE)), corresponding DSE and MI-DSE values are given in parentheses.
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Appendix E
Molecular Transformations 
Additional Information
For the 146 molecular transformations that frequently introduce activity cliffs
according to the search criteria detailed in Chapter 7, SMIRKS representations
are provided in Table E-1.
Table E-2 reports on the potency directionality of cliff-forming transformations.
SMIRKS representations for the identified set of 96 biosisosteric replacements
are given in Table E-3.
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Table E-1: Activity cliff-introducing chemical replacements
SMIRKS #cliffs #targets #MMPs #records freq.
[*:1]C(=O)N[O-]>>[*:1]P(=O)([O-])[O-] 5 4 4 6 83.3
[*:3]C(=O)c1c(O)cc(cc1[*:1])C(OC1C[NH2+]CC1[*:2])=O
>>[*:3]C(=O)c1c(O)cc(cc1[*:1])C(OC1Cc2c(cccc2)C1[*:2])=O
18 6 5 26 69.2
[*:2]NC1CCCC1OC(=O)c1cc(O)c([*:1])c(O)c1
>>[*:2]NC1c2c(CC1OC(=O)c1cc(O)c([*:1])c(O)c1)cccc2
17 6 4 26 65.4
[*:3]C(=O)c1c(O)cc(cc1[*:1])C(OC1CC(O)CC1[*:2])=O
>>[*:3]C(=O)c1c(O)cc(cc1[*:1])C(OC1Cc2c(cccc2)C1[*:2])=O
22 6 4 34 64.7
[*:3]C(=O)c1c(O)cc(cc1[*:1])C(OC1CC(CC1[*:2])C[NH3+])=O
>>[*:3]C(=O)c1c(O)cc(cc1[*:1])C(OC1Cc2c(cccc2)C1[*:2])=O
22 6 4 34 64.7
[*:2]NC1CC(CC1OC(=O)c1cc(O)c([*:1])c(O)c1)CO
>>[*:2]NC1c2c(CC1OC(=O)c1cc(O)c([*:1])c(O)c1)cccc2
20 6 4 34 58.8
[*:1]CCC([NH3+])CC(P(=O)([O-])[O-])O
>>[*:1]CCC([NH3+])CCS(=O)(=O)[O-]
9 4 4 16 56.3
[*:1]CCC([NH3+])CC(=O)[O-]
>>[*:1]CCC([NH3+])CC(P(=O)([O-])[O-])O
9 4 4 16 56.3
[*:1]CCC([NH3+])(CO)CO
>>[*:1]CCC([NH3+])CC(P(=O)([O-])[O-])O
8 4 4 16 50.0
[*:1][O-]>>[*:1]c1ccccc1 8 4 4 16 50.0
[*:1]C(=O)CCc1c2c([nH]c1)cccc2>>[*:1]C(=O)Cc1ccccc1 8 4 4 17 47.1
[*:2]C(=O)NC(C(=O)NC[*:1])C
>>[*:2]C(=O)NC(CCCC)C(=O)NC[*:1]
10 5 5 22 45.5
[*:1]Nc1ccccc1>>[*:1][O-] 4 4 4 9 44.4
[*:2]C(OC1CCC[NH2+]CC1NC(=O)c1ccc([*:1])cc1)=O
>>[*:2]C(OC1Cc2c(cccc2)C1NC(=O)c1ccc([*:1])cc1)=O
22 6 6 51 43.1
[*:1]CCCC>>[*:1]C[NH+]1CCOCC1 6 4 6 14 42.9
[*:2]NC1CCCCCC1OC(=O)c1cc(O)c([*:1])c(O)c1
>>[*:2]NC1c2c(CC1OC(=O)c1cc(O)c([*:1])c(O)c1)cccc2
14 5 4 34 41.2
[*:1]c1ccc(cc1)C(C)C>>[*:1]c1ccccc1C 27 4 22 66 40.9
[*:1]C(=O)[O-]>>[*:1]NC(=O)C 10 8 5 25 40.0
[*:2]C(CCP(=O)([O-])[O-])C[*:1]
>>[*:2]C(COP(=O)([O-])[O-])C[*:1]
8 5 5 20 40.0
[*:2]C(C(=O)N[*:1])C>>[*:2]C(CC(C)C)C(=O)N[*:1] 10 8 6 26 38.5
[*:1]N=[N+]=[N-]>>[*:1]O 5 4 5 13 38.5
[*:1]Br>>[*:1]C(=O)[O-] 8 8 6 21 38.1
[*:2]C([*:1])CCCC>>[*:2]C[*:1] 6 5 5 16 37.5
[*:1]CCCC[NH3+]>>[*:1]Cc1ccccc1 7 4 7 19 36.8
[*:2]C(=O)NC([*:1])CC(C)C>>[*:2]C(=O)NC[*:1] 7 5 4 19 36.8
[*:1]CC(C)C>>[*:1]CCCCOCc1ccccc1 6 4 4 17 35.3
[*:1]CC(C)C>>[*:1]Cc1c2c(ccc1)cccc2 6 5 4 17 35.3
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Table E-1: Activity cliff-introducing chemical replacements (continued)
SMIRKS #cliffs #targets #MMPs #records freq.
[*:2]C[*:1]>>[*:2]c1ccccc1[*:1] 27 4 27 77 35.1
[*:2]C(C(C)C)C(=O)N[*:1]>>[*:2]CC(=O)N[*:1] 9 8 6 26 34.6
[*:1]c1cc(OC)c(OC)cc1>>[*:1]c1ccccc1OC 5 4 4 15 33.3
[*:2]C(=O)C([*:1])=O>>[*:2]C([*:1])=O 6 4 4 18 33.3
[*:2]c1ccc([*:1])cc1>>[*:2]c1sc([*:1])nn1 17 4 7 51 33.3
[*:2]C=CC[*:1]>>[*:2]CC[*:1] 12 4 6 36 33.3
[*:3][S+2]([*:2])([*:1])c1ccc(OC)cc1
>>[*:3][S+2]([*:2])([*:1])c1ccc(Oc2ccccc2)cc1
16 6 7 49 32.7
[*:3]C(NC(=O)C([*:2])[*:1])C>>[*:3]C1N(CCC1)C(=O)C([*:2])[*:1] 9 5 8 29 31.0
[*:2]C(=O)C(NC([*:1])=O)Cc1ccc(O)cc1
>>[*:2]C(=O)C(NC([*:1])=O)Cc1nc[nH]c1
19 4 14 62 30.6
[*:2]C(NC(=O)C([*:1])[NH3+])CCCC
>>[*:2]C1N(CCC1)C(=O)C([*:1])[NH3+]
7 4 6 23 30.4
[*:1]C>>[*:1]c1cc(Cl)ccc1 7 7 7 24 29.2
[*:1]C(C)C>>[*:1]O 6 4 5 22 27.3
[*:2]C([*:1])O>>[*:2]O[*:1] 7 4 4 26 26.9
[*:1]C(C)C>>[*:1]C[NH3+] 4 4 4 15 26.7
[*:2]C([*:1])Cc1ccccc1>>[*:2]C[*:1] 17 10 15 64 26.6
[*:1]C(C)C>>[*:1]CC[NH3+] 9 6 6 34 26.5
[*:1]C>>[*:1]CCCCCCCC 9 6 7 34 26.5
[*:1]O>>[*:1]OC(=O)NC 6 5 5 23 26.1
[*:1]N>>[*:1]Nc1ccccc1 9 8 7 37 24.3
[*:1]S(=O)(=O)N>>[*:1][N+](=O)[O-] 8 7 4 33 24.2
[*:1]N>>[*:1]NCC[NH+](C)C 4 4 4 17 23.5
[*:1]Br>>[*:1]C(C)(C)C 7 5 4 30 23.3
[*:1]C(=O)[O-]>>[*:1]P(=O)([O-])[O-] 9 7 7 39 23.1
[*:1]c1ccc(Cl)cc1>>[*:1]c1ccc(S(=O)(=O)C)cc1 5 5 4 22 22.7
[*:1]c1ccc(SC)cc1>>[*:1]c1ccccc1 5 4 4 22 22.7
[*:2]C([*:1])C>>[*:2]C1([*:1])CCCC1 6 4 5 27 22.2
[*:2]C[*:1]>>[*:2]Cc1ccccc1[*:1] 5 4 4 23 21.7
[*:1]C>>[*:1]CCC(C)C 8 4 8 37 21.6
[*:1]C(=O)[O-]>>[*:1]C(F)(F)F 6 6 5 28 21.4
[*:1]c1cc[nH+]cc1>>[*:1]c1ncccc1 4 4 4 19 21.1
[*:1]C(=O)[O-]>>[*:1]CC 8 8 4 38 21.1
[*:1]C(=O)[O-]>>[*:1]F 9 9 8 43 20.9
[*:1]C(=O)c1ccccc1>>[*:1]c1ccccc1 7 4 5 36 19.4
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Table E-1: Activity cliff-introducing chemical replacements (continued)
SMIRKS #cliffs #targets #MMPs #records freq.
[*:1]C(F)(F)F>>[*:1]NC(=O)C 5 4 4 26 19.2
[*:1]C(C)C>>[*:1]c1ccc(Cl)cc1 5 4 5 26 19.2
[*:2]C(=O)N[*:1]>>[*:2][NH2+][*:1] 9 6 6 47 19.1
[*:2]C(=O)C([*:1])C>>[*:2]C(=O)C([*:1])Cc1ccccc1 12 6 10 64 18.8
[*:2]C(=O)CCCCCC[*:1]>>[*:2]C([*:1])=O 5 5 4 27 18.5
[*:1]F>>[*:1]S(=O)(=O)C 10 7 9 55 18.2
[*:1]CC>>[*:1]N 4 4 4 22 18.2
[*:2]O[*:1]>>[*:2]S([*:1])(=O)=O 12 11 9 66 18.2
[*:1]C>>[*:1]CCCCCCC 11 6 9 63 17.5
[*:1]NC>>[*:1]Nc1ccccc1 12 5 11 69 17.4
[*:1]NCc1ccccc1>>[*:1][O-] 4 4 4 23 17.4
[*:1]N>>[*:1]c1ccccc1 5 5 4 29 17.2
[*:1]N>>[*:1]NCc1ccccc1 6 6 6 36 16.7
Ic1ccc([*:1])cc1>>[*:1]c1ccccc1 11 4 10 66 16.7
[*:1]C>>[*:1]C[NH+]1CCOCC1 9 6 7 55 16.4
[*:1]C(=O)[O-]>>[*:1]c1ccccc1 8 7 5 49 16.3
[*:2]C(=O)N([*:1])C>>[*:2]C([*:1])=O 5 5 4 31 16.1
[*:2]C1CC[NH2+]CC1[*:1]>>[*:2]C1C[NH2+]CC1[*:1] 9 6 4 56 16.1
[*:2]CC(=O)N[*:1]>>[*:2]C[*:1] 5 5 4 31 16.1
[*:1]c1ccccc1OC>>[*:1]c1ncccc1 6 6 5 38 15.8
[*:1]C(=O)[O-]>>[*:1]Cl 8 8 7 51 15.7
[*:2]C(=O)C([*:1])C>>[*:2]C(=O)C([*:1])C(C)C 8 4 8 51 15.7
[*:1]OCc1ccccc1>>[*:1]Oc1ccccc1 11 5 8 70 15.7
[*:1]C#N>>[*:1]NC(=O)C 4 4 4 26 15.4
[*:1]C(=O)[O-]>>[*:1]OC 8 8 6 54 14.8
[*:2]CCCCCCCC[*:1]>>[*:2]C[*:1] 5 4 5 35 14.3
[*:1]c1ccc(Oc2ccccc2)cc1>>[*:1]c1ccc(cc1)-c1ccccc1 6 5 5 42 14.3
[*:1]C(F)(F)F>>[*:1]N 6 5 5 42 14.3
[*:2]CCCCCCCCCC[*:1]>>[*:2]CC[*:1] 6 6 6 43 14.0
[*:2]C(=O)NC([*:1])CC(C)C>>[*:2]C(=O)NC([*:1])Cc1ccccc1 6 5 5 43 14.0
[*:1]C(=O)[O-]>>[*:1]O 9 8 8 65 13.8
[*:1]C>>[*:1]CC(F)(F)F 8 6 7 59 13.6
[*:2]C[*:1]>>[*:2]Cc1ccc([*:1])cc1 9 7 9 66 13.6
[*:2]C([*:1])=O>>[*:2]C([*:1])O 13 11 11 96 13.5
[*:1]O>>[*:1]c1ccccc1 6 5 5 45 13.3
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Table E-1: Activity cliff-introducing chemical replacements (continued)
SMIRKS #cliffs #targets #MMPs #records freq.
[*:2]C[*:1]>>[*:2]c1cc([*:1])ccc1 4 4 4 30 13.3
[*:2]C(=O)CCCCC[*:1]>>[*:2]C([*:1])=O 5 4 5 38 13.2
[*:1]C#N>>[*:1]N 5 5 5 38 13.2
[*:2]C(=O)N[*:1]>>[*:2]C([*:1])=O 33 13 23 252 13.1
[*:1]C>>[*:1][O-] 7 4 6 54 13.0
[*:1]Cc1cc2c(cc1)cccc2>>[*:1]Cc1ccccc1 16 8 11 124 12.9
[*:1]OC>>[*:1]OCc1ccccc1 15 8 11 116 12.9
[*:1]C>>[*:1]CC=C 10 5 7 78 12.8
[*:2]CCCc1ccc([*:1])cc1>>[*:2]CCc1ccc([*:1])cc1 9 4 6 71 12.7
[*:1]N>>[*:1][O-] 18 14 14 142 12.7
[*:1]C#N>>[*:1]C(=O)[O-] 7 7 5 55 12.7
[*:2]c1cc([*:1])c(OC)cc1>>[*:2]c1ccccc1[*:1] 7 6 5 55 12.7
[*:3]C(=O)C([*:2])([*:1])C>>[*:3]C(=O)C([*:2])[*:1] 12 7 12 95 12.6
[*:1]c1ccc(NC(=O)C)cc1>>[*:1]c1ccc(OC)cc1 4 4 4 32 12.5
[*:2]CCCCCCCC[*:1]>>[*:2]CC[*:1] 10 7 9 81 12.3
[*:2]C([*:1])=O>>[*:2]C[*:1] 22 15 22 184 12.0
[*:2]C(=O)C[*:1]>>[*:2]C[*:1] 6 4 6 50 12.0
[*:1]Cc1ccccc1>>[*:1]Cc1nc[nH]c1 5 4 5 42 11.9
[*:1]C>>[*:1]C(=O)[O-] 8 8 6 67 11.9
[*:1]CO>>[*:1]C[NH3+] 13 9 8 109 11.9
[*:2]N([*:1])C>>[*:2]N[*:1] 47 26 43 400 11.8
[*:1]Cc1ccc(cc1)C(F)(F)F>>[*:1]Cc1ccccc1 5 5 5 43 11.6
[*:1]C>>[*:1]CC1CCCCC1 5 4 5 43 11.6
[*:1]C[NH3+]>>[*:1]O 7 6 4 61 11.5
[*:1]Cc1ccccc1>>[*:1]Oc1ccccc1 6 6 5 52 11.5
[*:1]Cc1ccccc1>>[*:1]c1c2c(ccc1)cccc2 5 5 4 44 11.4
[*:2]c1cc(C)c([*:1])cc1>>[*:2]c1ccccc1[*:1] 5 4 4 44 11.4
[*:1]c1cc(Cl)ccc1>>[*:1]c1ccncc1 4 4 4 35 11.4
[*:2]C(=O)N[*:1]>>[*:2]S([*:1])(=O)=O 8 5 7 71 11.3
[*:1]C(=O)C>>[*:1]c1ccccc1 4 4 4 36 11.1
[*:1]C>>[*:1]C(=O)C 9 4 9 81 11.1
[*:1]c1cc(ccc1)C(F)(F)F>>[*:1]c1ccccc1OC 5 5 5 45 11.1
[*:2]C(=O)N[*:1]>>[*:2]N[*:1] 5 4 4 46 10.9
[*:2]C(O[*:1])=O>>[*:2]CC(O[*:1])=O 7 4 7 64 10.9
[*:1]C>>[*:1]CC[NH3+] 8 6 8 74 10.8
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Table E-1: Activity cliff-introducing chemical replacements (continued)
SMIRKS #cliffs #targets #MMPs #records freq.
[*:2]c1cc(Cl)ccc1[*:1]>>[*:2]c1cc([*:1])ccc1 8 4 8 74 10.8
[*:2]CN[*:1]>>[*:2]N([*:1])C 5 4 5 47 10.6
[*:1]c1ccc(cc1)C(F)(F)F>>[*:1]c1ccccc1C 6 6 6 57 10.5
[*:2]C([*:1])CC>>[*:2]C[*:1] 10 8 9 97 10.3
[*:2]Cc1cc([*:1])ccc1>>[*:2]c1cc([*:1])ccc1 6 6 6 58 10.3
[*:2]C(=O)C([*:1])C>>[*:2]C(=O)C[*:1] 20 5 20 195 10.3
[*:1]N>>[*:1][N+](=O)[O-] 7 5 7 68 10.3
[*:1]F>>[*:1]c1ccccc1 9 8 8 87 10.3
[*:2]CS[*:1]>>[*:2]S[*:1] 6 4 5 59 10.2
[*:2]c1cc(C)c([*:1])cc1>>[*:2]c1cc(Cl)c([*:1])cc1 5 4 5 49 10.2
[*:2]C([*:1])(C)C>>[*:2]O[*:1] 6 6 6 59 10.2
[*:1]N>>[*:1]NCC 5 5 5 49 10.2
[*:2]C[NH2+][*:1]>>[*:2][NH2+][*:1] 19 6 17 187 10.2
[*:2]C([*:1])c1ccccc1>>[*:2]C[*:1] 8 6 7 79 10.1
[*:1]C>>[*:1]C[NH3+] 7 6 7 70 10.0
[*:2]C(=O)Nc1ccc([*:1])cc1>>[*:2]c1ccc([*:1])cc1 4 4 4 40 10.0
SMIRKS representations for all 146 frequent cliff formers are provided. For each transformation, the number
of cliffs (#cliffs) in which it participates, the number of cliff-forming matched molecular pairs defined by
this transformation (#MMPs), the number of targets (#targets) for which this transformation forms cliffs,
the frequency of occurrence of the transformation over all ligand sets (#records), and the relative frequency
(percentage) with which activity cliffs are introduced (freq.) are recorded. Transformations are sorted in
descending order of the relative frequency with which they introduce activity cliffs. The number of cliffs reported
is often larger than the number of matched molecular pairs because the same compound pair can form activity
cliffs for multiple targets.
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Table E-2: Directionality of potency changes for individual targets
#scaffold pairs consensus no consensus
1 147 13
2 56 18
3 9 5
4 5 1
5 1 1
6 1 0
For those transformations defining multiple cliff-forming MMPs for a single target, the number
of different scaffold pairs represented by these compound pairs was extracted. Then, for all
compound pairs, the direction of the activity change following the molecular transformation
was recorded. If the direction was the same for all compound pairs, it was considered a
consensus direction for this transformation and ligand set. For different numbers of scaffold
pairs present in the cliff-forming ligand sets, it is reported how often a consensus or no
consensus was obtained, respectively.
Table E-3: Bioisosteric replacements
SMIRKS #records #MMPs freq. #targets #TF
[*:1]Nc1ccc(F)cc1>>[*:1]Nc1ccccc1 56 27 100.0 21 8
[*:1]C(C)C>>[*:1]CC1CC1 39 25 100.0 29 13
[*:1]C1CCCC1>>[*:1]CC(C)C 35 22 100.0 22 12
[*:1]Nc1cc(OC)ccc1>>[*:1]Nc1ccccc1 35 19 100.0 19 9
[*:2]C1CC[NH+]([*:1])CC1>>
[*:2][NH+]1CC[NH+]([*:1])CC1
31 25 100.0 11 7
[*:1]c1cc(Cl)ccc1>>[*:1]c1cc(O)ccc1 30 20 100.0 28 16
[*:1]S(=O)(=O)c1ccc(F)cc1
>>[*:1]S(=O)(=O)c1ccccc1
30 17 100.0 20 11
[*:2]CCCO[*:1]>>[*:2]CCC[*:1] 102 94 98.0 17 11
[*:1]NC(=O)CC>>[*:1]NC(=O)CCC 48 28 97.9 15 7
[*:2]S(=O)(=O)c1cc([*:1])ccc1>>
[*:2]S(=O)(=O)c1ccc([*:1])cc1
88 57 97.7 43 19
[*:1]Nc1ccc(cc1)C>>[*:1]Nc1ccccc1 38 18 97.4 15 7
[*:2]CC(=O)NCC[*:1]>>[*:2]CC(=O)N[*:1] 37 23 97.3 23 12
[*:1]c1cc(F)ccc1>>[*:1]c1sccc1 36 21 97.2 30 12
[*:2]Oc1ccc([*:1])cc1>>[*:2]Sc1ccc([*:1])cc1 35 25 97.1 25 15
[*:2]C(OCC[*:1])=O>>[*:2]C(O[*:1])=O 35 25 97.1 15 9
[*:1]Nc1ccc(Cl)cc1>>[*:1]Nc1ccc(F)cc1 35 16 97.1 13 5
[*:1]Cc1cc(F)ccc1>>[*:1]Cc1ccc(F)cc1 34 28 97.1 30 16
[*:1]C[NH+](CC)CC>>[*:1]C[NH+]1CCCC1 34 23 97.1 26 10
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Table E-3: Bioisosteric replacements (continued)
SMIRKS #records #MMPs freq. #targets #TF
[*:1]CC>>[*:1]CC=C 34 24 97.1 21 14
[*:2]C([*:1])F>>[*:2]C[*:1] 34 27 97.1 17 8
[*:1]c1cc(OC)ccc1>>[*:1]c1cc2OCOc2cc1 34 15 97.1 17 7
[*:1]CC(C)C>>[*:1]CCCC 134 109 97.0 51 23
[*:2]COc1cc([*:1])ccc1>>[*:2]COc1ccc([*:1])cc1 33 31 97.0 21 14
[*:2]Nc1cc(O[*:1])ccc1>>[*:2]Nc1ccc([*:1])cc1 33 14 97.0 12 6
[*:1]CF>>[*:1]CO 32 26 96.9 10 7
[*:1]c1ccc(Br)cc1>>[*:1]c1ccc(cc1)C(F)(F)F 62 44 96.8 29 18
[*:1]Cc1ccc(Cl)cc1>>[*:1]Cc1ccc(cc1)C 31 20 96.8 27 15
[*:1]c1cc(ccc1)C>>[*:1]c1sccc1 31 16 96.8 23 10
I[*:1]>>[*:1][N+](=O)[O-] 31 24 96.8 21 13
[*:1]c1cc(OC)ccc1>>[*:1]c1sccc1 30 21 96.7 27 15
[*:1]c1cc(F)ccc1>>[*:1]c1ccccc1 200 148 96.5 89 34
[*:1]CC(C)C>>[*:1]CCC 170 122 96.5 55 23
[*:1]c1cc(Cl)ccc1>>[*:1]c1cc(ccc1)C 83 57 96.4 48 17
[*:1]C1CCCC1>>[*:1]CCC 49 31 95.9 30 14
[*:2]Oc1ccccc1[*:1]>>[*:2]c1ccccc1[*:1] 96 65 95.8 50 19
[*:2]C(C[*:1])(C)C>>[*:2]C(C[*:1])C 48 34 95.8 32 19
[*:1]CCCCC>>[*:1]CCCCCCC 71 58 95.8 35 20
[*:1]Br>>[*:1]Cl 439 282 95.7 132 48
[*:1]CC>>[*:1]OCC 46 34 95.7 35 21
[*:2]c1cc(C(F)(F)F)c([*:1])cc1
>>[*:2]c1cc(Cl)c([*:1])cc1
45 35 95.6 14 5
[*:2]CCCOc1ccc([*:1])cc1
>>[*:2]CCOc1ccc([*:1])cc1
44 31 95.5 20 11
[*:2]C(=O)N1CCC(CC1)C[*:1]
>>[*:2]C(=O)N1CCC([*:1])CC1
44 32 95.5 9 5
[*:1]Nc1ccc(Cl)cc1>>[*:1]Nc1ccccc1 42 26 95.2 18 10
[*:1]c1ccsc1>>[*:1]c1sccc1 61 38 95.1 30 17
[*:2]C=CC[*:1]>>[*:2]CCC[*:1] 81 41 95.1 24 13
[*:1]c1cc(OC)c(OC)cc1>>[*:1]c1ccccc1 40 36 95.0 29 15
[*:1]c1ccccc1F>>[*:1]c1sccc1 40 23 95.0 27 14
[*:1]C(C)C>>[*:1]C1CC1 98 76 94.9 45 19
[*:1]S(=O)(=O)c1ccc(Cl)cc1
>>[*:1]S(=O)(=O)c1ccccc1
39 27 94.9 22 14
[*:2]Nc1cc(O[*:1])ccc1>>[*:2]Nc1ccc(O[*:1])cc1 57 35 94.7 26 14
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Table E-3: Bioisosteric replacements (continued)
SMIRKS #records #MMPs freq. #targets #TF
[*:2]CCCCCCCCC[*:1]>>[*:2]CCCCCC[*:1] 38 26 94.7 17 8
[*:1]CC[NH+](C)C>>[*:1]C[NH+](C)C 56 36 94.6 32 10
I[*:1]>>[*:1]OC 37 24 94.6 30 16
[*:2]Oc1cc([*:1])ccc1>>[*:2]c1cc([*:1])ccc1 91 65 94.5 55 25
[*:1]C(=O)c1ccc(cc1)C>>[*:1]C(=O)c1ccccc1 36 22 94.4 27 14
[*:1]Nc1cc(Cl)c(Cl)cc1>>[*:1]Nc1ccc(Cl)cc1 36 16 94.4 9 3
[*:1]c1cc(F)ccc1>>[*:1]c1ccccc1F 107 80 94.4 65 27
[*:2]c1cc(Cl)c([*:1])cc1>>[*:2]c1cc(F)c([*:1])cc1 89 57 94.4 39 16
[*:2]C(F)(F)O[*:1]>>[*:2]C([*:1])(F)F 89 65 94.4 34 18
[*:1]c1cc(ccc1)C>>[*:1]c1ccccc1OC 35 19 94.3 27 12
[*:1]c1cc(F)ccc1>>[*:1]c1ccsc1 35 23 94.3 24 12
[*:2]C([*:1])C(C)C>>[*:2]C([*:1])CC 35 23 94.3 23 14
[*:2]Nc1cc([*:1])c(Cl)cc1>>[*:2]Nc1cc([*:1])ccc1 35 15 94.3 13 4
I[*:1]>>[*:1]Br 103 51 94.2 53 21
[*:3]C([*:1])c1cc([*:2])ccc1
>>[*:3]C([*:1])c1ccccc1[*:2]
34 17 94.1 17 6
[*:2]C#CCC[*:1]>>[*:2]C#C[*:1] 34 15 94.1 12 5
[*:2]CCCCCCCC[*:1]>>[*:2]CCCCCC[*:1] 101 73 94.1 33 18
[*:1]CCC>>[*:1]CCCC 437 289 94.1 108 45
[*:1]c1ccc(Br)cc1
>>[*:1]c1ccc([N+](=O)[O-])cc1
50 24 94.0 20 9
[*:1]N(C)C>>[*:1]OC 66 54 93.9 42 21
[*:1]c1ccccc1F>>[*:1]c1ccccc1OC 66 43 93.9 41 18
[*:1]Cc1cccnc1>>[*:1]Cc1ccncc1 33 26 93.9 24 14
[*:2]CC(=O)NCC[*:1]>>[*:2]CCC(=O)NCC[*:1] 33 21 93.9 14 6
[*:2]c1c(F)cccc1[*:1]>>[*:2]c1ccccc1[*:1] 49 43 93.9 31 20
[*:1]CCc1ccccc1>>[*:1]Cc1ccc(F)cc1 49 28 93.9 30 16
[*:2]C(CC[*:1])C>>[*:2]CCC[*:1] 49 30 93.9 29 17
[*:1]C[NH+]1CCCC1>>[*:1]C[NH+]1CCOCC1 48 34 93.8 30 12
[*:2]C[NH+]([*:1])CC>>[*:2][NH+]([*:1])C 48 33 93.8 30 11
[*:1]S(=O)(=O)c1ccc(cc1)C
>>[*:1]S(=O)(=O)c1ccccc1
32 24 93.8 22 14
[*:2]C([NH2+]C[*:1])C>>[*:2]C[NH2+]C[*:1] 32 25 93.8 11 6
[*:2]CCC[NH+]([*:1])C>>[*:2]CC[NH+]([*:1])C 63 32 93.7 34 12
[*:2]CNC(=O)N[*:1]>>[*:2]NC(=O)N[*:1] 47 41 93.6 14 6
[*:2]CNS([*:1])(=O)=O>>[*:2]NS([*:1])(=O)=O 78 47 93.6 24 8
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Table E-3: Bioisosteric replacements (continued)
SMIRKS #records #MMPs freq. #targets #TF
[*:1]c1cc(F)ccc1>>[*:1]c1ccccc1OC 31 24 93.6 27 16
[*:2]c1cc(Cl)c([*:1])cc1>>[*:2]c1cc([*:1])c(Cl)cc1 31 25 93.6 22 18
[*:1]C=C>>[*:1]CO 31 17 93.6 21 12
[*:1]c1cc(Cl)ccc1>>[*:1]c1cc(F)cc(F)c1 31 27 93.6 20 12
[*:2]c1cc([*:1])c(F)cc1>>[*:2]c1cc([*:1])c(OC)cc1 31 19 93.6 15 7
[*:2]CCCCCCO[*:1]>>[*:2]CCCO[*:1] 31 20 93.6 11 7
[*:2]c1cc(F)c([*:1])cc1>>[*:2]c1ccc([*:1])cc1 262 186 93.5 76 34
[*:1]CCCc1ccccc1>>[*:1]CCc1ccccc1 92 57 93.5 43 23
[*:1]C1CCC1>>[*:1]C1CCCC1 46 32 93.5 30 15
[*:1]C(=O)C>>[*:1]C(OC)=O 46 38 93.5 29 17
[*:1]c1cc(Cl)c(Cl)cc1>>[*:1]c1ccc(Br)cc1 60 31 93.3 25 13
[*:2]Cc1cc(O[*:1])ccc1>>[*:2]Cc1ccccc1O[*:1] 30 23 93.3 25 13
[*:1]CCC[NH+]1CCOCC1
>>[*:1]CC[NH+]1CCOCC1
30 22 93.3 14 7
SMIRKS representations for all 96 bioisosteric replacements are provided. For each transfor-
mation, the number of its potency records (#records), the number of matched molecular
pairs (#MMPs) defined by this transformation, the percentage of potency records smaller
than one order of magnitude (freq.), as well as the number of targets (#targets) and
target families (#TF) for which this transformation occurs in active compounds are
recorded. Transformations are sorted in descending order of the relative frequency with
which they produce potency records smaller than one order of magnitude. The number of
potency records is often larger than the number of matched molecular pairs because the
same compound pair can be found in ligand sets of multiple targets.
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Appendix F
R-Group Table
For the analog series of 32 antagonists of the melanocortin receptor 4 discussed
in Chapter 8, the common core structure and substitution sites are provided
in a conventional R-group table format (Table F-1). For all individual analogs,
R-groups and potency values are reported.
Table F-1: SAR table
N
O
NH
S
23
0
1
N35
R0 R1 R3 R5 R23 pKi
5*
Cl 6.0
0*
NH3+ (R) 5*
Cl 6.2
0* NH3+ 5*
Cl 5.2
0*
H
N
O
O
(R) 5*
Cl 7.2
0*
H
N
NH3+
O
(R) 5*
Cl 7.4
0*
O NH3+
O
5*
Cl 6.5
0*
H
N NH3+
O
(R) 5*
Cl 7.7
0*
H
N
O
NH3+
(R) 5*
Cl 7.9
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Table F-1: SAR table (continued)
R0 R1 R3 R5 R23 pKi
0*
H
N
N
O
(R) 5*
Cl 7.4
0*
H
N
O
NH3+
(R) 5
*
Cl 7.2
0*
H
N
O
NH3+
(R)
5*
Cl 7.5
0*
H
N
S
O
F
O
F
F (R) 5*
Cl 6.4
0*
NH3+ (R) 3*
Cl
5*
Cl 7.0
0*
H2+
N
NH2
(R) 3*
Cl
5*
Cl 7.7
(R) 3
*
Cl
5*
Cl 7.6
0*
H
N NH3+
O
(R) 3*
Cl
5*
Cl 8.7
0*
H
N
O
NH3+
(R) 3*
Cl
5*
Cl 8.7
0*
H
N
O
O
O
(R)
3*
Cl
5*
Cl 8.6
0*
H
N
H
N
O
OH
(R) 3*
Cl
5*
Cl 8.5
0*
H
N
H
N
O
(R) 3*
Cl
5*
Cl 8.6
0*
H
N N
O
(R) 3
*
Cl
5*
Cl 8.7
0*
H
N
H
N
O
(R) 3*
Cl
5*
Cl 8.8
0*
H
N
H
N
O
(R) 3*
Cl
5*
Cl 8.9
0*
H
N
O
(R) 3*
Cl
5*
Cl 8.6
0*
H
N
O
O
(R) 3*
Cl
5*
Cl 8.3
0*
H
N
O
O
(R) 3*
Cl
5*
Cl 8.3
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Table F-1: SAR table (continued)
R0 R1 R3 R5 R23 pKi
0*
H
N
O
O
(R) 3*
Cl
5*
Cl 8.3
0*
H
N
O
O
F
(R) 3*
Cl
5*
Cl 8.5
0*
H
N
S
O
O
(R) 3*
Cl
5*
Cl 7.9
0*
H
N NH3+
O
(R) 5*
Cl
23* 6.7
1*
NH3+
5*
Cl 5.3
0*
NH3+
3*
Cl 6.0
For a subset of analogs, the stereocenter at substitution site 0 is in the R-configuration, as
indicated in the table (R).
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